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ABSTRACT OF THE DISSERTATION
An Informatics Roadmap Toward a FAIR Understanding 
of Mitochondrial Biology and Rare Mitochondrial Disease
by
Anders Olav Garlid
Doctor of Philosophy in Molecular, Cellular, & Integrative Physiology (MCIP)
University of California, Los Angeles, 2019
Professor Peipei Ping, Chair
Mitochondrial biology is integral to our fundamental understanding of human health and many 
diseases. They exist in every human cell type except for red blood cells and have critical functions 
in metabolism, oxidative phosphorylation, oxidation-reduction, and as signaling hubs responsible 
for mediating protective mechanisms. Rare mitochondrial diseases (RMDs) are devastating and 
complex, affect multiple organ systems, and disproportionately impact young children. Despite 
copious existing knowledge and increased public interest, the knowledge is fragmented and 
difficult to access. Clinical case reports (CCRs) on RMDs contain valuable clinical insights, but 
they are scarce and lack the metadata necessary to facilitate their discovery among the two 
million CCRs on PubMed. The unstructured text data of CCRs is also ill-suited to computational 
approaches, limiting our ability to derive the knowledge contained within.
To address these issues, I assembled all available informatics tools and resources with 
mitochondrial components and used them to contribute to Gene Wiki pages that enable easy 
access to mitochondrial knowledge for researchers, students, clinicians, and patients. Through 
these efforts, I made mitochondrial gene, protein, and disease knowledge widely accessible with 
contributions of over 4MB of content across 541 Gene Wiki pages. Concurrently, I used Gene 
Wiki as an educational platform to train over 50 students in the biosciences and pre-medical 
iii
studies in mitochondrial biology and disease, as well as instilling effective research and writing 
methods in biomedicine.
To impose structure on CCRs and render them FAIR (Findable, Accessible, Interoperable, 
Reusable), I developed and applied a standardized metadata template to RMD CCRs and 
codified patient symptomology with the International Statistical Classification of Disease and 
Related Health Problems (ICD) system. I created the open-source, cloud-based MitoCases RMD 
Knowledge Platform (http://mitocases.org/) to house data on 384 RMD CCRs, including 4,561 
instances of 952 unique ICD codes. Supplementing CCRs with structured metadata amplifies 
machine-readable information content and provides a distinct improvement in searching for CCRs 
as compared to indexing by title and abstract. Finally, I employed these resources to conduct a 
thorough review of Barth syndrome and characterized the diversity of presentations, range of 
genetic etiologies, and treatment paradigms.
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1Chapter I
Introduction:
An Informatics Roadmap Toward 
a FAIR Understanding
of Mitochondrial Biology 
and Rare Mitochondrial Disease
2Introduction
Overview
Mitochondrial biology is integral to our fundamental understanding of human health and many 
diseases, from exercise to aging, cardiovascular disease to neurological complications, and a 
wide variety of complex mitochondrial diseases. Despite a large volume of existing knowledge 
and increased public interest, its access and comprehension remain elusive to the scientific 
community and public at large. With the intensifying pursuit of omics investigations and recruitment 
of large-scale clinical cohorts, vast numbers of enormous datasets in a wide variety of data types 
and inconsistent structure are constantly being generated, all on top of the ever-increasing 
rate of publication. Clinical communications in the form of case reports are also on the rise, 
but the information contained within is largely inaccessible by any technological means due to 
the unstructured nature of text data and the lack of structured and meaningful metadata. These 
documents present a tremendous opportunity for deriving important clinical insights, but their 
utility is hampered by the necessity of manual curation and human processing. 
Challenges presented by this deluge of biomedical information require significant technological 
advances in order to increase our capacity to process, analyze, and integrate across data types 
so that we may derive scientific insight and medical knowledge. Overcoming these challenges 
also demands the widespread adoption of the FAIR Principles of Findability, Accessibility, 
Interoperability, and Reusability [1] to render biomedical data and other digital objects machine-
readable and increase their overall utility in informatics pipelines and machine learning applications. 
The projects discussed in the following chapters are driven by a commitment to firmly establish 
these principles in the study of mitochondrial biology and rare mitochondrial diseases, focusing 
on informatics tools and resources, imposing structure on unstructured clinical case reports, 
contributions to citizen science efforts, education, and a new mitochondrial disease knowledge 
resource. A roadmap to the contents of this thesis is depicted in Figure 1-1.
3Clinical Case 
Reports (CCRs)
Informatics
Resources
Scientific
Literature
Mitochondrial Biology and Rare Mitochondrial Disease (RMD) Knowledge
Methods & Applications
for Structured CCRs
MitoCases RMD
Knowledge Platform
Mitochondrial
Gene Wiki Project
FAIR Knowledge Representation 
of Mitochondrial Biology & RMDs
RMD in Focus:
Barth Syndrome & TAZ
Ch 2
Ch 5.1
Ch 6
Ch 3 Ch 4 Ch 5.2
Figure 1-1: Schematic overview of chapters and their interplay. The focus of this thesis is grounded in 
mitochondrial biology and rare mitochondrial diseases (RMDs), knowledge of which is represented in three 
primary media: clinical case reports (CCRs), informatics resources, and scientific literature. Chapter 2   
(Ch 2) reviews informatics tools and resources with mitochondrial components and their utility in modern 
research. The three sources of mitochondrial knowledge propagate upward to the second tier of entities, 
each of which form a component of the efforts undertaken in this project. “Methods & Applications for 
Structured CCRs” (left) is contributed to solely by CCRs, for which we developed a standardized metadata 
template to impose structure on the otherwise unstructured text data contained within those reports. 
Chapter 3 (Ch 3) provides details on the metadata template and instructions for its use by researchers and 
clinicians, while Chapter 4 (Ch 4) presents a collection of metadata extracted from 3,100 reports, 
characteristics of the dataset, as well as potential use cases for downstream analysis and text-mining 
applications. The “Mitochondrial Gene Wiki Project” (right), discussed in Chapter 5.1 (Ch 5.1), entails our 
contributions of over 4MB of content and 5,674 references across 541 Gene Wiki articles on mitochondrial 
genes and proteins by deriving information from all three sources of mitochondrial knowledge, including 
CCRs, Informatics Resources, and Scientific Literature. Chapter 5.2 (Ch 5.2) details the technical 
specifications and use cases for the cloud-based “MitoCases RMD Knowledge Platform” (middle), which 
is contributed to by Informatics Resources and CCRs, as well as Structured CCRs from Chapters 3 & 4 
and the Mitochondrial Gene Wiki Project contributions from Chapter 5.1. MitoCases houses structured 
metadata from RMD CCRs, detailed genetic information, and standardized symptomology records 
codified with the International Classification of Diseases and Related Symptoms, 10th and 11th revisions 
(ICD-10 and ICD-11), all searchable by a powerful query system that aids in case discovery and analysis. 
The efforts from Chapters 2-5 contribute synergistically to rendering the knowledge derived from the three 
sources of mitochondrial knowledge Findable, Accessible, Interoperable, and Reusable (FAIR). These 
efforts all feed upwards to contribute to a “FAIR Knowledge Representation of Mitochondrial Biology & 
RMDs”. Chapter 6 (Ch 6) makes use of this FAIR mitochondrial knowledge to present an “RMD in Focus: 
Barth Syndrome & TAZ”, a comprehensive review of a devastating disease caused by mutations in the TAZ 
gene and the resulting impairments to the tafazzin protein responsible for cardiolipin remodeling. Drawing 
content and data from efforts presented in previous chapters, Chapter 6 details the structure and function 
of tafazzin, the role of cardiolipin in mitochondrial structure and function, clinical presentations in Barth 
syndrome across organ systems, as well as current and proposed treatment paradigms.
4Chapter 2. Omics and informatics resources for understanding mitochondrial biology.
Mitochondria play an integral role in all aspects of biology, across cell types, organ systems, and 
in both health and disease. Gaining a complete understanding of development, aging, signaling, 
and any other aspect across physiology and pathology requires that we consider mitochondria 
and the complex nature of its pervasive involvement throughout eukaryotic systems. Since their 
discovery in 1890 by Altmann [2], who originally described them as “bioblasts,” researchers have 
made significant advances in our comprehension of these ubiquitous organelles and their diverse 
functions. With each advent of new technological breakthroughs, the interest in and activity around 
mitochondrial research sees a resurgence and advances our ability to comprehend them.
Part and parcel with each of these advances, the quantity and variety of data becomes ever 
greater and more complex, presenting significant challenges in managing and assimilating it all 
into a comprehensive understanding of the mitochondrial phenome. The widespread use of omics 
technologies and large-scale clinical cohort studies results in massive datasets that are driving 
the rise of Big Data and amplifying the inherent challenges of integrating high-dimensional and 
diverse data types. A staggering number of bioinformatics tools and resources are employed 
throughout research to address these needs, but it can be difficult to determine what tool or 
resource is appropriate for a particular field of study. It is becoming increasingly more important 
to have a roadmap to navigate the informatics landscape and find the appropriate tools for any 
given avenue of investigation. 
This chapter presents an overview of mitochondria-specific resources as well as the mitochondria-
related subsets contained within other larger tools, databases, and knowledgebases. We have 
compiled detailed descriptions and analysis of the various informatics resources that are helping 
researchers explore this vital organelle and gain insights into its form, function, and dynamics. We 
focus on integrated omics resources, including mitochondria-specific resources, mitochondrial 
components of general resources, available mitochondrial datasets, as well as analytical tools 
and computational methods for an informatics approach to understanding and amplifying the 
study of mitochondrial physiology. 
5Chapter 3. Methods for structuring text data in clinical case reports.
Clinical case reports (CCRs) are a fundamental mechanism for sharing observations and insights 
in medicine, facilitating communication between clinicians and providing a vital educational 
resource for medical students. Emerging diseases, disease subtypes lacking specific diagnostic 
consensus, and rare clinical presentations are frequently communicated in CCRs, along with their 
treatments and genetic etiologies [3-6]. The first treatment of rabies in humans by Louis Pasteur 
in 1885 [7, 8] and the first application of penicillin in patients [9] were reported in CCRs. Heart 
failure with preserved ejection fraction (HFpEF) may affect half of all heart failure patients [10], but 
it was only recognized as a distinct subtype of cardiovascular disease in the past few decades. 
Over two million CCRs are available on PubMed as of August 2019, over a quarter of which 
were published in the past ten years. These documents represent an invaluable resource for 
clinical insight across disease types and have great potential to aid in detecting disease trends, 
identifying at-risk subsets of the population, highlighting promising new therapeutic regimens, and 
preemptively stemming the damage done by unsafe drugs or treatment practices. The deluge 
of CCR publications begs for a computer-aided approach to process and analyze these reports 
as they are released; the sheer volume, complexity, and variety of the reports renders it all but 
impossible for humans to manage manually. Unfortunately, CCRs lack extensive, structured 
metadata and the information contained within is primarily unstructured text data, making them 
inaccessible to machine-based approaches and severely limiting our ability to derive clinical 
insight from them in an efficient manner.
To address this critical issue, we must envision a mechanism by which we can impose structure 
on the text data presented in CCRs, render them machine-readable, and thereby gain access to 
a treasure trove of medical insight as it becomes available. We must establish a standardized 
system for amplifying the utility of CCRs by supplementing them with extensive metadata and 
annotations that convey the clinical concepts they describe in a machine-readable format and 
provide detailed instructions for implementing such a system.
6Accordingly, we developed a standardized CCR metadata template and associated methods for 
annotators to extract detailed clinical information from the reports and establish structure atop an 
otherwise unstructured text data resource [11, 12]. To ensure the accessibility and usability of this 
approach, we have published a comprehensive guide to the methodology behind this process to 
enable others to generate structured CCR metadata as well [12]. An accompanying video of the 
protocol clarifies the instructions and motivations behind this effort.
Chapter 4. Dissecting informatics blueprints of disease.
As informatics tools and pipelines become ever more prevalent and ubiquitous throughout research, 
it is imperative that the data and publications we produce are FAIR, structured, and machine-
readable so that they can be utilized in these approaches. Natural language processing (NLP) and 
text-mining approaches require large collections of structured text data in order to successfully 
train machine learning models for named entity recognition (NER) and relationship extraction. 
The demand is particularly high in biomedical text-mining due to the complexity of the language 
and heterogeneity across domains. Medical Subject Headings (MeSH) and related tools [13, 14] 
facilitate indexing and enforce structure on biomedical documents, as do the curated resources of 
Informatics for Integrating Biology and the Bedside (i2b2) [15, 16] and the CRAFT [17], AnatEM 
[18], NCBI disease [19], and PubMed Phrases [20] corpora. Clinical narratives, however, like those 
presented in CCRs, present unique challenges with their wide variability in content, presentation 
of interrelated phenomena, and the temporal component of disease progression. Most existing 
resources for biomedical text-mining have not been designed to model these narratives and the 
indexing and structure for CCRs is limited. Furthermore, while clinical controlled vocabularies and 
coding systems including ICD-10 [21], LOINC [22], and SNOMED [23], are in widespread use in 
electronic medical records (EMRs), these systems are rarely utilized in published clinical reports. 
The lack of informative metadata to structure and index CCRs represents a significant challenge 
and hinders the utility of this important resource.
A standardized approach to enriching CCRs with metadata and imbuing them with structure is 
necessary to address these issues. Collaborative efforts between clinicians, researchers, and 
7data scientists will be required to establish these standards and ensure their implementation 
across existing and future case report publications. Furthermore, the utility of this metadata must 
be demonstrated by highlighting an increase in information content and providing use cases that 
can be implemented by key stakeholders in biomedical research and clinical care. Additionally, 
the added metadata must be made FAIR so that it can be widely disseminated and integrated into 
informatics pipelines. 
Recognizing the need to lead by example, we created a metadata template to impose structure on 
CCRs and aggregated metadata from a large collection of reports spanning 16 disease systems 
and covering over 100 rare diseases. We provide this extensive dataset of over 3,100 structured 
CCR metadata templates for others to employ in downstream analysis, developing text-mining 
tools, modeling medical language, and potentially automating the process for application to a 
more comprehensive set of reports [11]. Detailed use cases for the dataset guide those interested 
in incorporating it in their work, including researchers, physician investigators, clinicians, data 
scientists, IP officers, pharmaceutical companies for drug development, and those shaping 
government policies for clinical trials. The dataset also serves as an educational resource that 
highlights the variety of CCR writing styles and a range of completeness in describing clinical 
concepts. By offering a comparison between reports and the benefits of presenting a complete 
and detailed clinical narrative, we anticipate that clinicians and their co-authors will rise to the 
challenge and strive to produce better, more structured reports of their own accord using a 
standardized metadata template.
Chapter 5. Advancing FAIR mitochondrial biology via Gene Wiki and MitoCases.
Mitochondrial diseases are complex, rare, and fatal, frequently leading to disruption of 
mitochondrial proteomes and function. Unfortunately, decades after their discovery, our limited 
understanding of these diseases and their pathogenesis is still woefully inadequate, leading to 
delayed diagnoses and a dearth of treatment options. These issues are compounded by the 
fragmented nature of clinical case information, much of which is communicated entirely in the 
unstructured text data contained within clinical case reports. Similarly, much of the biomedical 
8research community’s accomplishments in advancing our understanding of mitochondrial biology 
are difficult to access, particularly for the general public. Wikipedia consistently ranks as one of 
the most popular websites across the world (currently 5th most viewed) and is widely regarded 
as a reliable source of scientific information; biomedical articles are both understandable to the 
average user and useful to those in scientific research for the comprehensive citations. However, 
many mitochondrial proteins and mitochondrial diseases have been inadequately represented 
and poorly annotated, posing a roadblock to knowledge discovery in mitochondria-related studies. 
FAIR data resources that support knowledge discovery and amplify progress in biomedicine are 
necessary to advance our understanding of mitochondrial biology and disease, improve our ability 
to provide timely and accurate diagnoses, and develop effective treatment paradigms. The Gene 
Wiki Project [24], an effort to inspire citizen science within Wikipedia, embodies FAIR Principles 
by making complex biomedical knowledge widely available. We have taken a concerted effort 
to address deficiencies in mitochondrial representation on Wikipedia and, concurrently, realized 
an educational opportunity to train students on concepts of mitochondrial biology, research 
methods, and FAIR Principles. Additionally, we set out to decode clinical narratives by imposing 
structure on CCRs relating to rare mitochondrial diseases (RMDs) using the metadata template 
discussed in the previous chapters [11, 12] and codified patient symptoms using standardized 
ICD codes to construct a systematic understanding of symptomology among these diseases. 
Text data standardization and integration with existing protein resources and clinical ontologies 
renders metadata FAIR and enables the biomedical community to elevate disease knowledge 
and improve patient care. 
With the participation of 35 high school summer interns, 12 undergraduate college students, and 
2 graduate students, we contributed over 4MB of content across 541 articles and added nearly 
5,700 references. We introduced critical research strategies and informatics tools to students 
and instilled FAIR Principles in the next generation of scientists, clinicians, and researchers. To 
house structured RMD CCR metadata, we built the MitoCases platform (http://mitocases.org/) for 
384 reports on 8 RMDs, including deficiencies in complex I through V of the electron transport 
chain, carnitine deficiency, Barth syndrome, and megaconial-type congenital muscular dystrophy 
9(MDCMC). Across 384 RMD CCRs, 4,561 instances of 952 unique ICD-10 codes, along with 
detailed metadata, highlights shared and common symptoms as well as rare and unique 
characteristics, revealing pathogenesis and mechanistic insights underlying RMDs. MitoCases is 
a highly structured, FAIR data resource with a powerful search interface through which to discover 
CCRs of relevance, aiding in literature curation, case review, and diagnosis.
Chapter 6. Rare mitochondrial disease in focus: Barth syndrome and tafazzin.
Mitochondrial diseases have devastating effects on organ systems throughout the body, and they 
frequently present themselves during infancy or childhood. Their rarity makes them particularly 
difficult to diagnose and treat due to the lack of collective medical experience on their etiology and 
presentation. Barth syndrome is a rare mitochondrial disease that effects almost exclusively males 
and causes significant cardiovascular defects within the first years of life, among other serious 
metabolic, hematologic, and muscular phenotypes [25, 26]. No treatment exists to address the 
root cause of the disease. Mutations in the TAZ gene impair cardiolipin remodeling by its protein 
product, the transacylase tafazzin, and compromise mitochondrial structure and function. As a 
result, the only recourse is to attempt to manage symptoms as the patient progresses towards 
heart failure or is plagued by severe infections.
Leveraging the resources, tools, and approaches that were uncovered, developed, and applied 
throughout the preceding chapters, I endeavored to gain a thorough understanding of this 
particularly interesting and devastating rare mitochondrial disease. I conducted a deep investigation 
of tafazzin structure and function, explored the complex role of cardiolipin in mitochondrial form 
and function, and delved into the clinical narratives and genetic etiologies across the population 
of Barth syndrome patients described in the clinical literature and in the TAZ mutations database 
managed by the Barth Foundation.
The cumulative product of these efforts is the comprehensive review of tafazzin, cardiolipin, and 
Barth syndrome presented in this chapter, as well as the highly structured clinical and genetic data 
on these patients that is housed on the MitoCases platform. The review and associated metadata 
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contain a wealth of information on a multi-factorial and inevitably lethal disease with no cure. 
We present a detailed view of the diverse genetic etiologies for Barth syndrome. Clinicians and 
researchers will find detailed discussions covering the spectrum of case presentations, including 
metabolic disorders and pathologies of the cardiovascular, musculoskeletal, neurological, and 
hematologic systems, as well as the range of treatments that have been attempted, disproven, or 
proposed for further study.
Closing statement
The chapters within detail efforts to establish “an informatics roadmap toward a FAIR understanding 
of mitochondrial biology and rare mitochondrial disease” by using and developing tools, resources, 
and protocols to make mitochondrial knowledge more Findable, Accessible, Interoperable, and 
Reusable through integration, standardization, and enforcing structure on otherwise unstructured 
text data.
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Abstract
Understanding the complex involvement of mitochondrial biology in disease
development often requires the acquisition, analysis, and integration of large-
scale molecular and phenotypic data. An increasing number of bioinformatics
tools are currently employed to aid in mitochondrial investigations, most notably
in predicting or corroborating the spatial and temporal dynamics of mitochon-
drial molecules, in retrieving structural data of mitochondrial components, and
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in aggregating as well as transforming mitochondrial centric biomedical knowl-
edge. With the increasing prevalence of complex Big Data from omics experi-
ments and clinical cohorts, informatics tools have become indispensable in our
quest to understand mitochondrial physiology and pathology. Here we present
an overview of the various informatics resources that are helping researchers ex-
plore this vital organelle and gain insights into its form, function, and dynamics.
Keywords
Computation • Data science • FAIR data • Metadata • Omics • Open access •
Visualization
1 Introduction
Mitochondria play a major role in a range of diseases and are promising targets for
therapeutic approaches to neurodegenerative and metabolic disorders, ischemia-
reperfusion injury and cardiomyopathies, and various forms of cancer (Lesnefsky
et al. 2001; Vlasblom et al. 2014). In spite of this, very few mitochondrial drugs
have completed clinical trials (Walters et al. 2012). Initially described as “bio-
blasts” in 1890 by Altmann, mitochondria are of vital importance in eukaryotic
systems (Altmann 1894). In the 1940s, Claude developed methods for cell frac-
tionation and differential centrifugation that allowed the separation of mitochon-
dria from the cytosol and a closer study of these fascinating organelles in isolation
(Bensley and Hoerr 1934; Claude and Fullam 1945; Claude 1946a, b). He esta-
blished the localization of respiratory enzymes to the mitochondrion; Kennedy and
Lehninger further identified this as the site of the citric acid cycle, oxidative phos-
phorylation, and fatty acid oxidation (Kennedy and Lehninger 1949). The distinc-
tive dual-membrane characteristic of the mitochondrion and the organization of
cristae within its matrix were uncovered in 1952 with the first high-resolution
electron micrographs of isolated mitochondria by Palade (1952, 1953) (Daems and
Wisse 1966). Imaging approaches also provided the means for the discovery of
mitochondrial DNA (Nass 1963; Nass and Nass 1963; Schatz et al. 1964) which
ultimately became the first component of the human genome to be completely
sequenced (Anderson et al. 1981) more than 20 years before the massive Human
Genome Project completed their goal of sequencing the entire human genome
(Lander et al. 2001).
Technological advances and physiological discoveries have fomented renais-
sance periods in mitochondrial research. A notable example is the work of Peter
Mitchell leading to the chemiosmotic theory (Mitchell 1961, 1966, 1968). Eventu-
ally accepted 20 years after its introduction, Mitchell’s proposal broadened the
scope from basic molecular biology and biochemistry to a more physiological
approach, including explorations of the intricacies of the potassium cycle and
matrix volume regulation through the study of channel and carrier membrane bio-
logy. These approaches have become progressively more advanced, leading to a
378 A.O. Garlid et al.
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greater understanding of mitochondrial physiology and its role in health and
disease. The scientific community is now progressing from the classical,
organelle-based study of mitochondria to the digital era of the informatics-based
mitochondrial phenome. Informatics combines computer science, engineering, and
statistics to develop tools and methods that empower researchers to navigate
biological data, put it into context, and extract knowledge. Under the increasing
influx of data, prowess in data science methods and awareness of available infor-
matics resources are becoming essential components of the modern researcher’s
tool chest.
The most common high-throughput data come in the form of omics datasets,
which assess the global conditions within the cell through one dimension of data,
be it whole-genome sequencing for genomics, RNA-sequencing (RNA-seq) for trans-
criptomics, tandem mass spectrometry (MS/MS) for proteomics, or NMR spectro-
scopy for metabolomics studies (Field et al. 2009). Integrating levels of expression
across many dimensions can elucidate physiological mechanisms underlying healthy
and diseased phenotypes not revealed or biasedly portrayed by a single dimension.
Developments in these technologies have manifested a dramatic increase in the sheer
volume of publicly available scientific data; genomics data has been growing at a rate
that exceeds Moore’s law by a factor of 4 since 2008 (Gomez-Cabrero et al. 2014;
O’Driscoll et al. 2013). This deluge of data has presented unique and unforeseen
challenges. Omics investigations rely heavily on effective database management and
annotation to contextualize molecular data and infer biological significance through
statistical enrichment and class discovery techniques. The completeness and preci-
sion of existing annotations are therefore instrumental to harness omics techniques
for disease phenotyping and mechanistic investigations. In light of these challenges,
funding agencies, research organizations, and publishers around the world are adop-
ting FAIR data principles, which maintain that data should be findable, accessible,
interoperable, and reusable (FORCE11 2014). Building on these principles, omics
datasets and analysis platforms must also be citable and scalable to allow the attri-
bution of the work to the appropriate research groups and expansion to new and
improved techniques with larger capacity. In this changing landscape, the concept of
open-access data is gaining traction, asserting that data should be freely available for
researchers to use, reuse, and disseminate (Molloy 2011).
This chapter provides an overview of the informatics tools and resources avail-
able to the modern researcher and how they may be used to inform a greater under-
standing of mitochondrial physiology. We focus on integrated omics resources,
including mitochondria-specific resources, mitochondrial components of general
resources, available mitochondrial datasets, as well as analytical tools and compu-
tational methods for an informatics approach to mitochondrial physiology.
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2 Mitochondria-Specific Resources
The mitochondrial research community has undergone several paradigm shifts in
conceptual focus and experimental design, progressing from hypothesis to data-
driven approaches. The discovery of mitochondrial DNA (mtDNA) fostered a period
of renewed interest in mitochondrial physiology and the development of new tools
and techniques. Mitochondrial DNA was first discovered in 1963 by Nass et al., who
described them as “intramitochondrial fibers with DNA characteristics” (Nass 1963;
Nass and Nass 1963). The entirety of the human mitochondrial genome was se-
quenced in 1981 by Anderson et al. (1981), and mutations were first discovered less
than a decade later, identifying the genetic basis of LHON, Kearns-Sayre, MELAS,
and MERRF (Wallace et al. 1988a, b). mtDNA is 3,000 kb long and encodes only
13 proteins in the mitochondrial proteome, compared to over 1,500 from nuclear
DNA. Aberrations in the mitochondrial genetic code result in diseases that are most
often fatal, demonstrating their integral role. Maternal inheritance of mtDNA has
provided a method for genotyping and tracing of genetic lineages. Computational
approaches have been employed to identify genetic pressures for phylogenetic re-
tention of mitochondrial genes as well as the debated mtDNA bottleneck mecha-
nism, whereby cell–cell variability is utilized to avoid aggregation of deleterious
mutations and loss of function of the uniparental mtDNA (Johnston and Williams
2016; Johnston et al. 2015).
Characterizing the mitochondrial genome and corresponding proteome requires a
tailored approach due to its unique quality of having genetic contribution from both
nuclear and mitochondrial DNA. The databases that contain these datasets must de-
lineate the genetic sources, and the protein localization information can vary between
datasets and detection methods. As such, the mitochondrial community has created a
variety of tools to decipher the principles of mitochondrial physiology. In this section,
we highlight mitochondria-specific resources geared exclusively toward the storage,
maintenance, and manipulation of mitochondrial datasets, from “omics” repositories
to community-curated resources of mitochondrial knowledge.
In genomics, analyses of an individual’s genome is compared to a reference
genome to determine individual genetic variations and aberrations; accordingly, the
Cambridge Reference Sequence (CRS) was created in 1981 (Anderson et al. 1981),
and updated in 1999 (Andrews et al. 1999). This reference sequence is stored with-
in GenBank [NCBI Reference Sequence: NC_012920.1] and within MITOMAP,
which provides information relating specifically to the human mitochondrial ge-
nome; this includes polymorphisms, mutations, and control regions, and allows
users to upload and analyze sequences through the MITOMASTER web interface
(Lott et al. 2013). Similarly, MitoCarta 2.0 provides a curated inventory of 1,158
human and mouse genes, as well as the proteins that localize to the mitochon-
drion. The inventory is generated using mass spectra of mitochondria isolated from
14 tissues and protein localization is determined via GFP tagging, microscopy, and
machine learning. MS and microscopy results are integrated with six other genome-
scale datasets of mitochondrial localization, lending greater accuracy to the deter-
mination of protein location (Pagliarini et al. 2008). Importantly, MitoCarta has
380 A.O. Garlid et al.
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integrated information from archived mitochondrial databases, such as MitoP2, in
order to ensure that the knowledge contained within said databases remains acces-
sible (Calvo et al. 2016). Datasets can be downloaded in Excel, MySQL, BED, and
FASTA file formats and are publicly available. Datasets within MitoCarta have led
to important insights such as the identification of targets for whole-exome sequenc-
ing disease analysis (Falk et al. 2012).
Characterizing the mitochondrial genome is particularly important in the context
of human disease, where maternally inherited mutations can lead to deadly diseases
such as MERAS and MERFF (Wallace et al. 1988a, b). Computational tools have
been essential in characterizing these mutations (see Table 1). MitImpact is a re-
pository of pathogenicity predictions as related to mitochondrial DNA mutations.
Predictions are generated by assembling estimations as well as structural and evo-
lutionary annotations for each missense mutation. The resource is comprehensive,
and provides assessments of susceptibilities for previously characterized and un-
known mutations resulting in amino acid sequence alteration (Castellana et al. 2015).
Mutations currently characterized across populations are stored in the Human Mito-
chondrial DataBase (HmtDB), which focuses on mitochondrial diseases in population
genetics (Rubino et al. 2012). The genome sequences within HmtDB are annotated
based on population variability factors, using SiteVar software. Users can query and
browse the database, analyze sequences for classification, and download the results
with reference genomes. As of August 2016, HmtDB contains 28,196 complete nor-
mal genomes spanning multiple continents, and 3,539 complete patient genomes.
Globally, the database contains data for close to 10,000 variant sites (Attimonelli et al.
2005). For more deleterious mutations, MitoBreak contains mitochondrial genome re-
arrangements comprising circular deletion, circular duplication, and linear break-
points. Spanning seven species including human, each case lists the positions of the
breakpoints, junction sequences, and clinical relevance found in publications. The
resulting resource is crucial for studying structural alterations of mtDNA (Damas et al.
2014). MitoSeek is a software tool for obtaining various mitochondrial genome in-
formation from exome, whole genome, and RNA-seq data (Guo et al. 2013). The tool
can be utilized for mitochondrial sequence extraction, assembly quality evaluation,
relative copy number estimation, detection of mitochondrial heteroplasmy, soma-
tic mutations, and structural mtDNA alterations (Jayaprakash et al. 2015). These
mitochondria-specific tools have enabled greater efficiency and standardization in
the analysis of genomics datasets.
Just a few short years after Marc Wilkins coined the term “proteome” in 1995
(Wasinger et al. 1995; Godovac-Zimmermann 2008), Rabilloud attempted the first
characterization of all mitochondrial proteins using 2-D electrophoresis (Rabilloud
et al. 1998). In the ensuing decades, tremendous progress has been made in defining
the mitochondrial proteome and its subproteomes (Lotz et al. 2014), owing primar-
ily to the remarkable developments in mass spectrometry technology (Yates 2013).
To house the massive amount of data generated in these studies, MitoMiner is used
as a data aggregator to store and analyze mitochondrial proteomics data obtained
from MS and fluorescent protein tagging studies (Smith et al. 2012). It integrates
with many other informatics resources, namely UniProt, Gene Homology, Online
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Table 1 Mitochondrial resources and websites
Tool URL Description
Last
updated
HmtDB http://www.hmtdb.
uniba.it:8080/hmdb/
Open resource hosting human
mitochondrial genome sequences
annotated with population and
variability data, the latter being
estimated through the application of
SiteVar
09/2015
MitImpact http://mitimpact.css-
mendel.it/
Repository of pathogenicity predictions.
These predictions are created through
the assembly of precomputed and
computed sets of estimations for all
missense mutations; these mutations are
then structurally and evolutionarily
annotated
07/2016
MitoBreak http://mitobreak.
portugene.com
Database containing mitochondrial
genome rearrangements through a list of
circular deletion, circular duplication,
and linear breakpoints
05/2014
MitoCarta 2.0 http://www.
broadinstitute.org/
node/7098/index.
html
Provides a curated inventory of 1,158
human and mouse genes encoding
proteins with strong scientific support of
localization to the mitochondrion
06/2015
MitoFish/
MitoAnnotator
http://mitofish.aori.u-
tokyo.ac.jp/
Contains the mitochondrial genomes of
many model systems, including zebra
fish. The database also contains
phylogenetic information, as lineage can
often be determined via mitochondrial
DNA. MitoAnnotator automates the
annotations of new sequences uploaded
to the database, and has also reannotated
the previously uploaded mitogenomes to
gain new insights
08/2016
MITOMAP http://www.mitomap.
org/MITOMAP
Provides information relating
specifically to the human mitochondrial
genome, including polymorphisms,
mutations, and control regions, and
allows users to upload and analyze
sequences through the MITOMASTER
web interface
06/2016
MitoMiner http://mitominer.
mrc-mbu.cam.ac.uk
Data aggregator for the storage and
analysis of mitochondrial proteomics
data obtained from MS and fluorescent
protein tagging studies
04/2016
MitoPedia http://www.bioblast.
at/index.php/
MitoPedia
Encyclopedic resource and discussion
platform specifically focused on
mitochondrial knowledge relating to
experimental design, methods, and
terminology
05/2016
(continued)
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Mendelian Inheritance inMan, HomoloGene, IntegratedMitochondrial Protein Index,
KEGG, and PubMed. As such, MitoMiner provides an all-in-one platform for mito-
chondrial researchers interested in probing the mitochondrial proteome. MitoMiner
currently encompasses 11 different species and integrates 46 large-scale proteomics
studies in its database, providing output data in XML, JSON, GFF3, UCSC-BED,
FASTA, and HTML formats, and programmatic access through REST APIs and
platform-specific clients (Perl, Python, Ruby, and Java). Most importantly,MitoMiner
is actively maintained and updated to accommodate changes to the integrated
resources.
Other databases have been created for specific animal models, such as MitoFish.
MitoFish contains the mitochondrial genomes of many fish species, including the
common model system, zebra fish. The database also contains phylogenetic informa-
tion, as lineage can often be determined via mitochondrial DNA. MitoAnnotator
automates the annotations of new sequences uploaded to the database, and has also
reannotated the previously uploaded mitogenomes to gain new insights (Iwasaki et al.
2013). MitoFish is particularly useful to mitochondrial researchers due to expert
curation and automated annotation. Data contained within MitoFish has spurred ef-
forts to determine the genetic basis for various adaptations in fish (Wang et al. 2016)
as well as advancements in phylogeographic studies (Hirase et al. 2016). This
includes the development of suffix tree-based marker detection methods for detecting
short genetic sequences, resulting in improved approaches to annotating mitochon-
drial genomes or to detecting and correcting erroneous annotations (Moritz et al.
2014).
Collaboration among domain-specific communities is integral to creating studies
for emerging physiological questions. Created in 2010 by Bioblast, MitoPedia was
created as an encyclopedic resource and discussion platform specifically focused
on mitochondrial knowledge relating to experimental design, methods, and termino-
logy. Content is generated by contributions from domain scientists and mitochondrial
physiologists with experience in cellular and mitochondrial isolation and experi-
mentation. Experts in the field write, discuss, and contribute to articles relating to
respirometry, fluorometry, spectrophotometry, mitochondrial swelling, membrane
potential (Δψ), and ion flux experiments. Members of the Mitochondrial Physio-
logy Society (MiPs) comprise the primary user base of the MitoPedia platform,
which has been accessed over 40,000 times, with approximately 100–200 page
views per month (Oroboros 2015). Many of the articles presented deal with respiro-
metry experiments and the MiPs group actively endorses a move to
Table 1 (continued)
Tool URL Description
Last
updated
MitoSeek https://github.com/
riverlee/MitoSeek
Software tool for obtaining various types
of mitochondrial genome information
from exome, whole genome, and
RNA-seq sequencing data
05/2015
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standardized experimental protocols, drug concentrations, and terminology so as to
have the most effective discussions among mitochondrial physiologists across the
world.
Use Case for Investigating Mitochondrial DNA Mutations
Biomedical question: An investigator would like to study the role of mtDNA
mutations in Leber’s hereditary optic neuropathy (LHON), whether poly-
morphisms exist predominantly for a particular demographic, as well as infor-
mation on current treatment efficacy and clinical trials.
Data science approach: Use HmtDB to find sequences, population genet-
ics, and polymorphisms in human mitochondrial genomes. Searching for
LHON returns 190 records in healthy and diseased patients. The same search
on MITOMAP yields 61 selected references, and MitoMiner was recently
used to identify mitochondrial proteins that are downregulated in LHON
patients due to an mtDNA mutation (Tun et al. 2014). MitoPedia contains
13 entries of references and abstracts relating to LHON and mitochondrial
function. Finally, clinicaltrials.gov (discussed in Sect. 3) lists a current Phase
2 randomized clinical trial on a small cohort (12 patients) “Investigating the
Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Oph-
thalmic Solution for the Treatment of Leber’s Hereditary Optic Neuropathy”
(https://clinicaltrials.gov/ct2/show/NCT02693119/). Using the patient records
from HmtDB, one could determine differential prevalence across demograph-
ics, or predict other mutations that would result in a similar phenotype using
the MitImpact tool.
3 General Bioinformatics Resources and Their Mitochondrial
Components
Approaches to the study of mitochondrial physiology have undergone tremendous
change with the advent of omics approaches and cloud computing, among other
technologies and advancements. The resulting influx of information has the poten-
tial to generate vast amounts of knowledge, but only with the proper infrastructure
in place to handle the load. Bioinformatics and cloud computing approaches allow
more efficient and effective management of the wide variety of data sources that
contribute to our generation of physiological knowledge and a greater under-
standing of mitochondria. Here we review the mitochondrial components of well-
established, curated omics resources (see Table 2).
Many resources span multiple dimensions, providing information on two or more
omics data types. Xfam is a collection of databases including Rfam for RNA families
(Nawrocki et al. 2015), Pfam for protein families (Finn et al. 2014a), and iPfam for
protein family interactions (Finn et al. 2014b). Each database provides annotations that
are crowdsourced throughWikipedia and links to other databases formore information
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on the protein sequence, protein structure, or RNA sequence of interest. Rfam contains
information about noncoding RNAs (ncRNAs), structured cis-regulatory elements,
and self-splicing RNAs. Each entry is represented by multiple sequence alignments,
consensus secondary structures, and covariance models (CMs), which allow simul-
taneous modeling of RNA structure and sequence (Nawrocki et al. 2015). Currently,
there are 861 mitochondrial RNA families within this database. Pfam utilizes hidden
Markov models (HMMs) to generate multiple protein sequence alignments, allowing
users to search sequence databases for homologous proteins with a specialized com-
putational package. Sequence information is organized into higher level groupings
of related families called clans, based on collections of Pfam-A entries related by
sequence similarity, structure, or profile HMM (Finn et al. 2014a). Pfam has over
16,000manually curated entries to date, 1,460 ofwhich are annotated asmitochondrial.
iPfam provides protein interaction information, based on structural information from
all known structures contained in the Protein Data Bank (PDB) (Berman et al. 2000).
Protein crystal structure is analyzed to identify protein domains, bonds, and small
chemical ligands in each structure and bond length is estimated based on geometric and
chemical properties of the sites (Finn et al. 2014b). There are 325 protein families and
44 ligands within iPfam that are mitochondrially related.
The Research Collaboratory for Structural Bioinformatics Protein Data Bank
(RCSB PDB) is the premier resource for protein structure data. The PDB contains
over 120,000 crystallographic structures of proteins, nucleic acids, and protein/
Table 2 Mitochondrial entries in existing big resources
Tool URL Data type(s)
Mitochondrial relevant
entries
Flybase http://flybase.org/ Fly genes, mutations, and
stocks
377 genes, 11,057 stocks
HMDB http://www.hmdb.ca/ Metabolites 17,682 metabolites
IMSR http://www.findmice.
org/
Mouse strains 4,011 strains
KEGG http://www.genome.
jp/kegg/
Pathway maps 55 relevant pathway maps
PDB http://www.rcsb.org/
pdb/
Protein structures 2,107 protein structures
Reactome http://www.reactome.
org/
Reactions and pathways 153 human pathways
UniProt http://www.uniprot.
org/
Proteins 4,889 reviewed proteins
Xfam http://xfam.org/
Rfam http://rfam.xfam.
org/
RNA families RNA families
Pfam http://pfam.xfam.
org/
Protein families 1,460 proteins
iPfam http://ipfam.org/ Protein family
interactions
325 protein families,
44 ligands
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nucleic acid complexes, along with complementary analysis and visualization tools
(Berman et al. 2000). The PDB also accepts data depositions from the community
and provides tools for data preparation and validation. Most data provided by the
PDB is available as PDBML or PDB files, and is accessible over two REST web
services: the SEARCH service for querying the database and the FETCH service
for retrieving the structure data. Over 2,000 of the structures within PDB are mito-
chondrially associated. Structural information about these proteins yields valuable
insight into their conformational arrangements and sites of posttranslational modifi-
cation, and can help identify active sites for drug development.
The PDB assists in these developments by providing a stable, organized resource
for accessing and sharing structural data. To supplement the structural data within
PDB, users rely on UniProt, a publicly accessible, comprehensive resource of protein
sequence, annotation, and localization data created and maintained by the European
Bioinformatics Institute. UniProt contains both highly curated and machine-generated
protein annotations, and has become the de facto source for protein information. As of
September 2016, this resource contains 550,000 manually reviewed proteins for hu-
man (SwissProt), of which 4,889 are related to the mitochondria.
Perturbation in protein expression is a crucial component of omics research; the
manifestations of such changes can be studied through metabolomics, which assess
the entire pool of small molecules within the cell or organelle. As proteins act on
metabolites, their fluctuations provide another, highly dynamic dimension of pheno-
typic data. One database, the Human Metabolome Database (HMDB), contains or
links chemical data, clinical data, and molecular biology/biochemistry data (Wishart
et al. 2007). The database has detailed, curated information for 41,993 water- and
lipid-soluble metabolites. Within each entry, there are 110 data fields, with a large
emphasis on chemical and clinical data; significantly, quantification information is
available on each MetaboCard entry, and there exists protein sequence information
for 5,701 entries. The HMDB supports extensive text, sequence, chemical structure,
and relational query searches (Wishart et al. 2009). The database interfaces with many
others, including some of those aforementioned, as well as PubChem, MetaCyc,
ChEBI, and GenBank (Wishart et al. 2013). Of the over 40,000 metabolites within
the database, mitochondrially related metabolites comprise over 17,000 MetaboCard
entries.
Metabolite fluctuations are best understood through visualization of their respec-
tive pathways, as it is becoming increasingly apparent that their complex interplay
is a burgeoning area of investigation. Two databases provide pathway visualization
tools: KEGG PATHWAY and Reactome. The Kyoto Encyclopedia of Genes and
Genomes (KEGG) currently contains 17 databases, each with a different focus in
the domains of systems biology, genomics, chemistry, and medicine. KEGG is
publicly accessible and supports tab-separated, plain text or KEGG database entry
data formats, while the KEGG Application Programming Interface (API) allows
customization of KEGG analyses (Kanehisa et al. 2014). These tools provide an
in-depth look at signaling pathways and interactions among proteins, allowing a
more complete view of pathways of interest, providing insight into related pro-
cesses and species that might deserve study. Specifically, within KEGG
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PATHWAY, there are 55 mitochondrial relevant pathway maps, many of which are
associated with the progression of common human diseases. Another resource,
Reactome, is an open-source platform for biological pathway visualization that is
manually curated and peer reviewed by experts, with a focus on human reaction
pathways (Matthews et al. 2009). The database contains deeply annotated pathway
information from 19 distinct species and includes 1,786 pathways for human as of
September 2016. Of these, there are over 150 mitochondrially associated pathways,
reactions, and complexes identified and annotated within the platform. Reactome
bundles many pathway-related visualization, interpretation, and analysis tools in
one resource (Stein 2004). The pathway data can be viewed and analyzed direct-
ly from the Pathway Browser, accessed programmatically through a REST API,
or downloaded in BioPAX, PSI-MITAB, SBML, and SBGN formats (Jupe et al.
2015). Reactome is widely used for different analyses, including the identification
of biomarkers in a neurological model of PTSD (Jia et al. 2012; Bai et al. 2007).
Use Case for Investigating Mitochondrial Localization or Involvement
Biomedical question: 12-Lipoxygenase has been implicated in ischemic pre-
conditioning pathways, but has it been identified as having mitochondrial
localization? What resource can an investigator use to answer this question?
Are lipoxygenases mitochondrially targeted? What metabolic changes result
from perturbations in lipoxygenase expression or function? What interacting
partners exist or is there any relevance as a drug target?
Data science approach: UniProt reveals a GO annotation of positive regu-
lation of mitochondrial depolarization. Querying HMDB for 12-lipoxygenase
returns five metabolites that are associated with the enzyme. These results also
connect the user to a multitude of resources, including primary research papers
that have been used for annotation and other sites or resources with relevant
information. KEGG and Reactome can also be used to investigate reaction
pathways related to the lipoxygenases; a KEGG query for 12-lipoxygenase
returns eight pathways and Reactome lists seven reactions and their corres-
ponding pathways.
4 Public Mitochondrial Datasets and Data Sharing
The digitization of scientific literature through resources like PubMed has made
scientific publications easy to find for a much wider audience. However, due to
the incremental nature of science, where new studies are based on the conclusions
reached by past endeavors, knowledge remains distributed across many publi-
cations. This creates a gap in our ability to reuse or repurpose existing knowledge
and renders high-throughput computational analyses of the literature immensely
difficult. The growing demand for access to the data behind scientific publications
assigns data repositories an increasingly important role as the backbone of modern
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scientific research. Sponsored by the National Institutes of Health, the National
Center for Biotechnology Information (NCBI) created the Database of Genotypes
and Phenotypes, or dbGaP, which contains hierarchical data of structured types.
The inputted data are organized into investigations that explore the interface of
genotype and phenotype and are linked to an accession number. Within the studies
are phenotypic datasets, whereby certain variables are measured. Investigators can
upload the raw datasets, provide important information, and give metadata to
encourage reusability. If investigators performed analyses, those may also be
uploaded. Upon study completion, investigators may upload supporting doc-
uments, which may contain further information such as study instructions, pro-
tocols/forms for data procurement, and other information necessary to use these
datasets (Tryka et al. 2014). Conducting a query for “mitochondria” returns 21 mito-
chondrial related studies spanning 216 variables. Within this, there are ten supporting
documents and 37 raw datasets. These are also documented in clinicaltrials.gov.
Currently, the database is openly accessible to institutions, and there is an avenue
by which individuals can gain controlled access. These resources are aggregated in
Table 3.
As the creation of new data exponentially grew, the scientific community real-
ized the need for consolidated, open omics repositories. One unique challenge was
to take raw, unprocessed datasets and provide information and resources to enable
Table 3 Publicly accessible mitochondrial datasets
Dataset URL Description
Mitochondrial
datasets and
components
dbGaP http://www.ncbi.
nlm.nih.gov/gap
The database of genotypes and
phenotypes contains hierarchical
data of structured types
21 studies:
216
variables
1 analysis
10
documents
37 datasets
ProteomeXchange http://www.
proteomexchange.
org/
Publicly accessible, centralized
repository for proteomics
datasets
32 datasets
OmicsDI http://www.
omicsdi.org/
Provides searchable metadata
such as accession, description,
sample/data protocols, and
biological corroborations
2,819 total
datasets:
326
proteomics
24
metabolomics
63
transcriptomics
122
genomics
208 multi-
omics
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access and collaborative analysis by other users. Founded by the creators of the
prominent primary proteomics resource PRIDE (PRoteomics IDEntifications), the
ProteomeXchange Consortium sought to create a repository for proteomics mass
spectrometry datasets. The consortium consists of investigators who created many
primary and secondary proteomics resources, and now has a publicly accessible,
centralized repository (Vizcaino et al. 2014). Users can proceed through a full or
partial submission workflow, using PRIDE as the initial resource. The PX Submis-
sion Tool facilitates the upload of datasets, as well as supporting documentation and
metadata (Ternent et al. 2014). Of the over 2,500 datasets compiled on the
ProteomeXchange resource, there are 32 proteomics datasets that are related to
mitochondria. While many repositories exist that are specific to one omics domain,
they are fragmented, operate independently, and highlight the need for an integrated
repository, whereby omics datasets can be organized and disseminated in a sys-
tematic fashion. Within the Big Data to Knowledge (BD2K) Initiative, there exists
OmicsDI, a repository for multiple datasets. One common challenge within omics
datasets is that data is generated through differential protocols; as such, this hinders
the analyses that can be performed. OmicsDI combats this by providing searcha-
ble metadata such as accession, description, sample/data protocols, and biological
corroborations (Perez-Riverol et al. 2016). Querying OmicsDI for mitochondrial
terms yields 2,800 datasets: of those, 122 are genomic, 63 are transcriptomic, 326
are proteomic, 24 are metabolomic, and 208 are multi-omic datasets.
The development of informatics resources for storage, maintenance, and ana-
lysis of scientific data addresses each component of the FAIR data doctrine. Stan-
dardization of experimental protocols in the “omics” sciences is necessary for more
reliable data, while consistency in data formats and annotation facilitates more
efficient data sharing. Curated resources and data repositories organize the infor-
mation, rendering “omics” data findable and accessible, and lending added value to
the data that might otherwise be undiscovered in an obscure format. Furthermore,
analytic tools and platforms have been developed by the scientific community to
facilitate the goals of interoperability and reusability. Analytic platforms make data
mining and the generation of metadata much easier and more widely accessible,
furthering data discovery and allowing others to try a novel approach on any of the
available datasets. Scientists benefit from making their datasets publicly available
and in a common format because their work becomes more visible, useable, and,
ultimately, citable.
In addition to the technical challenges of data sharing, there exist legal and cul-
tural considerations, especially with respect to clinical studies. One readily identifi-
able challenge is sharing clinical datasets in accordance with the Health Insurance
Portability and Accountability Act (HIPAA), which mandates the protection of pri-
vacy with regard to medical information. Research efforts must establish protocols
that de-identify information contained within electronic health/medical records
(EHR/EMR), and package them into usable, queryable data for research purposes
(Russo et al. 2016). More important, however, is the need to secure explicit consent
from study participants such that their personal data can be shared across groups
with different research foci. Currently, protocols are being developed to provide
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standardized consent forms for larger scale purposes with wide applicability, rather
than for individual studies. New studies benefit from incorporating these stipu-
lations into consent documents during study design, whereas researchers wishing to
disseminate older datasets must review their consent documents to determine if
sharing is appropriate or legal. Alternatively, a follow-up may be necessary to gain
further consent from study participants (Kaye and Hawkins 2014). Already,
research groups and agencies have created repositories with these issues in mind.
Because these data repositories are general and allow the storage of datasets origi-
nating from a broad range of biological fields, researchers may question the utility of
those that were not originally constructed with a mitochondrial focus. Previously, data-
sets were considered disposable material, only useful for supporting the conclusions of
the particular study. In the data science landscape, new methods and protocols have
been developed for managing and cataloging data, providing researchers the ability to
recycle and reuse datasets. There lies untapped potential in these datasets for mito-
chondrial researchers to explore and gain new insights, all while avoiding expensive
and laborious data generation until it is necessary. This is especially applicable to
large-scale omics datasets, which provide the opportunity for data-driven, untargeted
approaches to streamline experimental design and generate targeted approaches for
further hypothesis-driven, physiological studies.
5 Pipelines and Tools for Data Processing and Analysis
While access to datasets is crucial, it is only one step in being able to truly harness
the knowledge contained within them. The first and often most laborious aspect is to
process the data and wrangle it into a format that will be usable by intended tools
and pipelines. Investigative teams often perform their own processing protocols,
and do not leave adequate metadata and/or annotation for others to be able to
recreate the study. To mitigate this, some omics investigators have sought to create
best practice pipelines. The effects of a unified system and set of tools can be most
concretely seen in the area of genomics, specifically with the Genome Analysis
ToolKit (GATK), which focuses on sequence analysis to discover relevant variants
(McKenna et al. 2010). Having established best practices for genomics analyses,
GATK has also been expanded to have copy number and structural variation
analysis capacities (Tennessen et al. 2012). Currently, GATK hosts a wide variety
of tools to assist investigators along all steps of analysis, including sequence data
processing tools, such as sequence aligners and readers; variant discovery, eval-
uation, and manipulation tools, such as a Bayesian genotyper and a variant filter;
and annotation modules. The toolkit was originally intended for human exomes and
genomes sequenced from Illumina technologies, but has been expanded to other
experimental protocols and model systems, regardless of ploidy. GATK also hosts
third-party tools that can be integrated with the previously established pipelines
(DePristo et al. 2011; Van der Auwera et al. 2013). GATK and other analysis tools
and pipelines are highlighted in Table 4.
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Table 4 Analysis pipelines and platforms
Tool URL Description
COPaKB https://amino.
heartproteome.org/
Centralized platform featuring high-quality
cardiac proteomics data and relevant
cardiovascular phenotype information. The
organellar modules constitute the mass
spectral library and are utilized by COPaKB’s
unique high-performance search engine to
identify and annotate proteins in the mass
spectra files that are submitted by the user in
mzML or DTA formats
Cytoscape http://www.cytoscape.org/ Open-source software platform for the
visualization of complex biological systems,
such as molecular interaction networks and
biological pathways. The platform enables
enhancement of the network data through
integration of various formats of metadata
into the network structure
Galaxy https://usegalaxy.org/ Informatics workflow management system
and data integration platform that aims to
make computational biology accessible to
researchers with limited experience in
computer programming. Provides a graphical
user interface, customizable plug-ins, access
to public datasets, and other users’ workflows
GATK https://software.
broadinstitute.org/gatk/
Toolkit that focuses on sequence analysis to
discover relevant variants; originally intended
for human exomes and genomes sequenced
from Illumina technologies, but has been
expanded to other experimental protocols and
model systems, regardless of ploidy
MetaboAnalyst http://www.metaboanalyst.
ca/
Analysis pipeline spanning a wide variety of
data types; has the capacity for biomarker
identification, as well as a host of other
bioinformatics tools for the best standard
metabolomics analyses using an extensive
spectral library for enhanced metabolite
identification
MetaCore https://portal.genego.com/ Standalone program and Web application
comprising multiple different analysis
methods for varying types of high-throughput
molecular data, including sequencing and
gene expression, proteomic data, and
metabolomic data. Also contains a manually
curated database
MetazSecKB http://bioinformatics.ysu.
edu/secretomes/animal/
index.php
Database presenting subcellular protein
location based on manual curation of the
scientific literature combined with UniProt
sequence data and annotations. Employs an
algorithm that utilizes multiple prediction
tools, combining the predictions of publicly
(continued)
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Many other emerging areas of omics are developing best practice guidelines;
however, creating these guidelines requires significant effort for their implemen-
tation. To help investigators with this, OmicsPipe integrates multiple best practice
pipelines to provide a platform for processing raw data. OmicsPipe aims to reduce
the overhead for processing large datasets, and provides visualizations produced;
currently, the platform has automated workflows for processing RNA-seq, whole-
exome sequencing (WES), whole-genome sequencing (WGS), and ChIP-seq data-
sets (Fisch et al. 2015).
Upon processing the data, investigators are faced with myriad tools to perform
analyses; without distinct computational knowledge, navigating these platforms
can be daunting. Operating on a unified system can substantially streamline omics
analyses; that being said, there are many stand-alone tools specific to one branch
of omics that can elucidate valuable knowledge. Within the realm of proteomics,
identifying the subcellular location of a protein is important for determination of
function, genome annotation, drug development, and disease identification. Pro-
teins are designed to play their role in specific locations, defining their function
based on their environment. This becomes particularly important when discussing
mitochondrial proteins. Generally speaking, there are two parallel approaches to
Table 4 (continued)
Tool URL Description
available tools including TargetP, SignalP,
Phobius, ScanProsite, WolfPSORT,
FragAnchor, and TMHMM
OmicsPipe http://sulab.org/tools/
omics-pipe/
Integrates multiple best practice pipelines to
provide a platform for processing raw data;
aims to reduce the overhead for processing
large datasets, and provides visualizations
produced; currently, the platform has
automated workflows for processing
RNA-seq, whole-exome sequencing (WES),
whole-genome sequencing (WGS), and ChIP-
seq datasets
ProTurn http://heartproteome.org/
proturn
Scalable analysis platform that assesses the
turnover rate of proteins. Uses a deuterium
oxide (D2O) labeling protocol and determines
the kinetics by integrating MS peaks,
determining isotope abundances, and using
multivariate optimization. Available for use
on a wide variety of datasets
TargetP http://www.cbs.dtu.dk/
services/TargetP/
Web-based tool for predicting the subcellular
location of eukaryotic proteins and identity of
secretory signal or transit peptides using
N-terminal sequence information and a
combination of machine learning methods.
Commonly used by mitochondrial
physiologists analyzing proteomics datasets
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determine whether a protein is localized to the mitochondrion: the approach of the
biologist or biochemist, and that of the informatician. The former will devise a plan
for isolation, fractionation, assays, and copurification with other known mitochon-
drial markers to look for biochemical evidence of localization to one organelle or
another. The latter would investigate features of the gene or protein sequence uti-
lizing computational approaches that would identify it as localized to mitochondria.
Proteins bound for localization in mitochondrial membranes contain an amino
acid sequence signal at the N-terminus or an internal targeting sequence to direct
them to their appropriate position, both of which are managed by different species
of the translocase inner- and outer-membrane (TIM and TOM) complexes. An
amphipathic helix in a protein’s presequence is cleaved upon delivery (von Heijne
1986; Schatz and Gottfried 1993), while proteins lacking a presequence region
remain in the cytosol (Fox 2012).
TargetP is a Web-based tool for predicting the subcellular location of eukaryotic
proteins and identity of secretory signal or transit peptides using N-terminal
sequence information and a combination of machine learning methods. This tool
is commonly used by mitochondrial physiologists analyzing proteomics datasets, as
evidenced by over 2,000 citations of the tool’s two papers in the scientific literature.
The user submits either an amino acid sequence or a FASTA file as the input, and
retrieves a plain text file outlining the predictions (Emanuelsson et al. 2007). The
predictions were found to be 90% accurate for non-plant proteins and 85% accu-
rate for plant proteins (Klee and Ellis 2005; Emanuelsson et al. 2000). The tool is
publicly accessible as a Web service or downloadable for local computation. It
is one of the prediction tools used by UniProt to annotate mitochondrial peptides,
along with Predotar, TMHMM, and Phobius, all of which make predictions based
on N-terminal targeting sequences (Small et al. 2004; Ka¨ll et al. 2004; Krogh et al.
2001). In addition to localization prediction, TMHMM predicts transmembrane
helices in protein sequences with 97% accuracy (Krogh et al. 2001) while Phobius
was shown to predict the secondary structure of proteins with fewer instances of
false classification and identify signaling proteins with fewer false positives than
TargetP and TMHMM (Ka¨ll et al. 2004).
MetazSecKB combines results from each of these tools to increase prediction
accuracy for secretome and subcellular proteome localization. The database
presents subcellular protein location based on manual curation of the scientific
literature combined with UniProt sequence data and annotations. When this anno-
tation is lacking, MetazSecKB employs an algorithm that utilizes multiple predic-
tion tools, combining the predictions of publicly available tools including TargetP,
SignalP, Phobius, ScanProsite, WolfPSORT, FragAnchor, and TMHMM (Meinken
et al. 2015). The accuracy of localization predictions increased significantly when
these tools were utilized in concert, rather than individually. Accordingly, the
algorithm combs data from each of the tools simultaneously, and then applies
statistical and data mining techniques to acquire the most accurate localization
predictions for eukaryotic secreted proteins (Min 2010). Over 135,000 proteins in
Homo sapiens are represented in the database, approximately 21,000 of which
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localize to mitochondria; 3,737 of these are associated with the mitochondrial
membrane and 17,623 are non-membrane proteins.
The Cardiac Organellar Protein Atlas Knowledgebase (COPaKB) is a central-
ized platform featuring high-quality cardiac proteomics data and relevant cardio-
vascular phenotype information (Zong et al. 2013). As of September 2016, COPaKB
features 11 organellar modules, comprising 4,467 LC-MS/MS experiments from hu-
man, mouse, drosophila, and Caenorhabditis elegans. There are four mitochondrial
specific modules for each species with over 1,000 proteins represented in each spe-
cies. The organellar modules constitute the mass spectral library and are utilized by
COPaKB’s unique high-performance search engine to identify and annotate proteins
in the mass spectra files that are submitted by the user in mzML or DTA formats.
Data in COPaKB can be viewed within the browser, accessed via the REST API or
downloaded in Excel XLS, XML, and JSON formats.
Protein expression data does not take into account the rate of synthesis and de-
gradation of a certain protein, termed protein turnover. As such, measuring expres-
sion alone is not sufficient to understand the dynamics of protein levels within the
mitochondria. Accordingly, tools have been developed that align with dynamics
protocols. One such tool is ProTurn, which uses a deuterium oxide (D2O) labeling
protocol and determines the kinetics by integrating MS peaks, determining isotope
abundances, and using multivariate optimization. Most importantly, this tool is scal-
able, which enables users to perform analysis on a wide range of datasets (Wang
et al. 2014).
To elucidate the small-molecule perturbations that may occur in varying mito-
chondrial physiological states, two types of tools exist: one assesses the quantita-
tive levels of metabolites, while the other synthesizes metabolite lists into known
networks, so that these can be visualized by the investigator. Originally developed
in 2009 (Xia et al. 2009), MetaboAnalyst has gone through many iterations, with
updates in 2012 (Xia et al. 2012) and 2015 (Xia et al. 2015) bringing vital improv-
ements. The current version accepts a wide variety of data types, including NMR
spectra, MS spectra, and compound/concentration data. The user interface guides
investigators through the analysis pipeline, beginning with dataset quality control
by the user. Once quality control standards have been met, the platform will analyze
the data, using an extensive spectral library for enhanced metabolite identification.
The most current version, MetaboAnalyst 3.0, has the capacity for biomarker
identification, as well as a host of other informatics tools for the best standard
metabolomics analyses. The graphical output allows users to view the analysis
results in a user-friendly format. This platform has been used extensively in mito-
chondrial studies to understand mitochondrial physiological function in the spinal
cord in an ALS model, identify therapeutic targets of cardiomyopathy, and uncover
the role of mitochondrial protein quality control in the context of physiological
stress across many systems (Quintana et al. 2016; Cacabelos et al. 2016; Picard
et al. 2015).
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Cytoscape is an open-source software platform for the visualization of complex
biological systems, such as molecular interaction networks and biological pathways.
The platform enables enhancement of the network data through integration of various
formats of metadata into the network structure. One powerful aspect of Cytoscape is
its extendibility; third-party developers can access its API and develop applications on
top of Cytoscape that readily implement the desired functionality. As of September
2016, the Cytoscape App Store contains 228 Apps, with 305,000 downloads in total
(Ono 2015). Cytoscape is an excellent fit for visualization of networks, such as
microRNA networks in the brain stem (DeCicco et al. 2015).
Stand-alone tools created by members of the omics community have proven inte-
gral to furthering omics research. However, these tools exist as fragments, which
makes dissemination to the broader community a significant challenge. To combat
this, Galaxy was created as an informatics workflow management system and data
integration platform that aims to make computational biology accessible to researchers
with limited experience in computer programming (Goecks et al. 2010). Galaxy pro-
vides a graphical user interface, customizable plug-ins, and access to public data-
sets and other users’ workflows. This offers a robust peer-review mechanism in which
the analyses conducted previously can be reproduced with little effort (Sandve et al.
2013). Because the workflows are hosted on the cloud and Galaxy servers perform the
computational work, this greatly reduces the requirement for setting up expensive
infrastructure to achieve research goals. One branch of Galaxy, Galaxy-P, contains
workflows specifically designed to analyze proteomics datasets and integrate them
with other forms of omics data, such as transcriptomics (Sheynkman et al. 2014). In
addition to tools developed in the academic community, commercial tools have been
developed with similar infrastructure. MetaCore™, developed by Thomson Reuters,
exists as a stand-alone program as well as a Web application. The tool contains multi-
ple different analysis methods for varying types of high-throughput molecular data,
including sequencing and gene expression, proteomic data, and metabolomic data. In
addition to an internal, manually curated database, MetaCore™ contains genomic
analysis tools, a data mining toolkit, a pathway editor, and data parsers to adapt the
wide range of omics data that can be uploaded (Cambiaghi et al. 2016).
Using these tools requires significant computational power; the previously esta-
blished paradigm for in-house platforms is becoming extremely costly. The hardware
usually becomes dated in about 3 years, and must be updated in order to maintain
relevance. Even with extensive collaboration and shared infrastructure, the servers are
used for only a fraction of the time they are available, which creates a highly inefficient
cost per analysis. These problems have illustrated the need for a unified resource in
which researchers can take advantage of ever-improving capacities and features, with
significantly less up-front expense. Recent advancements point to cloud-based com-
puting and storage systems. Operations on the cloud provide the same computational
power but represent only a tiny fraction of the hardware and operational costs for an
in-house server-based computational platform. The National Institutes of Health has
proposed the cloud-based Commons environment, a cost-sharing model that will pro-
vide access to scalable storage and computational resources for the entire biomedical
community. Commons Credits will serve as the currency for computational efforts and
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require minimal effort to apply so as to reduce the administrative overhead of esta-
blishing computational infrastructure, be it in-house or on business cloud servers
(https://www.commons-credit-portal.org).
6 Conclusion
The current deluge of data brings significant challenges to which researchers must
respond by continually improving methods and technologies for data management
and dissemination. In adhering to the FAIR doctrine, data shall be accessible in all
respects, and their analyses will also be presented in an intuitive, structured manner.
As such, the resulting dataset and knowledge will be open to reuse, repurpose, and
reanalysis so as to investigate different targets of interest. In this chapter, we have
outlined a collection of tools and resources that serve to aid a deeper understanding
of mitochondrial physiology and its role in health and disease. These tools range
from community-generated encyclopedic resources, expert-curated databases, and
repositories for data management and access to tools for analysis and visualization
of biological processes. They allow greater access and reuse of data through anno-
tation, metadata, and analysis platforms. The development of these tools and
resources, as well as the openness of scientific data, has had a dramatic impact on
the breadth, depth, and structure of data, as well as the reproducibility of experi-
ments and analysis pipelines.
The physiology discipline stands at a unique cross section, and bridges data and
clinical applications. It is through these tools that investigators are able to unlock
mechanistic insight and access the potential for clinical translation. The advance-
ment of multi-omic approaches, bioinformatics analyses, and open-access data has
improved our basic understanding of physiology and pathology while spurring the
development of personalized medicine and discovery of biomarkers for disease
(Almeida 2010; de Graaf 2013). EHR is becoming more detailed, accessible, and
multidimensional, and natural language processing is making it easier to conduct
meta-analyses of disease treatments from de-identified patient records. With the
concept of precision medicine, the paradigm of health and disease classification is
shifting from broad generalization to distinct and individualized medical profiling
(Hayes et al. 2014). In this landscape, researchers can significantly benefit from
using computational and informatics tools to enable better scientific investigations.
Informatics science is transforming the scope of biomedical research, providing
ample tools and methods by which to address the requirements of Big Data,
personalized medicine, and next-generation scientific questions. New and improved
infrastructure in the research and health sectors have resulted in a burgeoning
expansion of data that requires research scientists and clinicians alike to investigate
novel approaches in data science and informatics. It is at the interface of domain
knowledge and computational bandwidth that mitochondrial research can syner-
gistically propel forward, at a velocity not seen in isolated studies. As this data is
shifting from disposable to indispensable, integrated approaches are rapidly
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demonstrating themselves as invaluable components of a biomedical researcher’s
tool chest.
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Abstract
Clinical case reports (CCRs) are a valuable means of sharing observations and insights in medicine. The form of these documents varies, and
their content includes descriptions of numerous, novel disease presentations and treatments. Thus far, the text data within CCRs is largely
unstructured, requiring significant human and computational effort to render these data useful for in-depth analysis. In this protocol, we describe
methods for identifying metadata corresponding to specific biomedical concepts frequently observed within CCRs. We provide a metadata
template as a guide for document annotation, recognizing that imposing structure on CCRs may be pursued by combinations of manual and
automated effort. The approach presented here is appropriate for organization of concept-related text from a large literature corpus (e.g.,
thousands of CCRs) but may be easily adapted to facilitate more focused tasks or small sets of reports. The resulting structured text data
includes sufficient semantic context to support a variety of subsequent text analysis workflows: meta-analyses to determine how to maximize
CCR detail, epidemiological studies of rare diseases, and the development of models of medical language may all be made more realizable and
manageable through the use of structured text data.
Video Link
The video component of this article can be found at https://www.jove.com/video/58392/
Introduction
Clinical case reports (CCRs) are a fundamental means of sharing observations and insights in medicine. These serve as a basic mechanism
of communication and education for clinicians and medical students. Historically, CCRs have also provided accounts of emerging diseases,
their treatments, and their genetic backgrounds1,2,3,4. For example, the first treatment of human rabies by Louis Pasteur in 18855,6 and the first
application of penicillin in patients7 were both reported through CCRs. More than 1.87 million CCRs have been published as of April 2018, with
over half a million within the last decade; journals are continuing to provide new venues for these reports8. Though unique in form and content,
CCRs contain text data that are largely unstructured, contain a vast vocabulary, and concern interrelated phenomena, limiting their use as a
structured resource. Significant effort is required to extract detailed metadata (i.e., "data about data", or in this case, descriptions of document
contents) from CCRs and establish them as a findable, accessible, interoperable, and reusable (FAIR)9 data resource.
Here, we describe a process for extracting text and numerical values to standardize the description of specific biomedical concepts within
published CCRs. This methodology includes a metadata template to guide annotation; see Figure 1 for an overview of this process. Application
of the annotation process to a large collection of reports (e.g., several thousand of a specific type of disease presentation) permits assembly of
a manageable and structured set of annotated clinical texts, achieving machine-readable documentation and biomedical phenomena embedded
within each clinical presentation. Though data formats such as those provided by HL7 (e.g., Version 3 of the Messaging Standard10 or the Fast
Healthcare Interoperability Resources [FHIR]11), LOINC12, and revision 10 of the International Statistical Classification of Diseases and Related
Health Problems (ICD-10)13 provide standards for describing and exchanging clinical observations, they do not capture the text surrounding
these data, nor are they intended to. The results of our methodology are best used to enforce structure on CCRs and facilitate subsequent
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analysis, normalization through controlled vocabularies and coding systems (e.g., ICD-10), and/or conversion to the clinical data formats listed
above.
Mining CCRs is an active area of work within biomedical and clinical informatics. Though previous proposals to standardize the structure of
case reports (e.g., using HL7 v2.514 or standardized phenotype terminology15) are commendable, it is likely that CCRs will continue to follow a
variety of different natural-language forms and document layouts, as they have for much of the past century. Under ideal conditions, authors of
new case reports follow CARE guidelines16 to ensure they are comprehensive. Approaches sensitive to both natural language and its relation to
medical concepts may therefore be most effective in working with new and archived reports. Resources such as CRAFT17 and those produced
by Informatics for Integrating Biology and the Bedside (i2b2)18 curation support natural language processing (NLP) approaches yet do not
specifically focus on CCRs or clinical narratives. Similarly, medical NLP tools such as cTAKES19 and CLAMP20 have been developed but
generally identify specific words or phrases (i.e., entities) within documents rather than the general concepts commonly described in CCRs.
We have designed a standardized metadata template for features commonly included within CCRs. This template defines features to impose
structure on CCRs—an essential precursor for in-depth comparisons of document contents-yet allows for sufficient flexibility to retain semantic
context. Though we have designed the format associated with this template to be appropriate for both manual annotation and computationally-
assisted text mining, we have ensured it is particularly easy to use for manual annotators. Our approach noticeably differs from more intricate
(and, therefore, less immediately understandable to untrained researchers) frameworks such as FHIR21. The following protocol describes how to
isolate document features corresponding to each template data type, with a single set of values corresponding to those in a single CCR.
The data types within the template are those most descriptive for CCRs and patient-focused medical documents in general. Annotation of these
features promotes findability, accessibility, interoperability, and reusability of CCR text, primarily by giving it structure. The data types are in
four general categories: document and annotation identification, case report identification (i.e., document-level properties), medical content
concepts (primarily concept-level properties), and acknowledgements (i.e., features providing evidence of funding). In this annotation process,
each document includes the full text of a CCR, omitting any document contents material independent to the case (e.g., experimental protocols).
CCRs are generally less than 1,000 words each; a single corpus should ideally be indexed by the same bibliographic database and be in the
same written language.
The product of the approach described here, when applied to a CCR corpus, is a structured set of annotated clinical text. While this methodology
can be performed fully manually and has been designed to be performed by domain experts without any informatics experience, it complements
the natural language processing approaches specified above and provides data appropriate for computational analysis. Such analyses may be of
interest to audiences of researchers beyond those who frequently read CCRs, including:
• those concerned with disease presentations, their key symptomology, usual diagnostic approaches, and treatments
• those who wish to compare the results of clinical trials with events described within the clinical literature, potentially providing additional
observations and greater statistical power.
• bioinformatics, biomedical informatics, and computer science researchers who require structured medical language data sets or high-level
understandings of medical narratives
• Government policy researchers focusing on how clinical trials may best reflect how diagnosis and treatment as it occurs in reality
Enforcing structure on CCRs can support numerous subsequent efforts to better understand both medical language and biomedical phenomena.
Protocol
1. Document and Annotation Identification
Note: Values in this category support the annotation process.
1. Using the annotation template, provide an identifier specific to this metadata set, e.g., Case123. The identifier format should be consistent
throughout the project (e.g., Case001 through Case500).
2. Specify the date on which a document was read and annotated. Use a format resembling “Jan 10 2018” for consistency and readability.
2. Case Report Identification
Note: Values in this category provide document-level features and contribute to a document’s findability.
1. Be consistent with the format of each field across all annotations, e.g., individual values should be separated by semicolons without following
spaces in all entries. Use identical formats to those used in the original document or those used in a bibliographic database such as
MEDLINE.
2. Provide the title of the document.
3. Provide the names of all authors of the document in the provided order. Normalize the format of all names, such that all names take the form
of a single last name followed by any number of initials, e.g. Jane B. Park becomes Park JB. Do not include titles. Separate multiple authors
with a semicolon without additional punctuation, such that John A. Smith, Jane B. Park takes a form of Smith JA;Park JB.
4. Provide the year of publication of the document.
5. Provide the full title of the journal in which the document was published. A list of controlled journal names is provided by the NLM Catalog
(https://www.ncbi.nlm.nih.gov/nlmcatalog).
6. Provide the address of the home institution of the authors of the document, as specified in the document. This may include departments,
geographic locations, and postal address details.
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1. If multiple locations are provided (e.g., if affiliations differ between authors), specify only details for the corresponding author. If a
corresponding author cannot be identified, use that of the first author, or do not specify an institution. If a corresponding author has
multiple affiliations, specify both and separate with a semicolon.
7. Provide the corresponding author of the document, as specified within the document heading using the same format as that used in the
Authors data type.
8. Provide a document identifier (e.g., a PMID).
9. Provide a Digital Object Identifier, where possible and available, resolvable to the document URL (through https://www.doi.org/), not a
PubMed Central page.
10. Provide a stable URL to the full text of the document, if available. To maximize accessibility, this may refer to the PubMed Central version.
11. Provide the document language. For documents available in multiple languages, provide both, separated with a semicolon.
3. Medical Content
Note: Values in this category identify document-level, concept-level, and text-level features. They serve to enhance a document’s accessibility,
interoperability, and reusability. These features provide ways to observe conceptual and semantic similarities between document content, with a
focus on biomedical topics and events. Most categories in this section can include multiple text statements and each should be separated using
a semicolon.
1. Include contextual detail in each field (e.g., “mother had breast cancer at age 50”) rather than providing only terms from a controlled
vocabulary (e.g., not “breast cancer” alone). Do not include extensive detail beyond each observation.
2. Omit commonly repeated words and phrases (e.g., pronouns, the word “patient”, and the phrases “complained of” or “presented with”).
Though subjectivity across multiple annotators is likely, it may be reduced by having multiple annotators for each document and through
automated normalization after data collection. Computational post-processing approaches will vary by subsequent analysis needs and are not
discussed here in detail.
3. Provide the following information in the annotation template.
1. Provide specific terms identified within a document, usually in its header, as key terms. Separate with a semicolon as terms may
include other punctuation.
2. Provide demographic values, specifically any text statements describing a patient's background, including sex and/or gender, age,
ethnicity, or nationality.
3. Provide geographic locations mentioned within the clinical narrative, other than specific institution addresses. This should not include
anatomical locations/parts, but may include any geographic locale where the patient resides or travels.
4. Provide life style values, including any text statements describing frequent patient activities or behaviors relevant to their general
health. In practice, this frequently involves smoking or alcohol consumption habits, but may also include sun exposure, diet, or
frequency of specific types of physical activity.
5. Provide medical history values referring to family history. Include any text statements describing clinical observations of and events
experienced by siblings, parents, and other family members. This includes genetic conditions and negative observations (i.e., family
history was negative for a disease).
6. Provide values referring to Social History, including any text statements describing patient background not covered in Demography or
Life Style. There may be overlaps in content between these categories. The statements may include occupational history and social
habits.
7. Provide values referring to the patient’s medical and surgical history. Include any text statements describing any medical observations,
treatments, or other events taking place prior to the beginning of the clinical presentation. This includes obstetric history and periods of
good health, where noted.
8. Specify one or more of the following 16 disease system categories. Note that these values are categorical rather than free-text.
Categories are not comprehensive but should indicate most systems impacted by the events described in the clinical presentation and
diagnosed disease.
1. Follow a specific set of categories, based on the categories used in the International Statistical Classification of Diseases and
Related Health Problems, revision 10 (ICD-10) code system. See Table 1 for the list of disease system categories along with
corresponding ICD-10 code ranges.
9. Provide details of all signs and symptoms. Include any text statements describing any medical observations of signs or symptoms
beginning at initial presentation, including their onset, duration, severity, and resolution, if provided. Do not include symptoms described
in the outcome. These values may overlap with other types if symptoms continue from history to initial presentation.
10. Provide details of any comorbidities. Include any terms or phrases describing distinct diseases present at the time of initial clinical
presentation. There is likely overlap between these values and those in clinical history, though Comorbidity should not include terms
identical to those in the Diagnosis.
11. Provide details of all diagnostic techniques and procedures. Include the names of medical procedures done for diagnostic purposes,
including examinations, tests, and imaging, as well as the conditions under which these tests were performed and relevant anatomical
locations (e.g., “upper extremity venous ultrasound”). Exclude test results.
12. Provide details of diagnosis. Include any text statements describing diagnoses of disease, even if the final diagnosis is ambiguous.
13. Provide all laboratory values and test results. Include names of diagnostic tests, their values, and conditions under which they were
performed. This will involve overlap with terms used in the Diagnostic Techniques and Procedures data type. Both numerical and
qualitative values (e.g., complete blood count was within normal limits) are acceptable. If the names of diagnostic tests are not
provided, use terms describing the results (e.g., leukopenia), though they should also be included in the Signs and Symptoms.
14. Provide details of pathology. Include any text statements describing results of pathology and histology studies, including gross
pathology, immunology, and microscopy studies. Terms may overlap with those used in Diagnostic Techniques and Procedures (step
3.11), e.g., with the procedures performed to obtain samples such as biopsy.
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15. Provide all pharmacological therapies. Include any text statements describing drug therapies used in the course of treatment, including
general terms such as antibiotics or specific drug names. Also, include descriptions of when and how drug therapies were stopped.
16. Provide all interventional procedures. Include any text statements describing therapeutic procedures used in the course of treatment,
including invasive procedures, implantation of medical devices, and procedures done to facilitate other therapies. Also, include
descriptions of when and how ongoing therapeutic procedures were stopped, if necessary.
17. Provide the patient outcome. Include any text statements describing health of the patient as of the end of the clinical presentation
described in the report, including any follow-up tests.
18. Provide counts of all diagnostic images, figures, videos/animations, and tables. Include all counts of visual media included in the report,
in the following format: Count of images; Count of figures; Count of videos or animations; Count of tables.
1. Distinguish between images and figures in this way: images include any products of clinical diagnostics, including photographs,
micrographs, electrocardiogram rhythm images, and other products of diagnostic imaging, while figures are all other images,
generally including data plots and illustrations.
19. Provide evidence of relationships to other CCRs. This field may include identifiers (e.g., PMIDs) of other reports in the data set cited by
or referencing this report.
20. Provide evidence of relationships to clinical trials. This field may include identifiers of clinical trials citing this CCR. Identify trials by their
ClinicalTrials.gov identifiers, preceded by NCT, or other stable identifier.
21. Include database crosslinks corresponding to this document, including identifiers, preferably as database names and stable URLs.
4. Acknowledgements
Notes: Values in this category identify document-level features yet have little consistent structure across publications. They provide details
regarding the organizations providing support for a CCR and related work. This category also includes a field for the total count of references
cited by an article: this is intended to provide a rough metric of the degree to which a document has conceptual relationships with other
biomedical documents of any type. Within the four data types in this section, provide the following.
1. Specify all funding sources supporting the work and corresponding PI as well as relevant award numbers. The first value, Funding Source,
should include the names of all organizations providing financial support for the work.
1. Separate organizations with semicolons and spaces, e.g., National Institutes of Health/National Cancer Institute; DOE; Smith-Park
Foundation.
2. For the following value, Award Number, specify any award numbers or specific designations provided along with the recipients
of the awards, where appropriate, as initials of the recipients in parentheses, e.g., R01HL123123 (to JP), NS12312 (to JP, JS),
research training fellowship (to JS). Authors may explicitly state that no corresponding information is available (e.g., “no funding was
received”); in these cases, use the text provided by the authors as the Funding Source value. Otherwise, the value should be NA.
2. Specify disclosures/conflicts of interest as specified by the authors, e.g., JP is a consultant for DrugCo. Authors may explicitly state that no
corresponding information is available (e.g., “no conflict of interest is declared”); in these cases, use the text provided by the authors as the
Disclosures/Conflict of Interest value. Otherwise, as above, the value should be NA.
3. Specify a numerical count of all references cited by the document, not including those provided in any supplementary material. No reference
text should be included in this field.
Representative Results
An example of the annotation process is shown in Figure 2. This case22 describes a presentation of infection by the bacterial pathogen
Burkholderia thailandensis. For reference, the relevant portion of this CCR is provided in plain text format in Supplementary File 1; some
research findings are also presented in this report and are included for comparison. In practice, converting reports provided in HTML or PDF
format to plain text may improve the efficiency and ease of metadata extraction.
Examples of two sets of completed CCR metadata annotations are provided in Table 2. The first of these examples is mock data to illustrate
the ideal format of each value, while the second example contains values extracted from a published CCR on a rare condition, acrodermatitis
enteropathica23.
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Figure 1. Workflow for Case Report Annotation. The protocol described here provides a method for identification of textual features frequently
present within clinical case reports. This process requires assembly of a document corpus. The product of the annotation process, once
aggregated into a single file, permits identification of text features associated with medical concepts and their descriptions within case reports.
Please click here to view a larger version of this figure.
Figure 2. Identification of Concept-Specific Text in a Clinical Case Report. Beginning with the text of a case report, a manual annotator may
progress through the document, identifying segments of text corresponding to each component of the metadata template. Identification features
are highlighted in blue. Text corresponding to medical concepts are in red and labeled with their type; all highlighted text in the third column
refers to the Pathology type. Please click here to view a larger version of this figure.
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Category Description ICD-10 Chapter ICD-10 Code Range
cancer Any type of cancer or malignant
neoplasm.
II C00-D49
nervous Any disease of the brain, spine, or
nerves.
VI G00-G99
cardiovascular Any disease of the heart or
vascular system. Does not include
hematological diseases.
IX I00-I99
musculoskeletal and rheumatic Any disease of the muscles,
skeletal system, joints, and
connective tissues.
XIII M00-M99
digestive Any disease of the gastrointestinal
tract and digestive organs,
including the liver and pancreas.
XI K00-K95
obstetrical and gynecological Any disease relating to pregnancy,
childbirth, the female reproductive
system, or the breasts.
XIV; XV O00-O9A; N60-N98
infectious Any disease causes by infectious
microorganisms.
I A00-B99
respiratory Any disease of the lungs and
respiratory tract.
X J00-J99
hematologic Any disease of the blood, bone
marrow, lymph nodes, or spleen.
III D50-D89
kidney and urologic Any disease of the kidneys or
bladder, including the ureters,
as well as the male reproductive
organs, including the prostate.
XIV N00-N53; N99
endocrine Any disease of the endocrine
glands, as well as metabolic
disorders.
IV E00-E89
oral and maxillofacial Any condition involving the mouth,
jaws, head, face, or neck.
XI; XIII K00-K14; M26-M27
eye Any condition involving the eyes,
including blindness.
VII H00-H59
otorhinolaryngologic Any condition of the ear, nose, and/
or throat.
VIII H60-H95; J30-J39
skin Any disease of the skin. XII L00-L99
rare A special category reserved
for reports of rare diseases,
defined as those impacting
fewer than 200,000 individuals
in the United States (see https://
rarediseases.info.nih.gov/diseases)
NA NA
Table 1. Disease Categories for Document Annotation. The categories listed here are those to be used for the Disease System data type
in the document metadata template. As each disease presentation may involve multiple organ systems or etiologies, a single clinical case
report may correspond to multiple categories. These categories largely follow those used to differentiate sections of the International Statistical
Classification of Diseases and Related Health Problems, revision 10 (ICD-10) code system: corresponding ICD-10 chapters and code ranges are
provided. Some categories, such as that for oral and maxillofacial disease, correspond to multiple sections of the ICD-10 system.
46
Journal of Visualized Experiments www.jove.com
Copyright © 2018  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported
License
September 2018 |  139  | e58392 | Page 7 of 10
Data Type Example #1 Example #2 (Cameron and McClain 1986)
Document and Annotation Identification
Internal ID CCR005 CCR2000
Annotation Date Mar 2 2018 Mar 1 2018
Case Report Identification
Title A case of endocarditis. Ocular histopathology of acrodermatitis
enteropathica.
Authors Grant AB;Chang CD Cameron JD;McClain CJ
Year 2017 1986
Journal World Journal of Medicine and Case Reports British Journal of Ophthalmology
Institution Department of Medicine, Division of Cardiology,
First General Hospital, Boston, Massachusetts,
USA
Department of Ophthalmology, University
of Minnesota Medical School, Minneapolis,
Minnesota 55455
Corresponding Author Grant AB Cameron JD
PMID 25555555 3756122
DOI 10.1011/wjmcr.2017.11.001 NA
Link https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC9555555/
https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1040795/
Language English English
Medical Content
Key Words brucellosis; endocarditis; mitral valve NA
Demography 37-year-old male male child
Geographic Locations Florida; Rio de Janeiro, Brazil NA
Life Style smoker; drinks alcohol occasionally NA
Family History third of five children of consanguineous
parents; younger brother has chronic eczema
NA
Social History construction worker NA
Medical/Surgical History history of fatigue 8 pound 9 ounce (3884 g) product of an
uncomplicated, full term pregnancy; in good
health until age 1 month when he developed
a blistering skin rash on his cheeks; rash
spread to involve the skin around the eyes,
nose, and mouth; skin lesions were also
noted on the abdomen and extremities;
diarrhoea and failure to thrive; skin biopsy
at that time showed parakeratosis typical of
acrodermatitis enteropathica; treated over
the next six years with intermittent courses of
broad spectrum antibiotics, breast milk, and
diodoquin; partially responded; developed
total alopecia, intermittent acrodermatitis, and
intermittent diarrhoea with suboptimal weight
gain; spasticity attributed to central nervous
system involvement by the ae had developed
by 8 months of age; several episodes of
cardiopulmonary arrest at 11 months; lack of
co-ordination of his vocal cords; tracheostomy;
by age 18 months the child developed
searching nystagmus associated with bilateral
optic atrophy and slight attenuation of retinal
vessels as well as signs of psychomotor
retardation; bilateral keratoconjunctivitis; skin
rash; second skin biopsy performed at age
3 again showed parakeratosis typical for ae;
severe skin rash and diarrhoea; bilateral gross
anterior corneal opacities were seen which
had completely resolved by the time he was
reexamined at age five; frequent infections
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including otitis media, urinary tract infections,
and skin infections
Disease System cardiovascular; infectious digestive; skin; eye; rare
Signs and Symptoms palpitations and dyspnea in the previous week;
presented with lethargy, headache, and chills
severe blepharoconjunctivitis and bilateral
anterior corneal vascularisation; severe skin
rash and diarrhoea; gram-negative bacterial
sepsis; skin lesions typical of acrodermatitis
enteropathica, absence of thymic tissue,
marked degeneration of the optic nerves,
chiasm, and optic tracts and extensive
cerebellar degeneration
Comorbidity hypertension; hyperlipidemia NA
Diagnostic Techniques and Procedures Physical examination; electrocardiography;
blood cultures
ocular examination; necropsy
Diagnosis Brucella endocarditis acrodermatitis enteropathica
Laboratory Values increase in c-reactive protein (9 mg/dl); alkaline
phosphatase (250 u/l)
NA
Pathology Brucella melitensis was cultured from blood
samples
right and left eyes were similar in appearance;
corneal epithelium was reduced in thickness to
one to three cell layers of flattened squamous
epithelial cells over the entire surface of the
cornea; all polarity of the epithelium was lost.
bowman's membrane could be identified only in
the periphery of the right cornea. no bowman's
membrane could be identified in the left cornea.
neither degenerative nor inflammatory pannus
could be identified in either eye; extensive
atrophy of the circular and oblique muscles
of the ciliary body; some posterior migration
of lens capsular epithelium and early cortical
degenerative changes; extensive degeneration
of the retinal pigment epithelium throughout
the posterior pole; retina was attached and
showed mild autolytic changes throughout;
some preservation of rod and cone outer
segments in the posterior pole, however, these
structures were completely lost anterior to the
equator; extensive loss of the ganglion cell and
nerve fibre layers of both eyes; nearly complete
atrophy of the disc and adjacent optic nerve
Pharmacological Therapy gentamycin 240 mg/iv/daily NA
Inverventional Therapy prosthetic valve replacement NA
Patient Outcome Assessment recovery was uneventful; discharged home died in 1971 (age 7)
Diagnostic Imaging/Videotape Recording 2;1;0;1 7;0;0;0
Relationship to Other Case Reports 5555555 23430849
Relationship with Clinial Trial NCT05555123 NA
Crosslink with Database MedlinePlus Health Information: https://
medlineplus.gov/ency/article/000597.htm
HighWire - PDF: http://bjo.bmj.com/cgi/
pmidlookup?view=long&pmid=3756122;
Europe PubMed Central: http://europepmc.org/
abstract/MED/3756122; Genetic Alliance: http://
www.diseaseinfosearch.org/result/143
Acknowledgements
Funding Source National Institutes of Health/National Heart,
Lung, and Blood Institute
The Minnesota Lions Club; Research to
Prevent Blindness; Veterans Administration;
Office of Alcohol and Other Drug Abuse
Programming of the State of Minnesota
Award Number R01HL123123 (to AG) NA
Disclosures/Conflict of Interest Dr. Grant is a paid spokesperson for DrugCo. NA
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Table 2. Standardized Metadata Template for Clinical Case Reports, with Example Annotations. A set of features common to clinical case
reports and facilitating their concept-level annotations is shown here. This template is arranged into three primary sections: Identification, Medical
Content, and Acknowledgments, denoting the purpose and additional value afforded by each type of case report feature. This table contains
two sets of example annotations, one of a fictionalized case report, and another set derived from a report on the condition acrodermatitis
enteropathica23.
Supplementary File 1. Text of a clinical case report (Chang et al. 2017). Please click here to download this file.
Discussion
Implementation of a standardized metadata template for CCRs can make their content more FAIR, expand their audience, and extend their
applications. Following the traditional use of CCRs as educational tools in medical communications, healthcare trainees (e.g., medical students,
interns, and fellows), and biomedical researchers may find that summarized case report contents enable more rapid comprehension. The
greatest strength of metadata standardization with CCRs, however, is that indexing these data transforms otherwise isolated observations into
interpretable patterns. The protocol provided here can serve as the first step in a workflow for working with CCRs, whether this workflow consists
of epidemiological analysis, post-marketing drug or treatment surveillance, or broader surveys of pathogenesis or therapeutic efficacy. Structured
features identified within CCRs can provide a useful resource for researchers focusing on disease presentations and treatments, particularly
for rare conditions. Clinical researchers may find data on past treatment regimens to analyze recorded symptoms or side effects and degree
of improvement under previous standards of care. The data may also drive broader analyses of a new treatments based on efficacy, lack of
adverse effects or toxicity, or on drug targeting differences in gender, age group, or genetic background.
The benefits provided by structured metadata are similarly applicable to computational workflows designed to parse or model medical language.
Structured CCR features may also provide evidence of areas where report authors may provide more easily machine-readable (and in some
cases, human-readable) content. Variance among CCRs can result from a lack of explicitly provided observations: e.g., a patient's exact
age may not be specified. Similarly, clinicians may not mention tests if the diagnostics or their results were considered trivial. By providing
examples of gaps necessary for in-depth analysis, enforcing structure on CCRs highlights potential improvements. In a broader perspective, a
greater availability of structured text data from medical documents supports natural language processing (NLP) efforts to learn from big data in
healthcare24,25.
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Clinical case reports (CCRs) provide an important means of sharing clinical experiences about atypical
disease phenotypes and new therapies. However, published case reports contain largely unstructured and
heterogeneous clinical data, posing a challenge to mining relevant information. Current indexing
approaches generally concern document-level features and have not been speciﬁcally designed for CCRs. To
address this disparity, we developed a standardized metadata template and identiﬁed text corresponding
to medical concepts within 3,100 curated CCRs spanning 15 disease groups and more than 750 reports of
rare diseases. We also prepared a subset of metadata on reports on selected mitochondrial diseases and
assigned ICD-10 diagnostic codes to each. The resulting resource, Metadata Acquired from Clinical Case
Reports (MACCRs), contains text associated with high-level clinical concepts, including demographics,
disease presentation, treatments, and outcomes for each report. Our template and MACCR set render CCRs
more ﬁndable, accessible, interoperable, and reusable (FAIR) while serving as valuable resources for key
user groups, including researchers, physician investigators, clinicians, data scientists, and those shaping
government policies for clinical trials.
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Background & Summary
Clinical case reports (CCRs) are a fundamental means of sharing observations and insights in medicine.
A wealth of knowledge exists within this venerated and actively growing area of medical publishing1.
Unfortunately, many of these largely unstructured text data lack adequate metadata denoting speciﬁc
clinical events. As a result, our ability to curate a comprehensive set of reports relevant to a disease of
interest is inadequate, and extraction of the clinical insights contained within is limited. Our Metadata
Acquired from CCRs (MACCRs), prepared by domain experts, enriches CCRs with detailed metadata,
establishing a ﬁndable, accessible, interoperable, and reusable (FAIR)2 data resource and empowering
researchers to form in silico cohorts of disease, amplify small sample size studies, and leverage the
cumulative power of many reports for statistical analyses.
More than 1.89 million CCRs have been published as of August 2018, with over half a million in the
last decade. CCRs serve as teaching tools, elucidating the reasoning behind diagnoses and management
conclusions. Throughout history, CCRs have provided accounts of emerging diseases, their treatments,
and their genetic backgrounds3–5. The ﬁrst treatment of human rabies by Louis Pasteur in 18856,7, the
ﬁrst application of penicillin in patients8, and an early study of the retroviral human T-cell lymphoma
virus (HTLV)9 were all reported through CCRs3. CCRs are a ﬁrst line of evidence, serving as both a
source of individual pathologies and the basis of study for population-level trends that may otherwise go
unnoticed5,10. These reports remain the only formally published mechanism for exchanging clinical
observations and are not subject to the extensive privacy concerns of electronic health records (EHRs).
The text data in these CCRs are largely unstructured, vary widely in content, and contain interrelated
phenomena, limiting their use as a structured resource. Existing resources for indexing and enforcing
structure on biomedical documents, including Medical Subject Headings (MeSH) and their associated
tools11,12, the ongoing Informatics for Integrating Biology and the Bedside (i2b2) curated resources13,14,
and the CRAFT15, AnatEM16, NCBI disease17, and newly-available PubMed Phrases18 corpora are useful
for focused natural language processing (NLP) approaches. Annotations of free-text resources, such as
adverse reactions on drug labels19, are additional sources of expert-guided structure for unstructured text.
However, these resources have limited applications with CCRs, as most of them have not been designed
to model clinical narratives. As a result, there exists a signiﬁcant gap between the clinical data we generate
and our ability to convert it to knowledge. Clinical controlled vocabularies and coding systems (e.g.,
ICD-1020 or LOINC21) can help to bridge this gap but have rarely been used with published clinical
reports. Furthermore, despite the existence of several resources (e.g., immuneXpresso22) offering utility
on biomolecular text mining in the context of disease, information is fragmented with limited clinical
perspective. Therefore, we set out to expand the value of CCRs as a vital biomedical knowledge resource
through extensive metadata creation.
This MACCR dataset contains free-text selections from 3,100 CCRs, with over 32,000 manually
annotated medical features across a variety of clinical presentations structured into 15 different types of
medical concepts (Table 1; Figs 1 and 2). We curated the CCRs to ensure they would provide a general
model of clinical language, then performed expert-guided annotation to extract a comprehensive and
nuanced array of textual features. As CCRs often describe infrequently observed symptoms and diseases,
our MACCR set includes over 700 reports of rare disease presentations, with additional focus on 7
selected mitochondrial diseases. Our goal in developing this resource is to provide a manageable,
structured set of metadata on clinical events and case descriptions. In so doing, we render case reports
more ﬁndable and the information contained within more accessible. One effect of making CCRs more
FAIR is to facilitate the discovery and study of these invaluable sources of clinical insight, enhancing the
potential for researchers and clinicians to gain a better understanding of diseases and their treatment. To
guide those interested in employing the MACCR dataset in their research, we present 5 feasible primary
study objectives (detailed in Usage Notes) that may be pursued through downstream analysis by
researchers, physician investigators, clinicians, data scientists, IP ofﬁcers, pharmaceutical companies, and
those shaping government policies for clinical trials.
Methods
To assemble our set of Metadata Acquired from Clinical Case Reports (MACCRs), we performed three
primary stages of tasks. First, we designed a structured data template including the primary features of
most case reports and curated a corpus of case report documents along with their associated metadata
records. Next, we extracted metadata from each document in the corpus using manual and automated
methods. Finally, all metadata records were aggregated into a single set of documents and veriﬁed. An
overview of our approach is provided in Fig. 1.
Metadata template and curation
Our data template (Table 1) includes metadata on three aspects of information collected for each CCR:
identiﬁcation, medical content, and acknowledgements. The identiﬁcation features are primarily used to
distinguish documents by bibliographic features, including the title, authors, journal, publication date,
and unique identiﬁers such as DOI and PMID. The majority of the metadata collected in the medical
content is concept-level. This includes text segments corresponding to 15 different clinical concepts,
detailed in Table 1, where a segment may vary in length from a single word to multiple sentences. A
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Field Data Type Example
Case Report Identiﬁcation (Findable)
Title Text Case report: a case of cardiogenic shock and hyperparathyroidism.
Authors Text Neeley AB, Mossman ET
Year Text 2017
Journal Text Midwest Journal of Medicine
Institution Text Department of Cardiology, Mt Vernon Hospital, Mt Vernon, Wisconsin, USA
Corresponding Author* Text Neeley AB
PMID Identiﬁer 29999555
DOI Identiﬁer 10.1011/mwjmed.2017.10.001
Link Identiﬁer http://www.mwjmed.org/doi/full/10.1011/mwjmed.2017.10.001
Language* Text English
Medical Content (Accessible, Interoperable, Reusable)
Key Words Text Shock, cardiogenic; hyperparathyroidism; fatigue; headache
Demography** Text Male; 40 years of age
Geographic Locations*** Text Mt Vernon, Wisconsin, USA
Life Style Text Smoker
Family History Text no family history of heart disease
Social History Text worked as a truck driver
Medical/Surgical History Text history of fatigue; splenectomy performed six years previously
Disease System Text Cardiovascular diseases
Signs and Symptoms Text presented with lethargy, headache, diaphoresis, and twitching in all four limbs; cardiac enzyme levels were
elevated, ventricular tachycardia
Comorbidity Text alopecia
Diagnostic Techniques and Procedures Text Electrocardiogram; dual energy X-ray absorptiometry (DXA)
Diagnosis Text hyperparathyroidism
Laboratory Values Text serum calcium concentration was 3.0 mmol per liter; complete blood cell counts normal
Pathology Text endomyocardial biopsy did not reveal a myocardial pathology
Pharmaceutical Therapy Text bisphophonates
Interventional Therapy Text ventilated on the 2nd day post-surgery due to respiratory distress
Patient Outcome Assessment Text Patient developed refractory shock; died of persistent ventricular tachycardia
Diagnostic Imaging/Videotape Recording**** Numerical 3;0;0;0
Relationship to Other Case Reports* Text / Identiﬁer PMID: 5555555
Relationship with Clinical Trial* Text / Identiﬁer PMID: 5551111
Crosslink with Database* Text / Identiﬁer MedlinePlus Health Information : https://medlineplus.gov/parathyroiddisorders.html
Acknowledgements
Funding Source Text National Institutes of Health/National Heart, Lung, and Blood Institute
Award Number Identiﬁer R01HL123123 (to AN)
Disclosures/Conﬂict of Interest Text Dr. Neeley is a paid consultant for Medicaltech Inc.
References Numerical 12
Table 1. Standardized metadata template for clinical case reports. ∗The template and associated
processing workﬂow support use of these ﬁelds, though their values are not provided in the MACCR set.
∗∗Demography details are converted to consistent values prior to inclusion in the MACCR set. ∗∗∗If not
provided within document text, geographic location is inferred from the associated institution. ∗∗∗∗Purely a
numerical count of the total number of clinical images, ﬁgures, videos, and tables, respectively, published along
with the main text of the report.A set of features common to clinical case reports and facilitating their concept-
level metadata extraction. This template is arranged into three primary sections: Identiﬁcation, Medical Content,
and Acknowledgments, denoting the purpose and additional value afforded by each type of case report feature.
Here, we have also included relevancy of the ﬁrst two categories to promoting FAIR standards. A single document
contains the majority of these features; metadata records include the span of these features (i.e., the value referring
to a single concept). Examples shown here are simulated but representative of dataset contents. Data Type refers to
the type of source data, rather than the dataset contents; this may be “Text” if free-text (this may contain numerical
components, though these are identiﬁed in subsequent processing steps), “Identiﬁer” if a unique database identiﬁer
or other structured value speciﬁc to the document, or “Numerical”. Please note that the Acknowledgements section
provided here, including the Disclosures/Conﬂict of Interest statement, is an example only and not intended to
claim any funding provided to or competing interest by the authors.
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single concept may also correspond to multiple text segments within a given document. The
acknowledgements metadata provides details for disclosures and sponsorship.
The metadata in our dataset are sourced from CCRs indexed by MEDLINE. We ﬁrst deﬁned the CCR
corpus from which our metadata are extracted using our heartCases software (https://github.com/UCLA-
BD2K/heartCases); heartCases aggregates metadata provided with each MEDLINE entry to determine
features common to a set of documents (e.g., their top publication years, journals, and MeSH
descriptors). We then assigned each CCR to at least one of 16 disease categories based on their MeSH
descriptors or presence of a MeSH descriptor in a title (Table 2). The set of terms for each disease
category was deﬁned using corresponding segments of the MeSH Tree (https://meshb.nlm.nih.gov/
treeView); for example, all CCRs in the “digestive” category match primary and entry terms at or below
the following points on the MeSH Tree: A03.159, A03.556, A03.620, A03.734, C06.130, C06.198, C06.267,
C06.301, C06.405, C06.552, C06.689, C06.844, and G10.261, or a total of 3,356 different terms. A match
may include a matched MeSH term used to index the document or presence of the term in the document
title. With the goal of assembling a generally representative set of CCRs, we selected documents from the
larger corpus such that the assignment to each disease category resembled that seen across all CCRs. The
most popular topics across CCRs in general are therefore popular topics in our source CCR set as well. In
an effort to ensure representation of a variety of disease presentations – one of the inherent strengths of
case reports – we also selected reports of rare diseases (i.e., those affecting fewer than 200,000 individuals
in the United States, as deﬁned by the NIH NCATS Genetic and Rare Diseases Information Center
[https://rarediseases.info.nih.gov/diseases/]) such that the set included 5 to 10 reports each for over 100
rare diseases. The resulting reference metadata set is sourced from 3,100 CCRs spanning 15 major disease
categories, as well as a subset of rare diseases (Table 2).
Manual annotation was performed by 12 annotators familiar with medical terminology and, for
subsets of rare diseases, with the clinical features underlying these diseases (e.g., for rare mitochondrial
diseases, annotators possessed an understanding of the underlying mitochondrial physiology and
corresponding mutations). Our roster of curators comes from clinical fellows (4), post-doctoral fellows
(6), and senior graduate students (2). Full instructions followed by annotators are detailed in our
Metadata Extraction Guide, included with the data ﬁles (Metadata Extraction Guide, Data Citation 1).
For each CCR in the corpus, one annotator read the full text of the document and extracted text phrases
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Figure 1. Data creation workﬂow. To assemble the set of Metadata Acquired from Clinical Case Reports
(MACCRs) we ﬁrst assembled a corpus of 3,100 published case reports. Using a document metadata template
including document-level identiﬁcation and acknowledgement features (i.e., citation data such as title; Medical
Subject Headings [MeSH terms]) and concept-level medical content features (e.g., descriptions of patient
demography, clinical signs and symptoms, or outcomes), a team of medical experts manually identiﬁed text
from each document corresponding to each feature. More speciﬁc terms were identiﬁed through automated
approaches. To ﬁnalize this dataset, we aggregated all document metadata records into a single ﬁle. We
normalized categorical features, veriﬁed, and cleaned these data, which are available as the MACCR set.
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Figure 2. Contents of the MACCR dataset. (a) Concept overlap among CCRs in the MACCR set. We
assigned each report to one or more disease categories based on involvement of particular organ systems.
Reports describing presentations of rare diseases, including mitochondrial rare diseases, were assigned to the
Rare Disease category as well. Here, we show the total count of reports labeled with single or multiple disease
categories (Disease Category Overlap, top) as an UpSet plot59. Counts of reports involving rare diseases (n =
751) are highlighted in red. Total counts irrespective of overlap with other categories are also shown at right.
For example, 435 CCRs involve cardiovascular disease (CVD) without speciﬁc involvement of other organ
systems, yet 967 CCRs involve CVD alone or along with other disease categories. Otorhinolaryngologic reports
constitute the smallest category in the MACCR set (n = 58); their counts are omitted here. (b) Distribution of
disease categories across all published case reports. Here, we determined disease category assignment across all
1.89 million published CCRs (as of August 2018) using sets of MeSH terms corresponding to each category. As
in Part A, a report may belong to multiple categories. More than a quarter of all reports in this broad set involve
cancer, differing from the report distribution in the MACCR set, though in both sets, cancer, cardiovascular
disease, and neuronal disease are the most common three disease categories. (c) Contribution of mitochondrial
disease CCRs. 246 CCRs cover a sample of rare mitochondrial diseases, including Barth syndrome, carnitine
deﬁciency, and deﬁciencies of the respiratory chain complexes. The distribution of CCR publication year is
displayed on the left for each disease, and the affected components of the mitochondrion are represented in the
diagram to the right. Complex I, II, III, IV, and V deﬁciencies each cause impairment in their respective
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corresponding to each component of the data template, avoiding extended discussion sections or clinical
studies except when these sections were the only source of target metadata. They populated the template
with these phrases, delimiting each distinct phrase with a semicolon, then completed the annotation set
by adding bibliographic metadata as presented in the document. Annotators assigned each CCR one or
more of 16 different disease categories based on both document content and MeSH descriptors, each
corresponding to an organ system or general classiﬁcation of disease presentations (e.g., cardiovascular,
endocrine, infectious, or rare disease, etc.; Table 2). These categories were assigned based on presence of
related symptoms, co-morbidities, and etiologies rather than primary diagnosis in order to determine
conceptual overlap between cases. We did not include a category for congenital or genetic disorders and
focused instead on the clinical signs of these presentations. Finally, annotators determined the count of
additional data elements in each CCR, counting clinical images (i.e., any photograph, micrograph, or
direct result of a diagnostic procedure such as an electrocardiogram), ﬁgures (i.e., any assembled image or
data visualization), tables, and videos, not counting supplemental materials.
ICD codes and interoperability
In order to facilitate interoperability with existing ontologies and support efforts at gaining a systematic
understanding of disease, we assigned codes from a standard set of diagnostic identiﬁers to reports from a
subset of the MACCR set. We sought to reveal shared and common symptoms as well as rare and unique
characteristics underlying mitochondrial disease, constructing digital maps of disease symptomology for
documents in the rare mitochondrial disease (RMD) subset using ICD-10-CM codes (International
Statistical Classiﬁcation of Diseases and Related Health Problems, tenth revision, clinical modiﬁcation,
2018 release). The document corpus is assembled from 246 CCRs, each describing an individual
presentation of one of six selected mitochondrial diseases (Barth syndrome, primary carnitine deﬁciency,
or a deﬁciency of mitochondrial complex II, III, IV or V). For each document, two separate annotators
familiar with mitochondrial disease pathologies identiﬁed speciﬁc concepts within the full text of the case
component of the respiratory chain, resulting in a range of cardiovascular, neurological, muscular, and
metabolic phenotypes. Barth syndrome is caused by a mutation in the tafazzin protein that renders it incapable
of creating properly formed cardiolipin (CL) for the inner mitochondrial membrane (IMM). Phosphati-
dylcholine (PC) is unable to form the tight bends of the cristae, severely limiting energy generation and leading
to cardiovascular complications. The timeline below depicts key advancements and discoveries relating to rare
mitochondrial disease diagnosis. OMM: outer mitochondrial membrane. IMS: intermembrane space.
Category Description
cancer cancer or neoplasms
nervous brain, spine, or nerve involvement
cardiovascular heart or cardiovascular involvement, not including conditions speciﬁc to the blood
musculoskeletal and rheumatic muscle, bone, joints, or connective tissue involvement
digestive gastrointestinal involvement, including liver, pancreas, or gallbladder
obstetrical and gynecological pregnancy, childbirth, the female reproductive system, or the breasts
infectious infection by microorganisms
respiratory respiratory tract involvement
hematologic blood, bone marrow, lymph nodes, or spleen involvement
kidney and urologic kidney or bladder involvement; any involvement of the male reproductive organs
endocrine endocrine gland involvement and metabolic disorders
oral and maxillofacial mouth, jaws, head, face, or neck, including dental issues
eye eye involvement and visual issues
otorhinolaryngologic ear, nose, or throat involvement, including hearing issues
skin skin involvement
rare rare diseases; see above
Table 2. Disease system categories. A set of categories for grouping case reports on the basis of related
symptoms, co-morbidities, and etiologies. A report may belong to more than one category, particularly in
clinical presentations involving multiple disease systems and/or cancer of one or more systems. The special
category of ‘rare’ is speciﬁc to reports of rare diseases affecting no more than 200,000 individuals in the United
States at a time.
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report corresponding to ICD-10-CM codes, including those for symptoms. Codes are included if their
concepts are part of a given patient’s clinical presentation, but not if they are only discussed or proposed.
In ﬁnal data ﬁles, observations are treated as binary values (1 if identiﬁed, 0 if not identiﬁed) and split
into two different sets: in the ﬁrst, each code is provided separately, while in the second, codes are
aggregated into categories on the basis of their ICD-10 code blocks (https://www.cdc.gov/nchs/data/icd/
10cmguidelines_fy2018_ﬁnal.pdf). For example, one or more codes between C00 and D49 assigned for a
given document will yield a score of 1 for the “Neoplasms” category corresponding to this code block. By
incorporating ICD-10 codes and MeSH descriptors, we enhance interoperability in this subset of the
MACCR set.
Data quality control and validation
Quality control was implemented throughout the manual curation process with regular milestone
meetings and a closely collaborative research environment designed to align and standardize methods for
metadata extraction and foster consistency among all curators. Manual metadata extraction from
individual CCRs was followed by aggregation and additional quality control through post-processing. All
metadata records were combined into a single ﬁle using Python and R scripts (Extract.py and
QualityControl.R; see Code Availability). This workﬂow uses basic natural language processing functions
to perform the following: retrieval and veriﬁcation of document details (e.g., title, database identiﬁers, and
publication details), assignment of each document to one of our major disease categories, and conversion
of patient age to a numerical value. For patient age identiﬁcation in particular, all values are treated
as integers, rounded down (e.g., a patient aged 5.5 years is assigned a value of 5; those aged o1 year are
assigned a value of zero), or are estimated when not explicitly provided (e.g., a report of a patient in their
“sixties” is assigned an age value of 65). Features with insufﬁcient detail in the text are assigned a value of
“NA”. All text features are checked to ensure formatting consistency, and to verify database cross-links:
titles and author names are compared to MEDLINE records, DOIs and links are conﬁrmed and added
where missing, and journal names are normalized to include their full names as presented in the NLM
Catalog (https://www.ncbi.nlm.nih.gov/nlmcatalog/journals), but with the preceding “the” omitted. All
text ﬁeld delimiters (i.e., those denoting separate text segments within a single ﬁeld) are conﬁrmed to be
semicolons. Additionally, most text ﬁelds are converted to lowercase characters to enable easier
comparison and named entity recognition (NER23,24). Final validation of the dataset is performed
through observation of distributions of features within the MACCR set comparable to those seen in larger
collections of clinical documents (see Technical Validation for additional details).
Geographic distribution analysis is performed for validation and visualization of MACCR set features.
We developed an R Shiny app designed speciﬁcally for performing this analysis with clinical case reports
(see Code availability). Brieﬂy, this app ﬁrst identiﬁes the occurrence of all case reports indexed by
MEDLINE on the basis of their AD, or Afﬁliation, ﬁeld. This ﬁeld is largely unstructured and has changed
in format over time, so in order to provide additional detail and consistency, the text is processed to
identify speciﬁc names of countries and US states. Then, the institutional afﬁliation ﬁeld of each MACCR
record is parsed in an identical manner. Using a 2-proportion Z-test, counts of locations are compared
between the set of all available CCRs and those in the subset contributing metadata to our MACCR set to
identify locations with a statistically signiﬁcant (i.e., higher or lower) difference in proportion. The
differences are visualized on a world map with US states treated independently from each other.
Three additional ﬁles contain citation details, corresponding MeSH headings, and named entities
contained within the MACCR set. The citations for documents corresponding to each metadata record
are loaded into a Mendeley citation database and converted to BibTeX format. The list of all unique
MeSH headings is prepared by isolating unique MeSH descriptors, without modiﬁers, from each
MEDLINE-format citation of those corresponding to each metadata record in the MACCR set. To
determine the extent to which the metadata text segments correspond to a controlled vocabulary of
biomedical terms (i.e., with NER), we identify all named entities up to three words long present in each
medical content ﬁeld across all 3,100 MACCRs, based on entities within MeSH and SNOMED-CT as per
the UMLS Metathesaurus25.
Code availability
The code used to process and verify the MACCR dataset, along with documentation, is available at
https://github.com/UCLA-BD2K/MACCRs. This repository includes all utilities used in the assembly and
veriﬁcation of the MACCR metadata set, with the exception of the following two pieces of software.
Analysis of the complete corpus of CCRs, as part of the veriﬁcation of this dataset, was done using
heartCases, available at https://github.com/UCLA-BD2K/heartCases. The R Shiny App used for analysis
and visualization of case report geographic distributions is available at https://github.com/UCLA-BD2K/
Signiﬁcant-Mapping.
Data Records
Starting from the manually curated set of CCRs as deﬁned above, we obtain the full text records of each
report from PubMed/MEDLINE corresponding to each respective PubMed entry identiﬁer (PMID). Text
corresponds to the PubMed Central document version where possible; all other text is curated from
publicly-available document PDFs provided by journal publishers. As CCRs vary in structure and format
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(e.g., section headings vary, and a case description may be just one component of a document), curators
identify a single, primary case presentation section within each published record, then identify text
corresponding to the concepts within the CCR metadata extraction template (Table 1). The contents of
the MACCR set are, therefore, metadata with respect to each CCR.
The primary data ﬁle (MACCRs.tsv, Data Citation 1) is provided in UTF-8, tab-delimited format, such
that the metadata for each CCR is a single line in the ﬁle. Each column corresponds to a distinct metadata
type. Within text columns, distinct text segments are delimited using semicolons and most are in
lowercase only to facilitate easier searching. This ﬁle contains 1 metadata record for each of 3,100 unique
documents. The corresponding reports have publication dates spanning from 1956 to 2018 and were
originally published in 1,020 different journals. Across the 15 different concept-level free-text features
identiﬁed within each report, the set contains 2,980 unique descriptions of diagnostic techniques/
procedures and 3,026 unique clinical diagnoses, among other descriptions in context. Descriptions of all
data ﬁelds are provided in our MACCR File Guide (MACCR File Guide, Data Citation 1). Full citations
for all CCRs in the MACCR set are provided in BibTeX format within the citation ﬁle
(MACCR_citations.bib, Data Citation 1).
We have provided our metadata extraction template (TEMPLATE.xlsx, Data Citation 1) to facilitate
adaptation to new studies through the creation of similar CCR-based datasets. The template is provided
as an Excel spreadsheet to ensure universality and ease of use. Each data type is identiﬁed in each row of
the ﬁrst column and corresponding values extracted from the CCR text are provided in the fourth
column. The ﬁfth column is used to identify values provided through PubMed records and indexing
alone; for medical content, these values are MeSH descriptors (if they exist) and any provided modiﬁers.
The second and third columns contain counts to indicate the presence of content in the fourth and ﬁfth
columns, such that a value of ‘1’ corresponds to any value other than a blank cell. To enable this
comparison, cells without any relevant information for a particular CCR are left blank. Please see the
Metadata Extraction Guide (Metadata Extraction Guide for the MACCR set, Data Citation 1) for further
details of the process.
We additionally provide the set of all unique MeSH headings applicable to the source CCRs for the
MACCR set (MACCR_mesh.tsv, Data Citation 1). This ﬁle provides a list of headings in the ﬁrst column,
with one unique heading per line and without further modiﬁcations. The second column provides the
MeSH root category (as per the 2018 release; https://www.nlm.nih.gov/mesh/) for each heading as a
single letter, e.g., the heading “Spleen” is in the Anatomy category, or category A. For headings with
multiple potential codes within the MeSH hierarchy, the category of the ﬁrst listed in the MeSH index ﬁle
is used (e.g., “Outcome Assessment (Health Care)” has codes in categories H and N and is considered to
be in category H). The headings “Male” and “Female” have no location in the MeSH tree and no category.
Here, all reports contributing metadata to the MACCR set have at least one associated MeSH descriptor
through MEDLINE.
Named entity recognition (NER)23,24 results (MACCR_entities.tsv, Data Citation 1) are provided as an
additional means of illustrating concepts within the MACCR set. Each line in this ﬁle contains the PMID
of the report corresponding to each metadata set, followed by a list of named entities identiﬁed within
selected metadata ﬁelds, as indicated in the heading. Named entities are MeSH descriptors and
SNOMED-CT terms, as available through UMLS resources25.
Mitochondrial disease reports, covering six different diseases (Barth syndrome, primary carnitine
deﬁciency, or a deﬁciency of mitochondrial complex II, III, IV or V), contribute 246 reports to this
dataset. As the majority of these reports describe rare mitochondrial diseases, we refer to this subset as the
RMD subset. Metadata in the RMD subset include codes from ICD-10-CM such that symptoms and
diagnoses mentioned within each CCR are each identiﬁed using the most closely matching and speciﬁc
ICD-10-CM code, including symptom codes (codes R00.0 through R99). 500 unique codes were
identiﬁed across all RMD CCRs, with a total of 2,119 codes assigned. The presence or absence of each of
these 500 ICD-10-CM codes for each CCR is provided in its own ﬁle (MACCR_RMD_ICD10.tsv, Data
Citation 1), with one CCR per row, identiﬁed by its PMID in the ﬁrst column and the RMD category
(barth [for Barth syndrome], carnitine [for primary carnitine deﬁciency], or complex_I through
complex_V [for mitochondrial complex deﬁciencies]) in the second column. Each of the 500 unique
ICD-10-CM codes identiﬁed in the RMD set is represented in the following 500 columns. A value of “1”
indicates a given code matches clinical events described in the CCR, while a value of “0” indicates
matching material is not observed, though its omission from CCR text may not conclusively indicate its
absence. Additionally, we provide a compressed version of these data indicating presence or absence of
categories of codes in lieu of individual codes (MACCR_RMD_ICD10_Categories.tsv, Data Citation 1).
This ﬁle contains the PMID for one CCR and an RMD category in its ﬁrst and second columns,
respectively, as in the ﬁle described above. The following columns correspond to one of 20 chapter titles
from ICD-10-CM, each represented by a block of codes. A value of “1” indicates at least one ICD-10-CM
code in the speciﬁed chapter’s code block matches clinical events described in the CCR, while a value of
“0” indicates matching material was not observed. Inclusion of category-based observation only in this
ﬁle reduces the total observations to 1,073 across 20 blocks of codes.
This dataset itself meets the FAIR Data Principles. All ﬁles are provided through both Figshare (Data
Citation 1) and through Dryad (Data Citation 2). Metadata are assigned a globally unique and persistent
identiﬁer and registered through both of these searchable resources to make them Findable; the metadata
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are retrievable via this identiﬁer using an open, standardized, and free communications protocol to make
them Accessible; the metadata set uses a formal, broadly applicable vocabulary and domain-recognized
ontologies (MeSH and ICD-10) to make them Interoperable; and the metadata ﬁles contains detailed
provenance, licensing, and versioning information to make them Reusable. Out of the 9 metrics used by
FAIRShake (https://fairshake.cloud/), our dataset provides all 9 of the necessary values (Table 3).
Technical Validation
Distribution of disease categories vs. published case reports
We intend the MACCR set to be representative of the semantic and lexical variation present in reports
from a wide variety of medical presentations and specialties. Rather than focusing on reports describing a
single type of disease, the metadata in the MACCR set is sourced from clinical presentations spanning 15
disease groups, along with an additional category for rare disease presentations (Fig. 2a, and Table 2).
CCRs often describe rare disease presentations and clinically-relevant relationships not accessible through
any other public source. As one example, CCRs provided evidence for the theory that gadolinium-based
contrast agents are a trigger for the rare disease nephrogenic systemic ﬁbrosis26,27. By including a wide
variety of medical concepts in our corpus, we highlight the value of CCRs, particularly in their
descriptions of novel and often complex diagnostic processes. Further, we provide validation of MACCR
content relative to that seen across all CCRs outside the corpus.
Both the MACCR set and the set of all published CCRs are predominantly composed of reports of
cancer, cardiovascular disease, and neuronal disease (Fig. 2a-b). The variety of topics covered within the
MACCR set is demonstrated by the number of MeSH descriptors among the contributing reports: the
source reports for the MACCRs are indexed with 5,326 unique terms (MACCR_mesh.tsv, Data Citation
1), or 12,980 unique terms with their modiﬁers. For comparison, the full 2018 MeSH ontology includes
28,239 descriptors (https://www.nlm.nih.gov/mesh/) and the set of all 1.89 million CCRs published as of
August 2018 is indexed with 24,842 unique terms, or 786,256 unique terms with modiﬁers. Of the 5,326
MeSH terms in the MACCR set, 2,042 describe Diseases (category C), 1,208 describe Chemicals and
Drugs (category D), and 793 describe Analytical, Diagnostic and Therapeutic Techniques, and
Equipment (category E).
Rare disease subgroup membership
Our curation process ensures that the MACCR set includes descriptions of rare diseases across a variety
of disease subtypes. Rare diseases are deﬁned as those with an incidence in the U.S. of fewer than 1 in
20,000 individuals. These diseases are infrequently reported on in CCRs, primarily due to their inherent
rarity. The contribution of these reports to the MACCR set offers a novel advantage by providing a more
comprehensive representation of the language used in presentations of these diseases as compared to
more frequently described clinical presentations. Figure 2a highlights the contribution of rare diseases to
the MACCR set.
The MACCR set includes a focused subset of 246 rare mitochondrial disease (RMD) reports that
describe presentations of one of six rare mitochondrial diseases. The distribution of these reports in the
FAIRshake metric Score Support for metric
1. A standardized ID or accession number
is used to identify the dataset.
Yes; 1 Dataset provided with unique DOIs by Figshare and Dryad.
2. The dataset is described with metadata
using a formal, broadly applicable
vocabulary.
Yes; 1 Dataset is described using formal biomedical terminology, including diagnostic techniques and
procedures, signs and symptoms, etc., as well as MeSH terms and ICD-10 codes.
3. Information is provided on the
experimental methods used to generate the
data.
Yes; 1 All methods for ACCR metadata template generation provided along with raw data ﬁles.
4. The dataset is hosted in an established
data repository, if a relevant repository
exists.
Yes; 1 Dataset is hosted on the Figshare and Dryad repositories.
5. The dataset can be downloaded for free
from the repository.
Yes; 1 Dataset can be downloaded in .tsv format for free from the Figshare and Dryad repositories.
6. Version information is provided for the
dataset.
Yes; 1 Versioning begins with v1, and updated versions of the set will be v2, v3 etc.
7. Contact information is provided for the
creator(s) of the dataset.
Yes; 1 Contact information for the lead investigator is provided (Dr. Peipei Ping).
8. Information is provided describing how
to cite the dataset.
Yes; 1 Citation information is provided along with this publication.
9. Licensing information is provided on the
dataset’s landing page.
Yes; 1 Licensing information is provided through Figshare, Dryad, and Scientiﬁc Data.
Table 3. Support for FAIRShake metrics. Here, we provide scores for each of the metrics in the
FAIRshake (https://fairshake.cloud) rating system. The MACCR dataset fully meets each metric and
therefore has a score of “1” for each.
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MACCR set across their years of publication reﬂects time points of discovery and increased diagnosis
(Fig. 2c, left); the timeline presented in Fig. 2c highlights signiﬁcant advances in the identiﬁcation of
mitochondrial diseases and their etiology, as well as the development of diagnostic tools and standards.
These mitochondrial diseases in particular can be distinguished on the basis of deﬁciencies in crucial
molecular components: complex I, II, III, IV, and V deﬁciencies impair individual components of the
respiratory chain, while Barth syndrome is characterized by malformed cardiolipin, disturbing
mitochondrial membranes and reducing respiratory chain function (Fig. 2c, right). Though the resulting
sets of symptoms overlap noticeably, the overall range of symptoms covers cardiovascular, neurological,
muscular, and metabolic phenotypes, as evidenced by the range of ICD-10-CM codes assigned to this
subset of CCRs. Our subset of mitochondrial diseases therefore demonstrates how a collective
understanding of the presentation of a speciﬁc condition may be best gained through comparisons with
those of biologically similar diseases.
To validate the ICD-10-CM codes we assigned to each RMD report, we compare our code assignments
to those expected for speciﬁc diseases. The list of diagnostic criteria identiﬁed for our set of six diseases
generally follows consensus statements on mitochondrial disease diagnosis and treatment provided by
Parikh et al.28,29 and the Mitochondrial Medicine Society (http://mitosoc.org/news/). Because these
recommendations involve conditions that are frequently more speciﬁc than those described by ICD-10,
we use this list primarily as a source of high-level types of symptoms. For example, acidosis (ICD-10-CM
E87.2) is routinely described in each of the selected diseases, with the exception of Complex III deﬁciency.
This symptom appears in 69 out of 246 reports, often as a speciﬁc form; some forms are represented by a
unique ICD-10 code, such as 3-methylglutaconic aciduria (E71.111), while others, including lactic
acidosis, rely on the general code for identiﬁcation. Among the 5 mitochondrial respiratory chain
complex deﬁciencies, none have a speciﬁc diagnostic code within ICD-10; we collectively annotate them
with two codes for mitochondrial metabolism disorders (E88.40 and E88.49). Complex II and Complex V
deﬁciencies are described in 12 and 7 reports in this subset, respectively, and are associated with novel
hypertrophic cardiomyopathies (I42.2; seen in 7 reports across both disorders) and a lack of development
in childhood (R62.50; seen in 7 reports across both). Complex III deﬁciency is associated with
hypoglycemia (E16.2) in 17 out of 29 cases but is otherwise notable for its lack of distinguishing
characteristics in this set. Generalized muscle weakness (M62.81), while common across all RMDs, is
especially frequently described within reports on primary carnitine deﬁciency (18 out of 45, compared to
32 out of all 201 other reports). We also compare our code assignments to Barth syndrome diagnosis
criteria; speciﬁcally, that the disease presentation frequently involves neutropenia and 3-methylglutaconic
aciduria30. Out of 30 Barth syndrome reports, 26 describe neutropenia (D70.9), 24 describe dilated
cardiomyopathy (I42.0), 16 describe cardiomegaly (I51.7), 11 describe acidosis (E87.2), and 8 describe 3-
methylglutaconic aciduria (E71.111).
Chronological features
The reports corresponding to metadata in the MACCR set were originally published between 1956 and
2018, with 455 CCRs published from 2017 to 2018. Out of all 3,100 reports contributing metadata to the
MACCR set, 2,112 (68.1%) were published since 2007. Among 1.89 million CCRs indexed through
PubMed/MEDLINE with publication dates from 1936 to August 2018, more than 595,000 (31.5%) were
published since 2007. This skew toward more recent years in the MACCR set, relative to the distribution
of all published CCRs, is partially a conscious choice made during curation to focus on cases with well-
deﬁned diagnoses and general similarity in terminology. This difference also reﬂects the greater
accessibility of clinical case reports within the last decade.1 Two prominent sources are British Medical
Journal Case Reports (BMJ Case Rep) and Journal of Medical Case Reports (J Med Case Rep), which began
publishing in 2008 and 2007, respectively. These two journals alone have published more than 20,000
CCRs and contribute 166 reports (5.3%) to the MACCR set. Publications with longer histories, such as
the New England Journal of Medicine (NEJM), continue to publish CCRs as well. Though their editorial
stance on CCRs has changed over time31, NEJM has published nearly 10,000 case reports since 1949 and
2,224 since 2007, of which 101 and 75 are included in the MACCR set, respectively.
Demographic and geographic distribution of MACCRs
The distribution of demographic features among patients described in our MACCR dataset shows it is
not excessively skewed toward one subset of the patient population. Patient age presents a generally
consistent distribution: 890 (28.7%) reports describe clinical presentations with pediatric patients (i.e.,
less than 21 years old), 1,104 (35.6%) reports describe patients of at least 21 and no more than 50 years
old, and 1,051 (33.9%) reports describe patients of 51 years old or older. Just 55 (1.7%) reports did not
provide enough information to know or infer patient age. Some reports may span years or decades of
symptoms or treatment, so age remains a rough demographic value (in this case, age refers to patient age
at the beginning of a given clinical narrative). Even so, we believe this is evidence that the MACCR set is
not excessively biased in favor of a single age group.
Patient sex provides additional evidence of demographic and conceptual variety among CCRs
contributing to the MACCR set. Over the 3,100 CCRs, 1,415 (45.6%) reports concern female patients,
1,536 (49.5%) concern male patients, and the remainder (149; 4.8%) did not specify a patient’s sex or
were unclear. One potential source of imbalance between male and female patients is the presence of
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numerous cardiovascular disease (CVD) CCRs in our set: male patients with CVD symptoms are more
likely to receive corresponding diagnostics and treatment vs. female patients32,33. Similarly, we ﬁnd the
assumption that all obstetrical and gynecological cases should involve female patients is generally true:
out of 176 cases in this category, 160 identiﬁed female patients speciﬁcally; 14 reports did not explicitly
state the patient’s gender, though it was implicitly inferred as female; and of the remaining 2 cases
involving male patients, both describe conditions impacting male fetuses. Across all female patients, 360
are pediatric (o21), 551 were at least 21 and less than 51 years old, and 480 were 51 or older. Of the male
patients, the same counts are 470, 513, and 530, respectively.
This demographic variety extends to the geographic origin of the MACCRs: Fig. 3 provides a global
view of differences between MACCR geographic origins and those of all CCRs. Across all CCRs published
as of August 2018, more than 700,000 originate from the United States. Additional visualizations of the
geographic distribution, including its breakdown by disease category, are shown in a supplementary
animation (MACCR Supplementary File 1, Data Citation 1). Their distribution in this set is very similar
to that seen across all MACCRs, even when accounting for individual states, though we note that location
indexing is rarely comprehensive and provides only a rough estimate. Most reports in the MACCR set
have corresponding authors from the US, Japan, and China, likely due to curation of reports from more
recent years, and hence more publications from nations with higher citation rates in recent years34. As a
result, China and Japan have a slightly greater representation in the MACCR set than in CCRs as a whole.
It is important to note that these geographic identities relate to the corresponding author, which does not
necessarily equate to the treatment location or origin of the patient. Patient geo-location data is not
available from CCRs, though these data would be highly informative. Still, knowledge of the lead
investigator’s geo-location provides crucial insight as to where important clinical work is occurring.
Quality and value of case report metadata
The value of the MACCR dataset is derived from features created through metadata extraction. We
recognize this is an added value, as the CCRs have existing metadata and subject headings provided by
MEDLINE and MeSH (e.g., the content of each title, author list, and other bibliographic information).
Unlike MeSH assignments available through PubMed, we have examined the full clinical narrative
communicated within each case report and therefore furnish more detail than that permitted by the short
list of MeSH descriptors associated with each document. Our inclusion of descriptions of clinical events
and activities as they are described in the case reports themselves covers terminology not present in
Figure 3. Geographic regions with difference in publication frequency. Here, we visualize the distribution
of locations of reports in the MACCR set across the world and within US states. Darker shades correspond to a
greater signiﬁcant difference between the count of CCRs in the MACCR set for a particular region (determined
by institutional afﬁliation of the corresponding author) and the count of all CCRs for that region (as speciﬁed
by MEDLINE index).
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MeSH, particularly for the names of drugs and diagnostic or therapeutic procedures. Our metadata
extraction approach also differs from a code-centric approach and from NER-driven text mining
approaches in that it relies upon assignment of document text to general clinical concepts rather than to
stringently-deﬁned concepts or entities. Neither MeSH nor ICD-10-CM have been designed with clinical
narratives in mind: the former is intended to index biomedical documents while the latter translates
clinical diagnoses into coded endpoints. Our metadata extraction approach ﬁlls the niche these methods
were not intended to address.
As part of our metadata extraction process, we used a scoring system to quantify the total number of
features manually identiﬁed across all MACCRs. A CCR with a full set of values corresponding to clinical
concepts (i.e., each of the concepts has at least one associated text value) is assigned a medical content
score of 18, the highest value. One point each is provided for presence of key words and for enough detail
to determine a disease category, while the remaining points reﬂect types of medical content. The
minimum medical content score is 1. The average medical content score across all metadata sets is 10.9
with a standard deviation of +/−3.52, indicating each set of metadata provides more than 10 new details
on average, relative to available metadata, or more than 33,000 new details across all metadata records in
the set. More than 7,400 details are from CCRs discussing rare disease presentations. It is relevant to note
that the presence of text values corresponding to each medical concept is not consistent across all
concepts and across the full MACCR set; we believe this indicates material was simply not included in the
CCRs rather than omitted during the metadata extraction process. For example, 2,980 (96%) of the
MACCRs contain material describing diagnostic techniques and procedures, 2,349 (75.7%) contain
material describing clinical outcomes, and just 186 (6%) provide descriptions of patient social history.
We may also consider the metadata value in terms of information entropy. Determining entropy on a
per-character basis (i.e., Shannon entropy) allows us to calculate an average entropy per concept, with all
“NA” values treated as a value with an entropy of 0 bits (as these values provide no additional
information). We use this metric in lieu of estimates of readability (e.g., Flesch-Kincaid35 or SMOG36
scores) as these metrics are heavily biased by the frequency of complex vocabulary common to medical
language. We intend the entropy values to serve as estimates of differences in information content
between ﬁelds in the main MACCR dataset. Table 4 contains these average entropy values, along with
character, word, and segment (i.e., each semicolon-delimited phrase) counts for each medical concept.
This approach essentially combines two metrics (i.e., average entropy for a measurement of overall
information content and treatment of “NA” values to adjust for missing values) such that the resulting
entropy values denote estimates of each concept’s overall semantic complexity relative to others.
Concepts with average entropy close to 4, such as Diagnostic Techniques and Procedures, not only
contain more values than other concepts but each value is more complex, primarily as a function of
length.
Usage Notes
We anticipate the MACCR set will aid clinicians and clinical researchers in gaining a better
understanding of disease presentations, including their key symptomology, diagnostic approaches, and
treatment. Researchers in bioinformatics, clinical informatics, and information extraction will ﬁnd the
MACCRs useful as a set of medical language labeled at multiple levels. Individual researchers faced with
small sample sizes may use the MACCRs to enhance their statistical power through incorporation of
additional observations, or as a starting point for the assembly of in silico patient cohorts. We envision a
researcher could generate MACCRs of their own using our metadata standard template to assemble these
cohorts and leverage the cumulative power for statistical analysis. The resulting metadata enables deep
text mining alongside MeSH, ICD-10, and other clinical ontologies. To establish the utility of the dataset
and guide those interested in employing it in their research, we present use cases that may be pursued by
researchers, physician investigators, clinicians, data scientists, IP ofﬁcers, pharmaceutical companies for
drug development, and those shaping government policies for clinical trials. This set of metadata in
medical language yields a rich resource for providing insight into the events and biological phenomena
within each clinical presentation.
Analysis of case report features
The immediately applicable uses of the MACCR set are those involving aggregation and analysis of
features particular to each CCR. As the reports contributing metadata to this set reﬂect a substantial
variety of disease presentations and features, our structured data provide a multitude of options for
subsequent analysis. In the simplest case, extraction of sets of terms associated with a particular disease or
disease category establishes a set of starter terms for further study. For example, extraction of all
diagnostic procedures used in respiratory disease cases in the MACCR set (e.g., chest x-ray, lung function
test, or CT scan) allows researchers to better direct future literature searches by including a set of
commonly used treatments. These terms, while not comprehensive for any particular topic, form a
representative set of term vs. concept associations and include nonspeciﬁc terms as well (e.g., CT scans
are not speciﬁc to diagnostics for respiratory tract disease).
The rich term vocabulary available within the MACCR set permits more in-depth analysis and
application to additional documents. Researchers may ﬁnd this metadata particularly helpful in studying
differences in treatment approaches across disease type or on the basis of the impacted organ system. We
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suggest that an initial analysis of this set be managed through extraction of a set of terms in a
comprehensive dictionary, such as RxNorm37. Starting with observations listed in the Drug Therapy
column in each metadata record, for example, rule-based and NER methods can identify compound
names of interest. Enrichment of any name or group of names among a given subset of the metadata will
reveal broader phenomena, e.g., antibiotics may correlate with infectious disease cases.
Because the MACCR set includes English medical language from a variety of locales, it is a
representative set of medical text not speciﬁc to a single region, organization, or population. The dataset
includes structured demographic features (including age, sex, and geo-location) to serve as easily-parsed
features for correlative analyses. A more in-depth search enables geography-based analyses: by combining
both document metadata and free-text from metadata categories (speciﬁcally, patient demographics or
other features describing the patient), these ﬁelds can be mined for names of major cities, states, and
countries. They may then be mapped and quantiﬁed to visualize the case report distribution (as
demonstrated in Fig. 3). Methodologies developed using this dataset are appropriate for multi-level
geographic term identiﬁcation (i.e., from speciﬁc to general location) with a larger set of clinical reports,
especially as researchers may ﬁnd that certain features of CCRs are more informative for geographic
location than others. Geographic trends revealed using the MACCR set may reveal broader phenomena
to be followed up in new studies. They may also provide evidence of an unexpected focus in regional
publication for speciﬁc diseases. We may expect CCRs involving a regional epidemic of a speciﬁc
infectious disease to be predominantly written by clinicians in that area. Alternatively, these cases may
also be popular among clinicians describing the spread of infectious disease to new locations.
Incorporating CCR analysis into broader studies permits exploration of undeﬁned or poorly deﬁned
diagnoses. Some rare diseases may only exist, conceptually, as subsets of more common disease
presentations. Heart failure, for example, is such a common condition that it may be responsible for more
hospitalizations than any other condition, yet half of heart failure patients may suffer from a particular
subtype of the syndrome, heart failure with preserved ejection fraction38, or HFpEF. Despite its current
prevalence, HFpEF was only recognized as a distinct condition within the last several decades. The ﬁrst
observations of disease presentations lacking speciﬁc diagnostic consensus may therefore be contained
only in CCRs and are unlikely to appear in formal epidemiological studies.
Support for mitochondrial and rare disease characterization
The MACCR dataset documented here contains a rare disease subset, including a set of rare
mitochondrial diseases. There are over 7,000 rare diseases affecting over 300 million individuals
worldwide, 58 of which are RMDs (https://rarediseases.info.nih.gov/diseases). We have generated
metadata acquired from CCRs describing 7 mitochondrial diseases for this dataset, as well as an
Concept Average Entropy (bits, +/−standard deviation) Character Count Word Count Segment Count
Keywords 2.17 +/− 2.04 127,932 8,326 6,636
Geographic Locations 0.35 +/− 1.01 6,085 901 358
Life Style 0.55 +/− 1.35 29,244 4,862 521
Family History 1.15 +/− 1.83 138,162 21,342 1,717
Social History 0.23 +/− 0.90 12,310 2,022 249
Medical/Surgical History 3.02 +/− 1.84 804,975 119,816 8,783
Signs and Symptoms 3.96 +/− 0.94 1,460,450 218,276 16,467
Comorbidities 0.96 +/− 1.63 33,978 3,918 1,329
Diagnostic Techniques and Procedures 3.98 + /− 0.87 1,369,668 195,000 15,936
Diagnosis 3.85 +/− 0.66 206,418 24,432 4,718
Laboratory Values 2.80 +/− 2.12 990,769 146,240 5,238
Pathology 2.32 +/− 2.11 853,084 121,009 2,865
Pharmacological Therapy 2.74 +/− 1.99 422,402 60,270 3,863
Interventional Therapy 2.60 +/− 1.94 399,831 57,967 4,909
Patient Outcome Assessment 3.07 +/− 1.77 440,602 66,786 4,526
Table 4. Text properties and entropy of medical concept metadata records. For each medical concept
used in the metadata extraction process, we determined its average character-level entropy (Shannon
entropy) across all text values in the concept, along with its standard deviation. As length of text can
contribute to estimates of its complexity, we also include counts of characters (not including delimiters or
spaces), words, and segments (i.e., phrases between delimiters) for each concept across the MACCR set.
Values of “NA” are considered to have an entropy of zero and do not contribute to character, word, or
segment counts.
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additional set of ICD-10-CM diagnostic and symptom codes. The RMDs curated for this dataset have a
limited number of publications in the medical literature, so our metadata collectively represent a
substantial portion of the published clinical observations of these diseases. Each of the RMDs shares
similar features in that they all involve mitochondrial abnormalities, yet each produces markedly different
phenotypes and clinical signs. A number of analysis routes are available with the current dataset. We
suggest that researchers use this set as a model to identify additional cases in the literature not explicitly
identiﬁed as mitochondrial diseases. These implicit cases may be more common than anticipated but may
be predicted based on presentations sharing numerous signs and symptoms with known cases. The
resulting predicted cases would comprise a model for future studies of rare and/or idiopathic disease. For
RMDs in particular, the MACCR set establishes a basis for both expected and frequently correlated
symptomology, facilitated by the ICD-10-CM on RMD CCR symptomology.
Additional data on the genetic and molecular basis of the selected RMDs provides a more speciﬁc
diagnostic picture and allows researchers to interface with knowledgebases to conduct proteome and
pathway analysis. This information can offer mechanistic insight for the potential pathogenesis of disease.
The etiology of many RMDs lies in mutations to mitochondrial DNA (mtDNA), but the majority are
caused by mutations to nuclear-encoded genes that play various critical roles in mitochondrial
biosynthesis and function (Fig. 2c). Barth syndrome, for instance, is caused by mutations to the TAZ
(G4.5) gene at Xq28, resulting in malformed mitochondrial membranes due to a nonfunctional tafazzin
enzyme that is responsible for adding linoleic acid to cardiolipin (CL) through its acyltransferase activity.
Because of its prominence in the mitochondrial inner membrane and its intimate association with the
electron transport chain complexes, improperly formed CL severely limits mitochondrial energy
production and results in a variety of complications, including dilated cardiomyopathy, hypertrophic
dilated cardiomyopathy, left-ventricular non-compaction, and endocardial ﬁbroelastosis. Barth syndrome
was ﬁrst described in 198330,39 and over 100 distinct mutations to the TAZ gene have been identiﬁed
since the genetic basis was discovered in 199640. Recognizing the common feature of diminished CL and
elevated concentrations of monolysocardiolipin (MLCL) in Barth syndrome, an HPLC-MS/MS bloodspot
assay was developed for diagnosis by an elevated MLCL:CL ratio41. The MACCR set can serve as a
valuable resource for uncovering common proteins, pathways, and metabolites of interest in RMDs,
which may lead to the identiﬁcation of potential biomarkers. The depth of information can be further
ampliﬁed by integrating this dataset with other publicly available resources and knowledgebases such as
UniProt42 (http://www.uniprot.org), Reactome43,44 (https://reactome.org), and the Human Metabolome
Database (HMDB)45 (http://www.hmdb.ca).
This dataset will aid users in gaining a better understanding of rare diseases and their treatments
through downstream analysis of the structured text data. The CCR metadata derived from reports on
Barth syndrome, for example, are directly relevant to developing and evaluating treatments for this and
related conditions, as well as diagnostic and treatment planning in the clinic. By reviewing existing CCR
metadata, a researcher could investigate past treatment regimens to analyze recorded symptoms or side
effects and the degree of improvement under prevailing standards of care. Similarly, clinicians could
employ metadata extracted from CCRs to support differential diagnosis and treatment planning in a
patient with a suspected mitochondrial disorder. Furthermore, we envision that researchers and clinicians
might utilize the metadata standard template and protocols to generate additional MACCRs and
construct in silico patient cohorts of their own, enhancing their ability to compare existing treatments and
evaluate newly developed therapies. For example, Elamipretide (Stealth Biotherapeutics, Newton,
Massachusetts) is currently under stage II and III clinical trials for treatment of Barth syndrome and
other mitochondrial myopathies by protecting properly formed cardiolipin from damage46. As new case
reports on patients treated with Elamipretide become available, additional MACCRs might be leveraged
to compare treatments, perhaps identifying side effects or varying efﬁcacy of the new drug in different
patient groups.
Support for congenital heart disease characterization
Congenital heart defects (CHD) and disease are unfortunately common clinical issues occurring in an
estimated 1% of births in the United States47. Similarly, they are frequently represented among the
reports in the MACCR dataset, 243 of which involve CHD. Though general descriptions of CHD
diagnoses (e.g., “ventricular septal defect” or “hypoplastic left heart syndrome”) lend themselves well to
indexing by MeSH, more nuanced narratives surrounding CHD presentations require more detailed
examination. As a brief example, among the CHD reports within the MACCR set, the top MeSH
descriptors include “Infant, Newborn”, “Echocardiography”, and “Abnormalities, Multiple”. A
comparison of the metadata for these reports reveals some variation in age: of the 240 CCRs for
which age is speciﬁed or can be inferred, mean age is about 22.7 years, with 76 cases involving patients
less than a year old and 137 involving pediatric patients (any under 21 years of age). In terms of
additional detail, however, just 49 (20.2%) of these CCRs speciﬁcally mention heart failure, but nearly as
many (47) mention cyanosis or cyanotic conditions. Though a larger collection of CHD reports may be
required, metadata extraction and investigation of these reports may provide solid evidence for new
biomarker candidates in an area where few currently exist.
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Models of medical language
The MACCR set contains rich, contextual descriptions of medical events. Individual words and phrases
in the set are not explicitly assigned to a given ontology or vocabulary but are included within our
medical concept categories. For example, instead of indicating a document describes a “myocardial
infarction” and/or identifying this phrase in each document, if a document mentions events such as a
heart attack, we assign the event to the appropriate medical concept (and assign a disease category; in this
case, cardiovascular disease). The corresponding text segment in each case includes phrases such as
“family history was positive for myocardial infarction in a sibling at age 54 years”48. As compared with an
approach of processing unstructured case report text with NLP tools, our resource supplies an
intermediate level of structure sufﬁcient to retain the context of the segment. This semantic context
contains information denoting relations between concepts and events with enough detail to assign
additional diagnostic categories and codes. In the example of a myocardial infarction, the metadata often
includes the details necessary to determine subtypes (e.g., ST-elevation vs. non-ST elevation, or ICD-10-
CM codes of I21.3 vs. I21.4). Employing NER alone on the source text may yield only phrases such as
“myocardial infarction”, and MeSH descriptors generally do not index documents to this level of detail.
The MACCR set labels text segments with medical concepts, allowing collections of phrases, rather than
named entities, to be associated with higher-level concepts. Our resource thereby enables an additional
degree of interoperability between CCRs, controlled vocabularies (e.g., MeSH), and diagnostic coding
systems (e.g., ICD-10), while supplying a rich collection of contextual and concept-labeled clinical text
features.
The contents of the MACCR set provide the structured training data necessary for developing
computational models of higher-level features in clinical text. Computational linguists as well as
researchers in clinical informatics and medical NLP may use the MACCR records to develop concept-
level models of medical language, allowing for context-based machine learning and alternatives to
dictionary-driven NLP approaches49,50. The MACCR approach supports generation of term frequency
sets, word vectors, and basic entity-level analysis (e.g., with UMLS resources25) while retaining clinical
concepts such as medical history or demographics. NER systems such as cTAKES49 (http://ctakes.apache.
org/) or CLAMP50 (http://clamp.uth.edu/) support identiﬁcation of procedures and signs/symptoms
using the features within MACCR records. Additionally, NER and rule-based phrase matching
approaches draw connections between MACCR content and biomedical knowledgebases (i.e., UniProt42
[http://www.uniprot.org], Reactome43,44 [https://reactome.org], or the Disease Ontology51 [http://disease-
ontology.org/]). The combination of extensive knowledgebases with advanced computational models
supports transformation of clinical observations into biomedical insight.
Our dataset facilitates expansion of ongoing developments in NLP principles and methods to medical
documents, especially alongside the substantial extant resources for contextualization and distant
supervision of computational approaches to understanding medical language. The broad demand from
the community and far-reaching signiﬁcance of NLP approaches has been a springboard for novel
approaches in biomedical research and beyond, evidenced by rapid development of tools and resources in
a variety of research ﬁelds52–55. Beyond clinical informatics research, tools developed to enforce structure
on otherwise unstructured biomedical text – including that in electronic health records – offer a major
source of untapped biomedical knowledge56,57. These tools will require signiﬁcant software development
and engineering efforts, yet once the resulting knowledge becomes structured and searchable, it will be of
greater interest and utility to clinicians, data scientists, and physician investigators, as well as intellectual
property specialists and ofﬁcials determining policies for clinical trials.
Manual curation is currently the most suitable option for capturing comprehensive details associated
with high-level concepts in biomedical literature. Though it may someday yield similar results,
automated, machine learning-driven medical language analysis presents distinct limitations in precision
and recall, producing numerous false positive and false negative results as compared to human
annotators58. With this dataset, we present a resource appropriate for training new machine learning
models on the types of language common to clinical case reports: vocabulary, common phrases, and
association with high-level medical concepts. The resulting models may then support further human
curation and metadata extraction, assembly of more ﬁne-grained knowledge structures (e.g., knowledge
graphs), and transfer learning to train more complex medical language models. Our dataset is therefore
entirely complementary to biomedical text resources such CRAFT15 and those available through i2b213,14.
Though these datasets provide records of speciﬁc concepts and features, the MACCR set furnishes rich
metadata of clinical concepts across a wide variety of disease types. In instances where machine learning
methods may require considerably a larger amount of text for training, we suggest using the MACCR set
as an initial training step and in combination with other text resources.
An educational resource for writing better case reports
The MACCR set contains metadata for reports spanning disease types and medical specialties,
highlighting a wide variety of CCR writing styles and a range of completeness in describing relevant
clinical concepts. In some cases, variance among MACCRs is the result of a lack of explicitly stated
observations: e.g. a patient’s exact age or family history may be omitted. Similarly, clinicians may not
mention tests if the diagnostics or their results were considered trivial. The richness of our dataset offers a
basis for comparison among cases. Clinical investigators may observe the extent to which expected
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clinical concepts are or are not discussed in case reports. This analysis may be particularly informative if
otherwise similar cases ares found to differ in diagnosis. Other features may be more useful for
subsequent analyses if provided in a more speciﬁc, quantiﬁable manner; a CCR with a patient described
as “55 years old”, for instance, will be more informative than one with the description “middle-aged.”
Further analysis of the speciﬁc features within CCRs will provide clear examples of how clinicians may
write more informative, citable, and computationally readable CCRs.
While, at present, case reports are primarily read by academic physicians for educational purposes,
implementation of the standardized metadata template to enrich these documents can expand the
audience and application of case reports. For example, case report user groups may include medical
students, interns and fellows, epidemiologists, and statisticians. These audiences would not only be able to
more easily identify relevant CCRs, but also derive valuable information from improved indexing and
categorization. In turn, these improvements will lead to better understanding of clinical phenotypes and
relationships of an individual case to a larger representative patient population. As another example,
healthcare organizations and policymakers (e.g., FDA) can retrieve CCR metadata as an additional source
for tracking unusual disease occurrences, epidemiological trends, and post-marketing drug surveillance.
Moreover, pharmaceutical industries can design a survey on case reports of drugs with unexpected
indications or unrecognized side-effects to assist in modifying usage instructions and direct future
development.
To address the key clinical items commonly missing in case reports, we envision a solution that
integrates what PubMed has already accomplished with MeSH terms using both metadata extraction and
coding with ICD-10-CM. This strategy would support further classiﬁcation with systems such as the
International Classiﬁcation of Health Interventions (ICHI) (http://www.who.int/classiﬁcations/ichi/en/)
to compensate for missing items. The resulting curated, indexed, and structured CCR metadata could
ultimately interface with preclinical -omics research, clinical cohort studies, and clinical trials to advance
understanding of disease progression, management, and clinical outcomes. To surmount the ever-
growing amount of free-text information with limited metadata, indexing, and accessibility,
computational platforms and in-depth search algorithms will enable better recognition of CCR contents
and relevant clinical trials to elevate text data analysis, advance medical science, and improve patient care.
As a time-honored tradition in medical publication and a treasured source of clinical data, clinical case
reports augment our understanding of disease etiology, pathogenesis, miscellaneous diagnosis, and
therapeutic efﬁcacy. These reports provide valuable clinical narratives relevant to clinicians and
biomedical researchers. The growing volume of case reports published each year stands testament to their
popularity and usefulness to their targeted clinical readership, but this size, coupled with the isolated,
unstructured, and heterogeneous nature of case reports’ contents, also presents a challenge to index,
annotate, and query case report data. In this report, we created a standardized metadata template and
metrics, as well as a test dataset consisting of 3,100 CCRs spanning 16 disease categories. In the course of
assembling our dataset, we evaluated the caliber of the existing metadata employed for case reports in
PubMed and conﬁrmed a discrepancy between the medical content and the metadata meant to describe
it. Our MACCR set addresses this discrepancy by adding rich metadata and serves as a valuable resource
for biomedical researchers developing novel approaches to advance medical science and improve
patient care20.
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Chapter 5. A FAIR Representation of Mitochondrial Biology 
and Rare Mitochondrial Disease via GeneWiki and MitoCases
Introduction
Mitochondria are responsible for a wide array of cellular processes including fatty acid and glycolytic 
metabolism, oxygen handling through oxidative phosphorylation, energy production through 
the electron transport chain, as well as inter- and intra-cellular signaling governing protective, 
apoptotic, and proliferative pathways. With its central role in these essential cellular functions, 
mitochondrial biology is integral to our fundamental understanding of human health, aging, and 
disease. Mitochondrial dysfunction is implicated in cardiovascular, neurological, and muscular 
disorders; rare mitochondrial diseases (RMDs) caused by mutations to mitochondrial genes in 
both nuclear and mitochondrial DNA are devastating and largely untreatable. Despite a large 
volume of existing knowledge and increased public interest in mitochondrial biology and related 
diseases, its access and comprehension remain elusive to the scientific community and largely 
inaccessible to the general public. Our limited understanding of RMDs and their pathogenesis, 
compounded by the fragmented nature of clinical case information and unstructured text data, 
leads to delayed diagnoses and leaves us with a dearth of treatment options. We must make 
the knowledge we do possess more readily findable, accessible, and integrated across data 
types, enabling researchers and clinicians to amplify their ability to advance our understanding of 
mitochondrial biology and related diseases.  
The FAIR Data Principles [1] promote the philosophy that scientific knowledge presented in any 
form should be made Findable, Accessible, Interoperable, and Reusable to ensure that it has 
the greatest impact in advancing our understanding of biology and disease. Briefly, publications, 
datasets, and metadata should be assigned a globally unique and persistent identifier such as 
a digital object identifier (DOI) to make them Findable; the digital objects should be retrievable 
via their identifier using an open, standardized, and free communications protocol to make them 
Accessible; data and metadata should use a formal, broadly applicable vocabulary and domain-
recognized ontologies to make them Interoperable; and metadata on the digital objects should 
contain detailed provenance, licensing, and version information to make them Reusable. The FAIR 
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Principles have been well-received and adopted internationally by government funding agencies 
[2]. The principles are relatively easy to implement and evaluate, with the potential to increase 
the reach and impact of any given research project or dataset. Many biomedical resources and 
knowledge, however, remain decidedly unFAIR, particularly the information that is conveyed only 
by unstructured text data. 
We have established the Mitochondrial Gene Wiki Project and the MitoCases Mitochondrial 
Disease Knowledge Platform to improve findability, accessibility, interoperability, and reusability of 
mitochondrial biology and mitochondrial disease related knowledge. The Mitochondrial Gene Wiki 
Project, discussed in Section 1, has made vast amounts of mitochondrial knowledge available 
through contributions to Wikipedia articles on mitochondria-related genes and proteins. This is 
an ideal starting point for researchers, students, and patients exploring mitochondrial biology 
and related diseases.  The project has also been an effective educational tool for introducing 
biomedical literature curation, research methods, knowledgebase access, and scientific writing 
to students contemplating academic research and pre-medical studies. The MitoCases Rare 
Mitochondrial Disease Knowledge Platform, presented in Section 2, houses detailed metadata 
on RMD clinical case reports (CCRs), provides a powerful search mechanism for case discovery, 
and makes all data available for download or via API access. Researchers can use the platform 
to identify case reports on a disease of interest or involving a particular gene, protein, or pathway; 
clinicians can search for a set of symptoms to find similar cases and provide better patient care; 
and data scientists can access the dataset to develop tools for natural language processing (NLP) 
and named entity recognition (NER).
Section 1. Gene Wiki
1.1 Background and Approach
1.1.1 Gene Wiki Project and citizen science.
A wide range of scientific and clinical concepts, biomolecules, and diseases are represented on 
Wikipedia, providing a reliable source of detailed information and references for the general public 
and biomedical community. The Gene Wiki Project [3], an effort within Wikipedia, was established 
to make biomedical knowledge readily available on the platform and to encourage the participation 
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of citizen scientists in contributing to the resource. They kickstarted the effort to annotate all human 
genes by automatically generating 9,000 “stub” pages [3] and populating them with basic content 
from Entrez Gene [4]. The Gene Wiki Project develops and maintains informatics tools to enable 
greater community contribution, including a simple “Gene Wiki Generator” web service that allows 
users to automatically create a similar stub page on their gene of interest [5]. The Gene Wiki 
Project has further elevated the utility of Wikipedia by automatically instantiating and populating 
“infoboxes” on each page with structured gene and protein data from Entrez Gene, UniProt, 
and the PDB. The Gene Wiki has since imported all human and mouse genes and proteins into 
Wikidata as structured entities, including nearly 60,000 human genes and 30,000 human proteins 
[6]. They have also implemented Semantic Wiki Links on the platform that facilitate machine-
readable triplets that can convey the relationship between entities [7]. The resulting product is 
a broad collection of structured pages that may be more effectively digested by the public and 
contributed to by citizen scientists.
1.1.2 Underrepresentation of mitochondrial knowledge on Wikipedia.
Mitochondrial gene, protein, and pathway articles are also available on Wikipedia, but many 
mitochondria-related entities remained inadequately represented and poorly annotated. We 
identified a large collection of pages related to mitochondrial genes and proteins in need of 
significant updates. Many of these were stub pages that had yet to see any contributions, while 
many others were altogether nonexistent. Researchers have a tendency to prefer studying and 
functionally annotating only a small collection of genes for which copious information exists [8]. 
Information is indeed available on these mitochondrial entities, but their pages had not seemed to 
garner the attention of the community. 
1.1.3 Project focus.
We have undertaken a concerted effort to identify and address these deficiencies on Wikipedia. 
The goal of the Mitochondrial Gene Wiki effort is to expand the breadth of the Gene Wiki Project, 
with a particular focus on the cardiac mitochondrial proteome. We have endeavored to establish 
well-organized examples of Wiki pages for the proteins within the conserved cardiac mitochondrial 
proteome, those with cardiovascular significance in coronary artery disease (CAD), as well as 
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genes and proteins implicated in rare mitochondrial diseases. We wrote detailed protocols for 
analyzing current Gene Wiki pages for both their organization and content, curating knowledge 
from PubMed and key knowledgebases, and writing well-referenced articles suited for the 
Wikipedia framework and its audiences.
We selected five sub-proteomes from the human cardiac mitochondrial proteome for analysis and 
improvement, including metabolism (312 genes), oxidative phosphorylation (101), proteolysis (58), 
apoptosis (54) and redox (31) proteins (Fig. 5-1). This list was initially derived from proteomics 
datasets covering the cardiac mitochondrial proteome [9, 10]. Additionally, we targeted a collection 
of membrane proteins (17) and tRNA (18) that are implicated in rare mitochondrial disease, 
contractile proteins (56) critical to cardiac function, as well as proteins identified as risk factors in 
coronary artery disease (CAD; 25). The entire collection of proteins was compiled in the master 
article record spreadsheet, with links to the article pages, assignments to specific team members, 
initial article analysis, improvement metrics for each section, and the total article content in bytes 
before and after editing. Trainees and team members chose assignments within one or more of 
these sub-proteomes, based on their expertise, training, and research interests, then analyzed 
each of the 672 protein pages within Gene Wiki and identified those in need of improvement and 
update. 
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Figure 5-1. Targeting cardiac mitochondrial subproteomes for article improvement on Gene Wiki. 
Five subproteomes from the human cardiac mitochondrial proteome were selected for analysis and 
improvement. These include metabolism (312 genes), oxidative phosphorylation (101), proteolysis (58), 
apoptosis (54) and redox (31). Additional clusters of mitochondrial membrane proteins, contractile 
proteins, proteins implicated as risk-factors for coronary artery disease (CAD), tRNA-related proteins, as 
well as proteins and genes implicated in rare mitochondrial diseases were chosen for article improvement. 
Trainees and team members chose to improve articles within one or more of these subproteomes, based 
on their expertise, training, and research interests.
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1.1.4 Gene Wiki as a training platform.
Wikipedia has been used successfully as an educational tool in several domains [11-13], and it 
provides a unique opportunity in the biomedical realm as well. Many students progressing through 
biology programs and pre-medical studies with the goal of entering into academic research or clinical 
professions lack essential research and writing skills necessary to communicate effectively in the 
scientific community. These skills are difficult to acquire and are rarely taught explicitly during the 
course of undergraduate studies. Without joining a research lab and actively participating in journal 
clubs and lab meetings, it is entirely possible to progress into medical school or graduate studies 
without ever learning how to find research papers, read them critically, or write an appropriate 
scientific discussion. Furthermore, the increasing prevalence of informatics tools and resources 
presents another challenge for aspiring biomedical professionals who will undoubtedly encounter 
them and need to navigate them throughout their continued studies and into their career. The 
large gap in coverage of mitochondrial genes and proteins provides a valuable space in which to 
introduce students to fundamental biomedical knowledge about mitochondria and impart these 
key skills for scientific research. Therefore, we used the Mitochondrial Gene Wiki effort to teach 
the basics of cardiovascular physiology, mitochondrial biology, and the role of mitochondria in 
health and disease. We imparted research skills in biomedical literature curation and critically 
assessing scientific publications, knowledgebase access, the effective use of informatics tools, 
and how to synthesize all of this information into impactful scientific communication.  In training 
students from all educational levels, we made significant contributions to Gene Wiki pages and 
instilled the FAIR Principles in the next generation of biomedical researchers and clinicians.
1.2 Methods
The high-level workflow followed throughout this project, depicted in Fig. 5-2, entails (i) Gene 
Wiki article analysis, (ii) manual curation of detailed protein and gene information from a variety 
of sources, including PubMed, WikiData, UniProt, COPaKB, and others, and (iii) knowledge 
synthesis into an updated and improved Gene Wiki article. Ultimately, these contributions of 
scientific knowledge and insight on key biomolecules in health and disease are (v) made available 
to the community in a FAIR and open-source manner in the form of Gene Wiki articles and (iv) 
publications. Each step in this process was supported by detailed standard operating procedures 
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(SOPs), as well as regular meetings and inter-operator evaluation of completed tasks. We 
designed a master record for article analysis before and after improvement by our team, providing 
a mechanism for detailed statistics on individual and group-wide contribution. 
1.2.1 User onboarding, training, and accounts.
Initial training and onboarding for new team members included an overview of the goals of the 
Mitochondrial Gene Wiki effort and an introduction to mitochondrial biology and cardiovascular 
physiology. Additionally, each team member read about the essentials of Wikipedia contributions 
detailed in the Wikipedia Tutorial article (https://en.wikipedia.org/wiki/Wikipedia:Tutorial), the 
Wikipedia Manual of Style (https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style), and the 
Wikipedia Etiquette article (https://en.wikipedia.org/wiki/Wikipedia:Etiquette). These provide all of 
the necessary information about basic editing instructions, how and when to create new pages, 
how to use Semantic Wiki links appropriately, citations, formatting style guides, standard practices 
regarding edit reversals or significant changes, indicating changes at the time of submission, as 
well as a general guide to etiquette within the Wikipedia community. These articles are particularly 
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Figure 5-2. Mitochondrial Gene Wiki article improvement workflow. (i) Articles of interest on Gene 
Wiki are first analyzed for completeness and quality of key sections (Introduction, Structure, Function, and 
Clinical Significance), the inclusion of ample and recent references, and the presence of extensive 
semantic linkages throughout the article. (ii) Upon identifying articles for improvement, comprehensive 
gene, protein, and clinical knowledge is curated from PubMed, UniProt, Reactome, WikiData, OMIM, and 
other knowledgebases and data sources to assemble a complete view of available information on the gene 
of interest. (iii) The assembled information is then synthesized and enhanced through integration into a 
complete Gene Wiki article and, (iv) for select genes of interest, submitted for publication to the Gene 
journal through their Gene Wiki Reviews mechanism. (v) The resulting articles are made available to the 
community, amplifying access to critical knowledge on mitochondrial biology.
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useful when unsure of how to accomplish a certain type of formatting, how to give appropriate 
attribution, and which citations require special tags for their Creative Commons licensing. Each 
team member within the Mitochondrial Gene Wiki effort created an individual user name so as 
to track their contributions. Institution and group user accounts are forbidden by Wikipedia terms 
of use, so each member submitted their user name for inclusion in our master article record for 
later analysis. Team members were asked to include a tag in their signature line to better track 
contributions outside of the master article record maintained in-house.
1.2.2 Gene Wiki article analysis.
Team members first searched for each of their assigned proteins and genes on Wikipedia for 
existing pages, checking for synonyms and alternate naming conventions before identifying 
missing pages as such within the master article record. The existing Gene Wiki articles were 
analyzed for completeness, organization, the quality and length of key sections (Introduction, 
Structure, Function, and Clinical Significance), the presence of the Gene Wiki infobox, the 
inclusion of ample, relevant, and recent references, and the presence of extensive Semantic Wiki 
links throughout the article connecting it to other biological concepts in articles across Wikipedia. 
Within the master article record, space is provided for scoring the key article sections on a scale 
of 1-3, indicating whether the section was nonexistent (1), incomplete (2), or complete (3). To 
be considered complete, the Structure, Function, and Clinical Significance sections are each 
expected to contain 250-500 words or more, accompanied by appropriate references for each 
statement and Semantic Wiki links to other articles, and be prefaced with an appropriate section 
heading. The Introduction is expected to be concise. Excessive information about a particular 
topic earns an “incomplete” rating for the section and is ultimately moved to a more appropriate 
section, such as Structure, Function, or Clinical Significance. The presence of the Gene Wiki 
infobox is also indicated and marked for addition or update if it is absent or incomplete. Finally, 
team members record the size of the article in bytes prior to any editing.
1.2.3 Knowledge curation.
Comprehensive gene, protein, and clinical information is curated for the protein of interest using 
a wealth of resources, including NCBI Gene, PubMed, UniProt, the Cardiac Organellar Protein 
75
Atlas Knowledgebase (COPaKB), the Research Collaboratory for Structural Bioinformatics 
Protein Data Bank (RCSB PDB), Reactome, IntAct, and Online Mendelian Inheritance in Man 
(OMIM). Under the SOP for research activities, team members are advised to begin their search 
on NCBI Gene (https://ncbi.nlm.nih.gov/gene) with the gene ID and the “[Homo sapiens(human)]” 
tag. The summary typically provides a reasonable overview of known characteristics of the 
gene, and basic information such as the location of the gene in the human genome is contained 
under the “Genomic context” section. The “Bibliography” and “GeneRIFs” (Genetic References 
Into Functions) sections supply a large collection of related articles that are directly relevant to 
the gene and its functions. Once these references have been exhausted, we query PubMed for 
the gene or protein name and search for recent review articles. These articles aid in becoming 
familiarized with the gene and/or protein. Their reference lists provide many avenues for deeper 
information. UniProt [14] (https://uniprot.org/) is a preferred source of information on the protein 
and its functions, from molecular weight, variants, post-translational modifications and interactions, 
as well as key functional and structural domains. COPaKB [15] is a cardiac proteome-focused 
knowledgebase containing mass spectrometry datasets and RCSB PDB (http://rcsb.org/) houses 
structural models of many proteins. UniProt, COPaKB, and RCSB PDB are recommended 
sources for fleshing out the Structure and Function sections of the Gene Wiki articles. Reactome 
[16] (https://reactome.org/) and IntAct [17] (https://ebi.ac.uk/intact/) furnish detailed pathway and 
interaction information to construct a comprehensive Interactions section. Finally, the Clinical 
Significance section is best addressed using OMIM (https://ncbi.nlm.nih.gov/omim) resource, an 
extensive collection of genetic phenotypes, allelic variants, and the associated references. 
1.2.4 Gene Wiki article improvement.
The assembled information is then synthesized and integrated into a Gene Wiki article, depending 
on the completeness of the existing page. Our team members are advised to write a draft of the 
document first, to avoid any loss of work due to a bad connection or accidentally closing the 
Wikipedia editing tab of their browser. Missing pages are instantiated according to the instructions 
provided (https://en.wikipedia.org/wiki/Wikipedia:How_to_create_a_page), and headings for the 
Structure, Function, Interaction, and Clinical Significance sections are created. Next, the relevant 
information from the curation step is incorporated into each section with references to support 
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each claim. The Introduction section is pared down to the essential information to provide a 
concise summary of the contents of the article and critical information relating to protein function 
and disease relevance. Longer explanations are moved to the relevant sections. Semantic Wiki 
links are added throughout the article and, in keeping with the Wikipedia Tutorial, only at the first 
appearance of a concept to avoid overlinking. If it is missing, the Gene Wiki infobox is populated 
on the page through the BioGPS site (http://biogps.org/) or by adding the ‘{{infobox gene}}’ string 
to the markup code editor at the top of the page. Upon submitting the edited article, infobox 
content is imported in the background by the ProteinBoxBot, managed by the Gene Wiki Project 
team [6]. Upon submitting the final version of the article, team members recorded key measures 
of their contribution, including the number of semantic links and references they added, which 
sections they improved or created, as well as the initial and final size of the article in bytes.
1.2.5 Converting Gene Wiki articles to peer-reviewed publications.
Select genes or proteins of interest, particularly those without recent or comprehensive review 
articles available, are submitted for publication to the Gene journal through their Gene Wiki Reviews 
mechanism [18]. This initiative provides a venue through which the contributions of scientists to 
the Gene Wiki platform can be recognized and provide tangible professional benefit in the form 
of a peer-reviewed publication in a well-known and circulated journal. Through the efforts of the 
Mitochondrial Gene Wiki team, two publications have been secured through this mechanism, 
including a comprehensive review of the Hsp70 family chaperone BiP (binding immunoglobulin 
protein), encoded by the HSPA5 gene [19], as well as a thorough review of the tafazzin-encoding 
TAZ gene implicated in Barth syndrome, a complex, rare mitochondrial disease affecting cardiolipin 
remodeling [20]. Scientific contributions to Wikipedia are largely underappreciated and garner no 
professional recognition. Gene Wiki Reviews provide an effective way to amplify the visibility of 
these efforts and to publish reviews on important genes and proteins from devoted researchers. 
1.2.6 Article standardization, evaluation, and quality control.
Each article followed a standardized format for ease of public consumption. Furthermore, articles 
were evaluated using the master article record and the metrics recorded by each contributor. The 
number of new pages created, sections improved, semantic links and references added, and 
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overall size of the articles in bytes were logged and used for subsequent analysis of the overall 
contributions by the team and by each individual team member. 
The efforts undertaken by the Mitochondrial Gene Wiki team were accomplished with significant 
contribution from younger students, including dedicated high school age students in advanced 
summer internship programs, undergraduates of all levels looking for research experience, as 
well as Master’s and Doctoral level graduate students working on projects related to some of 
the selected genes and proteins of interest. Each trainee was individually guided through the 
research, curation, writing, and editing process to ensure that the submitted articles represented 
the highest caliber and sufficiently covered the key pieces of knowledge on each protein. For their 
first two articles, trainees worked individually with a senior lab member – either a doctoral student, 
a postdoctoral scholar, a clinician, or a senior scientist with strong writing abilities and knowledge 
of the proteins under study. Many trainees worked in pairs or groups of three for another set of 
2-3 articles. For the remainder of their training they were assigned a small collection of related 
proteins to work on individually. All trainee articles were reviewed in depth with the assistance of 
a senior lab member upon submission and revised with their supervision when necessary. 
1.3 Results and Discussion
1.3.1 Initial article analysis.
Our article scoring protocols provided a mechanism by which to evaluate Gene Wiki pages and 
track the progress of the Mitochondrial Gene Wiki effort over time. At the outset, only 1% of the 
672 mitochondrial protein and gene articles slated for improvement achieved a score that would 
allow us to consider them “complete.” Another 8% already had a significant amount of content 
and required some restructuring, organization, and the addition of more recent references. About 
a quarter of the pages (24%) were rated as “somewhat complete,” and were typically lacking 
cohesive structure, organization, or were poorly cited. In total, roughly one third of our targeted 
proteins had at least a start at a reasonably well constructed article available. 
The majority of the pages, however, were either missing entirely or severely lacking in content. 
Nearly a quarter of the genes and proteins we identified (22%) lacked any representation on 
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Wikipedia whatsoever. These pages required construction from the ground up, including enlisting 
the ProteinBoxBot for initial instantiation of the Gene Wiki infobox and writing each of the key 
sections from scratch. Another half of the pages (46%) were rated “mostly incomplete,” which 
typically meant that they were little more than a placeholder with a title and perhaps an infobox 
with basic gene and protein information. These pages are referred to on Wikipedia as a “stub” 
page and are usually accompanied by a stub tag, which is used as an invitation to contribute to 
that page. Upon adding to these pages and writing a more complete article, the editor is expected 
to remove the tag. 
1.3.2 Article improvement progression and metrics.
The Mitochondrial Gene Wiki team worked to improve these articles over the course of several 
years (Fig. 5-3). The initial effort in the first year saw an increase of “complete” articles from 1% 
to 41%, primarily by tackling “mostly incomplete” articles and reducing their share from 46% to 
19%. Missing articles are frequently nonexistent due to the dearth of available information on 
these genes and proteins. They are frequently small subunits or chaperones that are not well 
characterized in the literature and require significantly more effort to unearth enough content for a 
full article. In the first year, these decreased from 22% to 13%. “Somewhat complete” articles also 
decreased from 24% to 17%, while “Mostly complete” pages increased from 8% to 10%.
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Figure 5-3. Mitochondrial Gene Wiki article improvement progression. (A) Initial scoring of the 
selected Gene Wiki articles revealed that only 1% of the articles could be deemed “complete.” Over the 
course of a year, the Mitochondrial Gene Wiki team worked to improve these articles. (B) Through this 
initial effort, we raised the number of “complete” articles from 1% to 41%, a result of the reduction of 
“mostly incomplete” articles from 46% to 19% and of “missing” articles from 22% to 13%. (C) All 
sub-proteomes were completed in the following two years along with other mitochondria-related protein 
clusters, including membrane, contractile, coronary artery disease (CAD), and tRNA-related proteins.
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In the following two years, Gene Wiki articles on all of the selected proteins were completed 
from the five key sub-proteomes, along with the membrane, contractile, coronary artery disease 
(CAD), rare mitochondrial disease, and tRNA-related proteins. The master article record allowed 
us to measure the size of our contribution by a collection of metrics, including pages created, 
improved, and completed; sections improved; and the number of references, Semantic Wiki links, 
and kilobytes (kB) added (Table 5-1). Given that all of the content added to these pages is free 
text, a total contribution of over 4MB is really quite significant. Over 5,600 references were added 
across 541 pages, making mitochondrial research more findable and accessible, and potentially 
more reusable through newfound citations and awareness of the work. Wikipedia is an excellent 
starting point for the beginning of a research or writing effort, particularly when ample references 
are made available and cited appropriately.
1.3.3 Mitochondrial Gene Wiki as an educational platform.
Beyond improving articles and access to scientific knowledge, the Mitochondrial Gene Wiki project 
was also implemented as an effective educational mechanism for imbuing students pursuing 
careers in science and medicine with effective research and writing techniques. Trainees from 
all educational levels were guided through each step of the process to develop critical skills in 
curation, both from the literature and a variety of informatics sources; article and data source 
evaluation; knowledge synthesis; and scientific writing. In all, we trained 35 high school summer 
interns, 12 undergraduate college students, and 2 graduate students over the course of three 
years. Throughout the process, we used the Mitochondrial Gene Wiki article improvement 
Cluster PagesCreated
Pages 
Improved
Pages
Completed
Sections
Improved
References
Added
Links
Added
kB
Added
Metabolism 21 139 160 650 1,153 4,224 963.57
OXPHOS 36 80 116 547 863 4,607 761.89
Proteolysis 6 66 72 287 997 1,966 674.43
Apoptosis 8 54 62 374 498 1,980 442.75
Redox 0 15 15 74 162 282 64.93
Membrane 0 17 17 77 148 842 110.84
Contractile 0 56 56 262 1,287 3,220 617.10
CAD 4 21 25 99 451 809 315.54
tRNA 0 18 18 62 115 456 79.39
Total 75 466 541 2,432 5,674 18,386 4,030.42
Table 5-1. Mitochondrial Gene Wiki article improvement metrics. Overall article improvements are 
shown by protein/gene cluster, including pages created, improved, and completed; sections improved; as 
well as references, Semantic Wiki links, and kilobytes (kB) added.
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efforts as a vehicle to introduce them to cardiovascular physiology, mitochondrial biology, clinical 
concepts, and FAIR Principles in biomedicine. We view this as a critical aspect of training for the 
next generation of researchers and clinicians.
Section 2. MitoCases
2.1 Background and Approach
2.1.1 Clinical reports on rare mitochondrial disease.
Rare mitochondrial diseases (RMDs) are complex and difficult to diagnose, with limited treatment 
options and no available cures. Rare diseases are defined in the U.S. by the Rare Diseases Act 
of 2002 as those affecting fewer than 200,000 individuals [21], or about 1 in 1,500 individuals. 
The low incidence of rare mitochondrial diseases makes it particularly difficult to develop effective 
treatments, conduct clinical trials, or ensure awareness among health care professionals. Clinical 
case reports (CCRs) provide clinicians and researchers with a wealth of information about a wide 
range of diseases, their defining characteristics, and successful as well as failed attempts at 
treatment. As of August 2019, PubMed hosts over two million CCRs, and the rate of publication 
of this type of report is continually increasing. A sample of 30 RMDs are covered by fewer than 
3,000 of these reports, demonstrating their rarity as well as the importance of being able to 
easily find and access the clinical insights contained within. However, much of this information 
remains relatively hidden as a result of ineffective indexing and a lack of comprehensive metadata 
on the reports. Unstructured text data is not accessible by computational means and requires 
extensive manual effort to curate, read, and evaluate cases before synthesizing the information 
into actionable clinical knowledge. 
2.1.2 CCR curation challenges.
The wide range of clinical signs and symptoms in mitochondrial diseases makes them particularly 
difficult to diagnose and to differentiate between without in-depth genetic profiling, which is 
sometimes not readily or quickly available. Furthermore, the rarity of these diseases means that 
comprehensive clinical profiles of patients and best practices in treatment and therapeutics are 
sometimes unavailable or difficult to source. Clinical case reports represent a key mechanism 
for communication between clinicians, particularly regarding rare and uncommon presentations. 
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However, this critical resource is poorly indexed, making it difficult to quickly and accurately 
identify relevant documents. PubMed is the primary source used for accessing CCRs, but the 
lack of extensive, case-specific metadata on these reports makes curating relevant reports an 
inordinately time-consuming task. Pertinent documents are easily missed while many irrelevant 
documents are acquired, slowing the sourcing of critical case information with the necessary 
investigation of inaccuracies and false leads. 
PubMed does have a feature for searching CCRs, but the search mechanism is limited to the 
title, abstract, and MeSH (Medical Subject Headings) terms [22, 23].  MeSH terms provide some 
metadata on the content of the reports, but the system is not ideally suited for complex queries 
probing the symptoms, genetics, or demographics of patients discussed within. MeSH terms 
related to patient age are aligned with common clinical classifications (“Infant”, including “Infant, 
Newborn”; “Child”, including “Child, Preschool”; “Adolescent”; and “Adult”, including “Young Adult”, 
“Middle Aged”, and “Aged”), but case reports are frequently mislabeled or tagged with multiple 
labels not related to the patient discussed in the report, making it difficult to filter cases using these 
tags. Similarly, gender tags exist but are inconsistently utilized. Frequently, CCRs are labeled with 
both “Male” and “Female” terms, compromising the utility of the tag as a search mechanism. 
MeSH terms exist for many disease classifications as well, but they are also used inconsistently; 
in a collection of 30 reports on Barth syndrome, only 10 were labeled with the “Barth syndrome” 
MeSH term, and 17 with the more general “syndrome” term. There are MeSH terms for a variety 
of symptoms, biomolecules, and other related concepts, but these, again, are used inconsistently 
and do not provide comprehensive or reliable metadata related to the reports. Searching for a set 
of symptoms typically returns very few results. 
In fairness, MeSH was not designed to provide highly detailed metadata on case reports. Still, the 
lack of such a system is hampering the ability of clinicians to access reports relevant to their cases 
and makes it more difficult for them to make accurate, timely diagnosis and provide adequate 
treatment and therapeutics to their patients. Researchers are similarly limited in their ability to 
study translational aspects of pathways and drugs related to particular diseases. Furthermore, 
data scientists and text-mining researchers lack reliable and accessible collections of text data or 
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comprehensive ontologies of clinical language, presenting a significant barrier to development of 
advanced NLP approaches necessary for powerful clinical decision support systems.
2.1.3 Rendering RMD CCRs FAIR.
We set out to make the knowledge represented in CCRs on RMDs more FAIR by generating 
detailed, highly structured metadata on the reports and creating a platform from which it can be 
effectively accessed, searched, and analyzed. We manually curated 384 reports on 8 RMDs, 
including deficiencies in complex I through V of the electron transport chain, carnitine deficiency, 
megaconial type congenital muscular dystrophy (MDCMC), and Barth syndrome. Leveraging the 
collective expertise of our group regarding mitochondrial physiology and clinical paradigms, we 
imposed structure on the reports using the standardized Metadata Acquired from CCR (MACCR) 
template [24, 25] discussed in Chapters 3 and 4, including detailed bibliographic, demographic, 
and medical content from the CCR. We also constructed a digital map of RMD symptomology by 
codifying patient symptoms described in each CCR using clinical controlled vocabularies ICD-10 
and ICD-11 (International Statistical Classification of Diseases and Related Health Problems, 10th 
and 11th revisions) [26, 27].
In alignment with the FAIR Data Principles, we built a cloud-based MediaWiki platform called 
MitoCases (http://mitocases.org/) to house all metadata and ICD codes, providing biomedical, 
clinical, and text-mining researchers with a large dataset of structured text data for downstream 
analysis. All metadata is downloadable in whole, by disease, or in subsets based on results 
via our Elasticsearch functionality, and the MitoCases API allows direct programmatic access to 
platform functionalities. We provide Jupyter notebooks and present potential use cases that may 
be pursued through downstream analysis by researchers, physician investigators, clinicians, data 
scientists, text-mining researchers, pharmaceutical companies, and clinical trial coordinators. 
The entirety of the underlying codebase and analysis tools are available to the public on GitHub 
(https://github.com/aogarlid/mitocases). The platform empowers biomedical researchers to 
create in silico RMD cohorts, amplify small sample size studies by integrating with larger cohorts, 
and leverage the cumulative power and value of many patient reports for statistical analysis. 
MitoCases provides a FAIR Data resource of standardized and structured CCRs on RMDs and 
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integrates existing ICD ontologies to enable the biomedical community to elevate understanding 
of mitochondrial disease and improve patient care. 
2.2 Methods
2.2.1 Manual case report curation.
There are currently more than two million clinical case reports available on PubMed, over 3,000 
of which describe patients with a sample of 30 different RMDs. We selected 8 of these diseases 
for article curation, including deficiencies in complex I-V of the electron transport chain, systemic 
carnitine deficiency, Barth syndrome, and megaconial-type congenital muscular dystrophy.  Our 
manual curation approach filtered the 788 CCRs discovered across these diseases for articles 
describing a single patient, written in English, with the full text available for download. The 
resulting set of articles slated for metadata extraction comprised 384 CCRs: Complex I deficiency 
(84 reports), Complex II deficiency (12 reports), Complex III deficiency (29 reports), Complex 
IV deficiency (170 reports), Complex V deficiency (7 reports), systemic carnitine deficiency (45 
reports), Barth syndrome (30 reports), and congenital megaconial type muscular dystrophy 
(MDCMC; 7 reports).
2.2.2 Metadata extraction with MACCR template.
To impose structure on clinical information relating to RMDs, we created a metadata template for 
CCRs (the MACCR template) with bibliographic, demographic, and medical content sections, as 
well as genetic information (Table 5-2) [24, 25]. Each section and the corresponding fields were 
developed in close collaboration with clinicians and researchers to ensure full representation 
of the relevant information contained within these reports. We manually extracted metadata 
from each CCR using the standardized MACCR template. Full instructions are provided in the 
Metadata Extraction Guide [28], originally published as a Data Citation in the Sci. Data manuscript 
[25] presented in Chapter 4. Annotators begin by filling the case report identification fields of 
the template with bibliographic information about the article, including the title, authors, year of 
publication, journal, institution, corresponding author, PMID, DOI, and the language in which 
the report is written. The fields in the Medical Content section identify document-level, concept-
level, and text-level features of the report. For this section, annotators read the CCR closely and 
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Table 5-2. Standardized metadata template for clinical case reports. The metadata template provides 
a set of features common to clinical case reports and facilitates concept-level metadata extraction. This 
template is arranged into three primary sections: Identification, Medical Content, and Acknowledgments. 
The first two categories are geared towards promoting aspects of FAIR standards, as indicated. A single 
document contains the majority of these features and the metadata template was designed in consultation 
with clinicians to ensure all key concepts were addressed. Data Type refers to the type of source data, 
including free-text (“Text”), unique database identifier or other structured value specific to the document 
(“Identifier”), or “Numerical” values, such as number of references. Examples shown here are simulated 
but representative of dataset contents. It should be noted that the Disclosures/Conflict of Interest listed 
here are fabricated and do not apply to the author. **Demography details are converted to consistent 
values to facilitate Case Report Search. ***If not provided within document text, geographic location is 
inferred from the associated institution. ****Numerical count of the total number of clinical images, figures, 
videos, and tables, respectively, published along with the main text of the report. 
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extract the exact text content from the report to fill the relevant fields: key words, demographics, 
geographic locations, life style, family history, social history, medical/surgical history, disease 
system, signs and symptoms, comorbidities, diagnostic techniques and procedures, diagnosis, 
laboratory values, pathology, pharmacological therapies, interventional therapies, patient 
outcome assessment, and counts of visual media included in the report (images, figures, videos 
or animations, and tables). Finally, the Acknowledgements section provides additional details 
about the report, including funding source, award number of any support mentioned, disclosures 
or conflicts of interest, and a numerical value of the number of references cited by the report. 
2.2.3 Digital symptomology map with ICD codes.
For added interoperability with existing standardized clinical vocabularies, we identified symptoms 
discussed in each report and represented them using ICD-10 and ICD-11 codes. The symptomology 
dataset includes the ICD codes and their descriptions, as well as the text content from the CCR 
describing the symptom. Each code is contained on a new row in an Excel sheet and identified 
by the article PMID. Annotators read the CCR line by line to identify all mentions of symptoms 
pertaining directly to the patient, but avoiding those symptoms mentioned in the background 
description of a typical case presentation, as well as those mentioned in the discussion of similar 
or related cases. For each identified symptom, annotators copy the text describing it into the 
appropriate column, then search for the symptom codes in the ICD-10 and ICD-11 browsers 
(ICD-10: https://icd.who.int/browse10/2016/en and the alternative https://icd10data.com/; ICD-11: 
https://icd.who.int/browse11/l-m/en). Symptoms are frequently presented in the case reports with 
descriptions that are quite different than that of the ICD code, which requires that annotators 
consult available resources such as Wikipedia and PubMed to find synonymous phrases that 
will help identify the appropriate code. When there are seemingly multiple valid coding options, 
annotators are instructed to identify the best fit.
Some ICD codes have an “Other specified” or “Unspecified” option. For example, the “Heart 
failure, unspecified” ICD-11 code (BD1Z) would be employed for a case report that describes 
the patient as having “died from cardiac failure” without specifying a particular form of cardiac 
failure. Similarly, the “Other specified abnormalities of breathing” ICD-11 code (MD11.Y) is used 
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for a case report describing a patient with “tachypnea”, as there is no unique code for this type 
of breathing issue.  Neither ICD-10 nor ICD-11 contain a specific code for “lactic acidosis” so the 
general code is used (ICD-10 E87.2 “acidosis” and ICD-11 5C73.Y “other specified acidosis”). 
Finally, it is important to note that while ICD-10 does contain some codes for specific diseases, the 
recent release of ICD-11 appears to focus on symptoms to the exclusion of diseases (e.g., Barth 
syndrome is included in ICD-10 but not in ICD-11). When there is a discrepancy in representation 
of a symptom between the two systems, the symptom will still be recorded with the available 
code and the column for the other coding system is filled with “NA”. As the dataset grows, we are 
logging these discrepancies and will submit important codes missing from ICD-11 for inclusion in 
an upcoming revision. 
2.2.4 Inter-annotator agreement.
To ensure comprehensive metadata extraction across all annotators and consistency between 
them, we monitored inter-annotator agreement by engineering a small degree of overlap between 
their assigned tasks [29]. Roughly 10% of the total collection of reports were assigned to all 
annotators and the resulting MACCRs and ICD codes were evaluated for consistency between 
team members as well as their relative comprehensiveness [30]. The identities of the repeat 
assignments were not revealed to the annotators so as to prevent any alteration in their typical 
methodology. Annotation tasks were assigned in batches, with each batch containing repeat 
assignments. This provided a mechanism for intra-annotator evaluation, or the consistency 
of a single annotator’s performance and comprehensiveness over time [29]. New annotators 
joining the team were assigned the past repeat tasks to evaluate their performance against past 
and existing team members, and to provide suggestions for improvement where necessary. 
Additionally, all new members were coached extensively and guided individually through their 
first set of assignments by an experienced annotator. 
2.2.5 Creating the MitoCases platform.
With extensive metadata on RMD CCRs in hand, we developed the cloud-based MitoCases Rare 
Mitochondrial Disease Knowledge Platform (http://mitocases.org/) to house the metadata and 
provide a user-friendly interface with a powerful search function, download capabilities, an upload 
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pipeline to contribute additional RMD CCR metadata, envisioned use case scenarios, and sample 
code for researchers to use in their own downstream analysis. MitoCases is hosted on an AWS 
instance and built upon a MediaWiki framework using MySQL for data storage and additional 
applications for API access (Flask) and search capabilities (Elasticsearch). The following section, 
2.3 Technical Specifications, details the front- and back-end components and architecture of 
the MitoCases platform.
2.3 Technical Specifications
The cloud-based MitoCases Rare Mitochondrial Disease Knowledge Platform is housed on an 
Amazon Web Services (AWS) Elastic Compute Cloud (EC2) t3.large instance with two virtual 
CPUs (vCPU) and 8 GB memory, providing ample computing power and storage space for the 
largely text-based datasets. MitoCases is built upon a MediaWiki framework with a MySQL 
database, Elasticsearch functionality, and a Flask-based API to allow for a modular, decoupled, and 
extensible platform (Fig. 5-4). All open source technologies, API access, detailed documentation, 
and use case scenarios for key user groups ensure that the platform and the data contained 
within is highly usable and FAIR, regardless of the technical capabilities of the user.
2.3.1 MediaWiki framework.
MediaWiki is built upon a free open source software (FOSS) bundle known as the LAMP 
Researchers
Data scientists
Clinicians
Figure 5-4: Cloud-based MitoCases platform architecture. The MitoCases platform is accessible to 
researchers, clinicians, and data scientists through a custom-configured MediaWiki user interface built on 
a LAMP stack (Linux, Apache, MySQL, and PHP). The Data API (application programming interface) is 
driven by the Python-based Flask web application framework and mediates all back-end functionality and 
data handling throughout MitoCases. The SQLalchemy SQL toolkit facilitates interactions with the MySQL 
database where MitoCases data is stored, and Elasticsearch provides a full-text search engine configured 
to query the MySQL database. JSON (JavaScript Object Notation) files are used for communication 
between the various components to deliver queries, download requests, and uploads. The MitoCases 
Platform is housed on an AWS (Amazon Web Services) Elastic Compute Cloud (EC2) T3.large instance.
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stack, combining the Linux operating system, Apache web server, MySQL Relational Database 
Management System (RDBMS), and the PHP programming language. For the purposes of the 
MitoCases platform, we used the proxy module so Apache can act as proxy and reverse proxy, 
allowing requests to pass through the website URL and be redirected to specified endpoints, such 
as the Flask API (application programming interface) used throughout the back end development 
for uploads, downloads, and data management. The WSGI (Web Server Gateway Interface) 
module allows Apache to receive requests from the API using Python code, which is used 
throughout this implementation for data handling, analysis, and visualization. MediaWiki furnishes 
clean, structured data entries in an easily recognizable and navigable format. The MediaWiki API 
enables programmatic page building with additional markup and easily incorporates new features.
2.3.2 MySQL database.
The underlying metadata and ICD codes extracted from CCRs on MitoCases utilizes the MySQL 
RDBMS for data warehousing and extract, transform, load (ETL) functions, chosen specifically 
for its inherent integration and optimization within the MediaWiki infrastructure. MySQL facilitates 
simple queries to link data by their common relationships, typically referred to as a primary key. 
To accommodate reports discussing multiple patients and to prevent reuse of the primary key, 
MitoCases employs a dual-column primary key: the article PMID (PubMed identification number) 
and the patient number (Fig. 5-5). The primary table (“demographics”) contains the article PMID, 
patient number, and individual patient demographics, including the age of onset and gender. The 
disease classifications and affected genes and mutations (where identified) are contained in the 
“gene_disease” table, which uses the PMID and patient number as a foreign key to accommodate 
cases with multiple diagnoses. The “symptomology” table contains structured metadata on patient 
symptoms encoded using ICD-10 and ICD-11 and also uses the PMID and patient number as 
a foreign to accommodate multiple symptom entries per patient. The “bibliographic_info” table 
contains detailed provenance information and the “medical_content” table houses the MACCR 
metadata templates assembled for each patient. The bibliographic and medical content tables 
employ the article PMID and patient number as the primary key to prevent any double entries 
and maintain data integrity and fidelity. This allows data retrieval across all tables with simple 
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left-join queries to link diseases, genes, and symptoms back to the patient in question and their 
demographic details. The design is easily extensible through instantiation of new tables sharing 
the PMID-patient key, allowing later incorporation of additional related data, such as ICD procedure 
codes or inclusion of SNOMED codes in the symptomology table. This data structure, with tight 
association across tables through a unique identifier, is better suited for an RDBMS such as 
MySQL as compared to a NoSQL solution, which is meant for data with no tabular relationships. 
2.3.3 Flask API.
Flask and additional Python libraries form the MitoCases API, which handles all user requests 
for search, uploads, and downloads, effectively decoupling the front-end user interface from the 
back end to allow for better extensibility and modularization. Flask is a microframework for web 
PMID gender age_onset
21932011 Male 5 years
28295041 Female 3 years
20018511 Female 5 years
PMID title authors journal year doi …
21932011 Barth syndrome diagnosed in… Takeda A, … Eur. J. Pediatr. 2011 10.1007/s00431-011-1576-5
28295041 Exome sequencing identifies… Lahrouchi N, … Eur J Hum Genet. 2017 10.1038/ejhg.2017.22
20018511 A novel mitochondrial MTND5… Alston CL, … Neuromuscul Disord. 2010 10.1016/j.nmd.2009.10.010
PMID demographics location family_history medical_history signs_symptoms …
21932011 13-year-old boy NA no family history of BTHS… male patient was born at 35 wks… Mild hypotonia and a myopathic face…
28295041 3-year-old girl Morocco two siblings dying young… normal development until age 2… fatigue, shortness of breath, pallor, …
20018511 7 year old girl NA maternal aunt with tremor… born in good condition at term… mild metabolic acidosis and raised…
PMID icd11 icd11_desc source_context
21932011 KB08.2 Congenital hypotonia Mild hypotonia
21932011 5C52.2 Neutral lipid storage disease lipid storage myopathy
21932011 BC44 Noncompaction cardiomyopathy Isolated Noncompaction of Ventricular Myo…
patient_demographics
bibliographic_info
medical_content
symptomology
PMID disease gene mutation
21932011 barth TAZ c.646G>A (p.Gly216Arg)
28295041 carnitine SLC22A5 NA
20018511 complex_I MT-ND5 NA
gene_disease
Figure 5-5: MitoCases MySQL database schema. The data on MitoCases is contained across five 
tables: “patient_demographics”, “gene_disease”, “bibliographic_info”, “medical_content”, and 
“symptomology”. The PMID serves as the primary key in the patient_demographics, bibliographic_info, 
and medical_content tables to ensure that only one entry per PMID is ever accepted. For the 
gene_disease and symptomology tables, PMID is used instead as a foreign key such that multiple 
diseases and genetic associations can be entered per patient, as well as a comprehensive record of 
symptoms. The bibliographic_info and medical_content tables are shown here with only a sample of the 
total column headings contained within each; the complete tables contain all fields represented in the 
MACCR metadata template depicted in Table 2. Additional tables (not shown) contain a master database 
of ICD-10 and ICD-11 codes and their descriptions.  
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application development in Python and ships with limited functionality beyond its ability to serve and 
receive HTTP requests. Apache’s proxy module redirects all URLs with the base URL “mitocases.
org/mito_api/” from the MediaWiki framework to Flask to handle all API endpoints (Fig. 5-6). The 
API provides language-agnostic programmatic access to all available data such that technically 
proficient users can employ any programming language that supports web requests to analyze 
the data in a controlled and easily accessible manner. 
MitoCases depends on several different applications and software, which are effectively 
compartmentalized and incorporated using Flask. The Apache web server grants access to the 
Flask server, facilitated by additional modules including mod_wsgi, reverse_proxy, and the settings 
listed in the mito_api.conf file. External Python libraries including Elasticsearch, Elasticsearch_
dsl, and requests allow interaction with search functionalities, and internal modules tie their 
functionality together for use as single functions. All database access is accomplished through 
the SQLalchemy Python library, allowing Flask to construct SQL queries in Python. Flask largely 
Data summary
Data acquisition
Data upload
POST
GET /current_diseases
Queries database for all disease mentions and returns unique entries.
GET /pmids_by_disease?disease=
Queries database for specified disease and returns associated PMIDs.
GET /icd_data_by_disease?disease=
Queries database for specified disease, acquires PMIDs from primary table, returns associated ICD records.
GET /icd_data_by_pmid?pmid=
Queries database for specified PMID(s) and returns all associated ICD records.
GET /metadata_by_pmid?pmid=
Queries database for specified PMID(s) and returns all associated metadata.
GET /metadata_by_disease?disease=
Queries database for specified disease, acquires PMIDs from primary table, returns associated metadata.
GET /case_report_search?query=
Converts JSON to an Elasticsearch query, sends it to the database, and returns the relevant data.
POST
/upload_templates
Upload template or folder of templates containing metadata extracted from RMD CCRs.
/upload_icd
Upload file containing ICD symptomology metadata extracted from RMD CCRs.
Figure 5-6: Data API endpoints. Data summaries, downloads, uploads, and queries to the MySQL 
database are all handled through the Data API. MitoCases allows direct programmatic access via the 
Data API for GET and POST requests from advanced users. 
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serves as a connector between other services and software designed in-house. Using Flask as an 
intermediary furnishes a common mechanism to incorporate other useful software in a language 
that has low onboarding time, with features that are easy to use and require minimal knowledge 
of web services for extensibility and modularization.
Flask serves as the back-end API for MitoCases, handling downloads, uploads, and case report 
search by sending and receiving JSON files between the Flask server and other web applications, 
including MediaWiki, Elasticsearch, and MySQL. API endpoints are easily generated using the 
Flask decorator function, which imbues simple Python functions with additional functionality. For 
instance, the app.route decorator associates a MitoCases URL with a Python function, sending 
requests to that URL directly to the Python code. The process takes one line of code and a new 
response object accessible by the input function. The response object contains all the data passed 
when making the request, what type of request was sent, and the status of the request. Our 
expected user community of data science and text-mining researchers is more likely to possess 
some Python experience than web development experience, providing an easy workflow, rapid 
development time, and ease of extension for even beginners in Python. 
The Flask framework offers a simple and lightweight solution for uniting diverse applications in 
comparison to other options such as Django and web.py; most other options supply features 
and packages (“batteries included”) that are unnecessary for the use case, or implement their 
features in such a way that could present a barrier to entry for new developers. Django, for 
instance, is a large framework with native support for an admin page, form submission, and its 
own ORM (object relationship mapper), but these features are implemented in a complex manner 
that may not be clear to a novice Python user. Similarly, web.py has a range of features that are 
unnecessary for this implementation. URL routing is much more complex, requiring all URLs to be 
listed in a separate object, a separate class for each endpoint, and, within each class, a method 
for every type of HTTP request supported by the endpoint. Additionally, request information is 
implicitly incorporated into the function defined in each class, rather than being provided in a 
corresponding request object. In contrast, Flask provides a simple one-page tutorial and requires 
only a rudimentary understanding of HTTP requests for a novice developer to begin accessing the 
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API or extending MitoCases functionalities for any desired purpose. Furthermore, Flask benefits 
from the built-in app.route decorator for fast API endpoint creation through a single line of code.
2.3.4 Elasticsearch.
Elasticsearch facilitates MitoCases user queries across all available metadata housed in the 
database, providing users with the ability to retrieve case report metadata by disease, keyword, 
demographics, or any combination using Boolean logic in a powerful search engine. Elasticsearch 
employs a RESTful (REpresentational State Transfer) software architectural style which ensures 
reliable interoperability between computer systems across the internet by using a stateless 
protocol and standard operations. The inherent extensibility of the Elasticsearch RESTful API and 
full Python support through SQLalchemy allows easy integration with Flask for communication 
with other web services, as well as seamless integration with the underlying code on MitoCases. 
Search and storage services are decoupled by assigning the roles to Elasticsearch and MySQL, 
respectively, avoiding a full system failure in the event that the search function fails.
The MitoCases Case Report Search functionality allows users to build complex queries governed 
by Boolean logic to include or exclude all documents with a particular search phrase, or based on 
a disease, age range, gender, or publication date (Fig. 5-7). The search mechanism is composed 
of a querybuilder function, a plotting function for the results summary, and functions that build the 
section titles, results lists, and download links. The querybuilder Queries are verified for proper 
formatting by the querybuilder package and the user is notified to address errors or empty fields 
before submitting. Once it has been constructed and submitted by the user, querybuilder converts 
it to a JSON and sends it to Flask to process into an Elasticsearch query. The Elasticsearch 
query is sent through Flask to SQLalchemy, which constructs SQL queries in Python to send to 
the MySQL database. Flask retrieves the search results and generates usable information for 
front-end display functions using the case_report_search API endpoint. A summary of the results 
is displayed as a donut chart, categorized by disease, using the create_donut_chart function and 
d3.js. The list of search results, categorized by disease, are generated by the create_title_section 
function. Download links call jszip to load .zip files with metadata from the results, either in entirety 
or by disease, and filesaver.js enacts the download to the local machine. 
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2.3.5 Downloads.
Downloads are furnished by the metadata_by_disease and icd_data_by_disease API endpoints 
to serve files. Users can acquire all available MitoCases data through the MediaWiki UI, which 
provides simple links to download all forms of metadata in .zip files. They may also use the search 
feature for a more limited set of reports related to their current study or patient. More advanced 
users may interact with the API directly to download all available data, retrieve specific subsets of 
the data, or construct queries of their own. 
2.3.6 Uploads.
MitoCases provides the ability to contribute metadata on case reports relating to diseases already 
included as well as those not yet represented on the platform (Fig. 5-8). A simple user interface 
facilitates uploading a single metadata file or multiple files contained within a folder on the user’s 
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Clinician
case_search
make_plot
list_results
querybuilder
Query Summary
Search phrases:
     cardiomyopathy
     delayed growth
     hypertrophy
Publication year: ≥ 2000
Age of onset: ≥ 3 yrs; ≤ 20 yrs
Search phrase
Search phrase
Search phrase
Age of onset
Age of onset
Pub Yr (YYYY)
=
=
=
≥
≤
≥
cardiomyopathy
delayed growth
hypertrophy
2 years
20 years
2000
Delete
Delete
Delete
Delete
Delete
Delete
AND  OR Add rule Add group
Search
Complex IV deficiency
Barth syndrome
Complex I deficiency
Complex II deficiency
Complex V deficiency
MDCMC
Carnitine deficiency
Download data for all CCRs matching your query
MDCMC: download metadata
* Megaconial muscular dystrophy by mitochondrial membrane homeostasis defect, new insights from 
skeletal and heart muscle analyses.
Barth syndrome: download metadata
* Cardiomyopathy of unknown etiology: Barth syndrome unrecognized.
* Barth Syndrome with Late-Onset Cardiomyopathy: A Missed Opportunity for Diagnosis.
* Novel missense mutation (R94S) in the TAZ (G4.5) gene in a Japanese patient with Barth syndrome.
View more
Carnitine deficiency: download metadata
* Systemic carnitine deficiency -- a treatable inherited lipid-storage disease presenting as Reye's syndrome. 
* Value of radionuclide assessment with thallium 201 scintigraphy in carnitine deficiency cardiomyopathy.
* Cardiac magnetic resonance findings in a case of carnitine deficiency.
View more
Complex I deficiency: download metadata
* Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and 
encephalopathy.
* Biventricular non-compaction hypertrophic cardiomyopathy in association with congenital complete heart 
block and type I mitochondrial complex deficiency.
* The first nuclear-encoded complex I mutation in a patient with Leigh syndrome.
Complex II deficiency: download metadata
* A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe 
mitochondrial complex II deficiency.
Complex IV deficiency: download metadata
* Mitochondrial complex IV deficiency, caused by mutated COX6B1, is associated with encephalomyopathy, 
hydrocephalus and cardiomyopathy.
Data API
Figure 5-7: MitoCases Case Report Search. MitoCases provides a powerful Case Report Search 
mechanism that allows users to design complex queries for cases of interest using keywords and phrases 
as well as filtering by disease, patient gender, age, and publication year. The user can define multiple 
groupings of search terms and filters, with AND/OR logical rules within and between the groups. The 
querybuilder module converts a valid query into a JSON object that is passed to Elasticsearch and MySQL 
through the Data API and on to the case_search module that displays the results. The user is presented 
with a summary of their search terms and filters and a donut plot summarizing the results, categorized by 
an interactive donut plot. The case reports matching the search terms are listed below, categorized by 
disease, with links to PubMed on each case report, links to download all available metadata for each 
disease, as well as a download link to acquire all available metadata across all diseases.
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local machine. Detailed instructions, blank templates, and examples are provided for collecting 
metadata from individual case reports and generating the MACCRs templates as well as ICD-11 
symptom metadata. Upon uploading, the Flask API delivers the templates to a Python validation 
script that will check that all fields are filled, no errant or unsupported characters exist, and that 
proper line separators are used. The script also communicates with the NCBI Entrez Programming 
Utilities (E-Utils) API [31] and the DOI.org resolution system (http://doi.org/) [32] to confirm that 
the submitted URLs, DOIs, PMIDs, and titles are correctly associated with one another. In the 
event of any errors, a report is delivered to the user to alert them to the specific fields that require 
attention with references to the relevant instructions that should be revisited and adhered to for 
a successful upload and inclusion in the dataset. Upon successfully passing the validation step, 
the user is notified that their submission has been delivered for manager review, and their e-mail 
address is requested so that they may be notified upon its ultimate approval. User accounts with 
fast-tracked approval will be provided for those who consistently submit valid and useful metadata. 
Upon data validation, the metadata is delivered to the cloud platform and stored pending approval 
by the MitoCases data managers. Once the data has been approved, it is routed through the API 
to the MySQL database and distributed across the relevant tables. 
MACCRs ICD codes
CCRs Error reportResearcher
Validation
script
Validated
metadata
Data API
Metadata Collection
Data API
Figure 5-8: Metadata upload functionality for user contributions. Researchers can contribute their 
self-assembled metadata templates and symptomology tables on a disease of interest via the MitoCases 
upload functionality. Blank and example templates are provided along with detailed instructions to guide 
metadata creation, which can be submitted individually or in bulk uploads by folder. The MitoCases Data 
API queries both the NCBI PubMed E-Utilities API and DOI.org for the PMIDs and DOIs identified in the 
upload files, then employs a Python-based validation script to confirm that both identifiers match the title 
supplied and that there are no missing fields or invalid characters. When necessary, an error report is 
generated and sent back to the user with specific issues and links to the relevant instructions needed to 
remedy them. Upon  successful validation, the templates are delivered through the Data API to the 
MitoCases server for approval by a data manager prior to its ultimate upload to  the MySQL database, 
where it will be made accessible to the MitoCases community and other researchers and clinicians.
MitoCases
Data Manager
MySQL
Database
MitoCases
Community
NCBI E-Utilities API
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2.4 Results and Discussion
2.4.1 Overview and summary of MitoCases metadata.
MitoCases houses a large collection of demographics, medical, and genetic metadata, all of which 
is available on the platform to browse or download. The metadata is also searchable using the 
Case Report Search feature, providing users the ability to assemble complex queries to identify 
cases of interest. Across all 384 curated CCRs, 4,561 instances of 952 unique ICD-10 codes were 
identified for the individual patients. Each of these codes, their descriptions, and the text content 
in the CCRs from which they were extracted is indexed by the Case Report Search functionality, 
providing a straightforward method for identifying case reports with a particular set of symptoms. 
Key characteristics of all metadata are summarized on the home page as well as on each disease 
page. This includes distributions reflecting the patients’ age of onset, gender, genetic information, 
as well as a geographic distribution of publication localities across the world. A summary of the 
metadata contents is provided in Table 5-3.
Age (in yrs, unless noted) Gender (%) ICD-10 codes
Disease # CCRs Median Mean Min Max Male Female Total Unique Top gene
Barth 30 7.5 mo 5 < 1 mo 30 97 3 340 95 TAZ
Carnitine 45 4 11.4 < 1 mo 68 48 52 366 153 SLC22A5
Complex I 84 1 7.2 < 1 mo 64 54 46 1463 482 MT-TL1
Complex II 12 7 mo 6.4 < 1 mo 33 62 38 141 69 SDHA
Complex III 29 10 mo 8.7 < 1 mo 57 57 43 347 141 MT-CYB
Complex IV 170 13 mo 7.7 < 1 mo 62 48 52 1715 503 SURF1
Complex V 7 < 1 mo 3.8 < 1 mo 22 43 57 73 39 TMEM70
MDCMC 7 2.5 6.1 < 1 mo 16 71 29 116 64 CHKB
Overall 384 1.1 yr 7.6 yr < 1 mo 68 yr 55 45 4,561 952 TAZ
Table 5-3. Summary statistics on MitoCases metadata contents. The MitoCases platform contains 
detailed metadata on 384 CCRs relating to 8 different RMDs, including Barth syndrome, carnitine 
deficiency, deficiencies in complexes I-V of the electron transport chain, and congenital megaconial-type 
muscular dystrophy (MDCMC). Patient ages range from newborns under 1 month of age up to patients in 
their 60’s, though the diseases disproportionately affect infants and young children. The gender 
distribution is quite balanced, aside from Barth syndrome, which occurs almost exclusively in males. 4,561 
instances of nearly 952 unique ICD-10 codes were used to codify the symptomology of these patients. The 
genetic etiology of Barth syndrome is entirely attributed to mutations in the tafazzin-encoding TAZ gene 
and only CHKB mutations were reported in the MDCMC cases. The genetic basis is more varied for the 
rest of the diseases investigated here, shown in Figure 5-10.
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2.4.2 Comparing representation of patient gender.
The gender reported for each patient is included in a top-level demographics table within the 
database, along with the genetic etiology of their disease. Frequently, gender is missing entirely or 
both male and female MeSH terms will be included for a given CCR on PubMed. In many cases, 
this appears to be due to a mention of other patients with a similar presentation that are discussed 
within the report. However, this presents difficulties when attempting to limit search results to one 
gender or the other. In the MitoCases dataset, metadata is derived only for the primary patient 
of the report, removing any ambiguity and facilitating a better search mechanism. The gender 
distribution across all diseases is presented on the main page of the MitoCases platform, and for 
the individual diseases on each disease page.
2.4.3 Comparing age categories and their utility.
The age categories available in the MeSH hierarchy are appropriate and aligned with clusters 
employed in the clinical community, but it is difficult to make use of these terms when searching 
for case reports. Inputting numerical values does not call up the relevant MeSH terms. Similar 
issues of ambiguity as in the gender tags also occur, with multiple, contradictory age groups 
listed for a single report. These issues further limit users’ ability to search for cases relevant to 
specific age ranges. In contrast, the MitoCases platform contains specific ages for each patient, 
with newborns classified as < 1 month, 1 month resolution for patients below 2 years of age, and 
1 year resolution beyond. The ages are presented in common written form on the site for ease of 
understanding by our users (i.e., “Under 1 month”, “13 months”, “25 years”, etc.), while the back-
end data handling treats months as fractions of years to ensure the appropriate search results are 
retrieved. The age distribution across all cases is included on the main page and also by disease 
on each individual page. Similar to the MeSH system, we chose to employ 10 age bins in our 
distribution presentations, including Newborn (<2 months), Infant (<2 years), Preschool child (3–5 
years), Child (6–13 years), Adolescent (14–18 years), Young adult (19–24 years), Adult (25–48 
years), Middle aged (49–64 years), Aged (65–78 years), and Elderly (79–98 years). 
2.4.4 Comparing representation of patient symptomology.
We analyzed PubMed MeSH terms in comparison to ICD codes in Barth syndrome CCRs to 
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evaluate the degree of additional information contained on MitoCases (Fig. 5-9). Excluding 
demographic terms (age, sex), the top MeSH terms identified in the 30 Barth Syndrome CCRs 
were “syndrome” (n=17), “transcription factors” (n=15), “cardiomyopathy, dilated” (n=13), “Barth 
syndrome” (n=10), and “neutropenia” (n=10). “Cardiomyopathy, dilated”, “neutropenia”, and 
“cardiomyopathies” are the only three symptoms identified in the top 10 MeSH terms. While they 
are indeed key features of the disease, the number of cases tagged with MeSH terms for those 
symptoms does not cover all of the cases in which they are discussed. Interestingly, only one 
third of the these CCRs are tagged with the proper MeSH term for “Barth syndrome”. Among 30 
CCRs on individual patients with Barth syndrome, we extracted 340 instances of 95 unique ICD-
10 codes and 332 instances of 123 unique ICD-11 codes, in addition to the rest of the detailed 
medical and demographic content contained in the MACCRs. The top ICD codes identified in 
the 30 Barth syndrome CCRs are “constitutional neutropenia” (n=25), “cardiomegaly” (n=23), 
“dilated cardiomyopathy” (n=18), “congenital hypotonia” (n=17), and “classical organic aciduria” 
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Figure 5-9. Comparing MeSH terms and ICD-11 codes for Barth syndrome CCRs. (A) Excluding 
demographic terms (age, gender), the top MeSH terms identified in the 30 Barth Syndrome CCRs were 
“syndrome”, “transcription factors”, and “cardiomyopathy, dilated”. Interestingly, only one third of the these 
CCRs have the proper MeSH term for “Barth syndrome”. (B) The top ICD-10 codes identified for the same 
reports were “constitutional neutropenia”, “cardiomegaly”, “dilated cardiomyopathy”, “congenital 
hypotonia”, and “classical organic aciduria”, followed by other forms of cardiomyopathy, heart failure, 
acidosis, and developmental issues. ICD annotation accurately represents the primary features of this 
disease and, with an effective query mechanism, improves case report indexing and findability.
Top 20 ICD-10 Codes: Barth syndrome
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(n=14), followed by other forms of cardiomyopathy, heart failure, acidosis, and developmental 
issues. These are the top symptoms seen in a classical presentation of Barth syndrome and 
they are representative of the symptoms discussed in each case. Codifying symptomology with 
ICD codes, therefore, provides more granular detail of each case and facilitates a more effective 
mechanism for physicians and biomedical researchers to identify cases of interest. 
2.4.5 Comparing representation of genetic information.
We evaluated the top genes identified in the metadata from 384 CCRs on 8 selected RMDs 
to explore the range of genetic etiologies across diseases (Fig. 5-10). The most frequently 
identified genetic mutations across all 8 diseases were in TAZ (n=25), which encodes the tafazzin 
protein altered in Barth Syndrome, large mt-DNA deletions (n=13), found primarily in complex IV 
deficiency, and mutations in SLC22A5 (n=13), which encodes the OCTN2 protein responsible 
for carnitine transport and is implicated in carnitine deficiency. This provides detail not otherwise 
available through a PubMed search. In the collection of Barth syndrome CCRs, for instance, 
there are several MeSH terms that allude to genetic information, including “pedigree”, “genetic 
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diseases, x-linked”, “mutation”, “chromosomes, human, x”, “mutation, missense”, and “exons”. 
All of these are certainly related to the disease and the causative TAZ mutations, but they do not 
provide much detail or utility in terms of indexing a case of Barth syndrome. Five of the Barth 
syndrome CCRs do not contain genetic information or identify a mutation in the TAZ gene; each 
of these were published prior to the identification of the genetic etiology of the disease or before 
genetic sequencing was in common usage for disease diagnosis.
2.4.6 Comparing search functionalities.
MitoCases Elasticsearch system handles complex queries constructed by the user and 
accommodates Boolean logic between and within groups of search terms. Users can filter CCRs 
by demographics and publication year, and they can construct search terms that probe the 
underlying database containing genetics, symptoms, and other medical and demographic details. 
This provides the ability to create a complex query with granular detail and elevates the current 
paradigm of searching by MeSH terms, abstracts, and titles. We compared the Case Report Search 
function on MitoCases to that of PubMed to evaluate whether the detailed metadata provides 
additional utility relative to searching across titles, abstracts, and MeSH terms. It appears that 
the added metadata enables MitoCases to significantly outstrip the capabilities of PubMed, which 
typically returns limited results for a search of more than two symptoms. For example, PubMed 
returns only three results when searching across the two million available case reports with the 
keywords “hypertrophy”, “cardiomyopathy”, and “delayed growth” (interpreted by PubMed as: 
(“hypertrophy”[MeSH Terms] OR “hypertrophy”[All Fields]) AND (“cardiomyopathies”[MeSH Terms] 
OR “cardiomyopathies”[All Fields] OR “cardiomyopathy”[All Fields]) AND (delayed[All Fields] AND 
(“growth and development”[Subheading] OR (“growth”[All Fields] AND “development”[All Fields]) 
OR “growth and development”[All Fields] OR “growth”[All Fields] OR “growth”[MeSH Terms])) 
AND Case Reports[ptyp]). The PubMed search is shown  in Fig. 5-11. We ran the same query on 
MitoCases with further constraints for a specified age of onset between 3 and 20 years old with 
a publication date after the year 2000, as depicted in Fig. 5-7. From the limited dataset of only 
384 CCRs available on MitoCases, the Case Report Search feature returns 31 results across 7 
different diseases. Results are available for download en masse or for each individual disease, 
and PubMed links are provided for direct access to the original reports. 
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2.5 Key Stakeholders and Use Cases
The MitoCases platform is designed for use by several key stakeholder groups, including 
clinicians, clinical researchers and other research scientists, as well as data scientist and text-
mining researchers. Here, we describe these key user groups and our currently envisioned use 
cases for the platform.
2.5.1 Clinicians.
MitoCases is of particular utility for clinicians seeing patients with mitochondrial disease or 
suspected mitochondrial disease, particularly those cases with complex presentations and 
sparsely available clinical literature. The platform was created initially to address the lack of 
an effective system for sourcing case reports on RMDs. The metadata provided on the current 
collection of 384 reports from 8 RMDs contains detailed case information relating specifically to 
the primary patient discussed in the report, including gender, age of onset, genetic information 
(where available), and a wide range of medical information from family history, medical history, 
Figure 5-11: PubMed Case Report Search Results. PubMed returns only three results when searching 
across the over two million available case reports with the keywords “hypertrophy”, “cardiomyopathy”, and 
“delayed growth”. For comparison, the same search was conducted using the MitoCases Case Report 
feature, with the added constraints for cases with an age of onset between 3 and 20 years old and a 
publication date after the year 2000, as depicted in Fig. 5-7. MitoCases returns 31 results across 7 
different diseases from the limited dataset of metadata on only 384 CCRs, representing a demonstrable 
improvement over the current paradigm of indexing by title, abstract, and MeSH terms.
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signs and symptoms, laboratory results, among others (Table 5-2). The Case Report Search 
function provides a mechanism for clinicians to search for reports within any age range, filter 
by gender, or enter search terms relating to genetics, and medical information contained within 
the reports. Patient symptoms have also been manually identified and codified by ICD-10 and 
ICD-11, and the search function probes these codes, their descriptions, as well as the contextual 
content from the report itself. 
This extensive database of carefully extracted metadata from a large collection of reports on a 
range of RMDs, paired with the powerful Elasticsearch mechanism, provides clinicians the ability 
to retrieve reports that are actually relevant to their patient’s specific symptoms, drug treatments, 
age, gender, genetic mutations, and other key medical concepts. Where PubMed searches 
give zero results, MitoCases consistently returns a collection of relevant reports, categorized 
by disease, with links to the article on PubMed for more in-depth reading, and download links to 
acquire the relevant metadata on those cases. MitoCases furnishes a sorely needed and capable 
search tool for clinicians to find relevant case reports with greatly improved accuracy and reliable 
results, reducing the time spent on literature curation so that they can develop a plan of action for 
differential diagnosis and effective treatment.
2.5.2 Research scientists and clinical researchers.
Much like clinicians, research scientists and clinical researchers are severely limited in their ability 
to curate a comprehensive set of case reports related to a disease of interest. In investigating the 
potential translational relevance of a signaling pathway, gene, or drug, researchers may turn to 
the clinical literature to determine whether there have been similar applications, and what kind 
of benefits and risks have already been discovered. Without an effective mechanism to conduct 
a more comprehensive search within the literature, they will spend a disproportionate amount of 
time curating reports and weeding out irrelevant results and false positives.
MitoCases allows clinicians and clinical researchers to create in silico cohorts of disease. Rare 
diseases present a particularly challenging area in conducting effective clinical trials because of 
the scarcity of patients with those diseases. By leveraging the cumulative power of large collections 
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of reports, better statistical models can be generated, and more reliable inferences can be made. 
For instance, when a new drug designed to treat RMDs is released, there is a limited patient 
population available to determine its effectiveness and safety. As these patients are treated and 
their clinical support teams monitor their progress, case reports are eventually published and 
provide insight into whether this might be a good treatment regimen for future patients with similar 
presentations. As more publications are released, the magnitude of benefits and risks can be 
weighed by creating in silico cohorts from the patients described in these reports. These efforts 
do not require patient consent, nor do they deal with any HIPAA (Health Insurance Portability and 
Accountability Act of 1996) considerations, presenting an opportunity for researchers to conduct 
studies across the patient population throughout history. 
Additionally, researchers can contribute to MitoCases by uploading metadata on a disease of 
interest, adding to the overall utility of the platform and presenting opportunities for collaboration 
and publications resulting from their submissions. The upload page has a simple user interface with 
detailed instructions for curation, filling the metadata template, and identifying symptoms and their 
corresponding ICD-11 codes. User submissions can include single or multiple metadata entries 
and are immediately subjected to a validation script that will alert them to any errors and direct 
them to the relevant information in the instructions to improve their dataset prior to resubmission 
(technical specifications detailed in 2.3.6 Uploads). The data will be subject to verification by 
the MitoCases team, and the user will be notified upon its ultimate approval and integration into 
the database. Regular users who consistently submit valid metadata will be offered fast-tracked 
approval status and will see their submissions immediately included in the MitoCases database. 
Data contribution will be credited to the uploader and any future publications utilizing the data will 
attribute credit accordingly. By submitting additional data to the MitoCases platform, researchers 
will be able to utilize search features to find other similar cases among an expanding collection of 
diseases, and further downstream analysis methods and features that will be continually added 
to the platform. 
2.5.3 Data scientists and text-mining researchers.
Clinical informatics is a rapidly growing field that is amplifying the abilities of clinicians and 
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researchers to access and analyze information across a broad range of scientific disciplines. Text-
mining has the potential to revolutionize the way we conduct curation efforts and handle electronic 
health records (EHRs). However, many of the current text-mining approaches attempting to 
accurately model clinical language or consistently identify and categorize relevant clinical terms 
are limited by the unstructured nature of text data. Without access to large datasets of structured 
text data, it is difficult to build these models and for clinical text-mining to reach its full potential. The 
MitoCases dataset provides access to carefully curated and manually generated metadata from 
domain experts on a range of RMDs. This is a valuable resource for modeling clinical language 
and gives researchers freely accessible, well indexed, structured text data. 
Text-mining researchers can download the entirety of the MitoCases dataset for use in modeling 
clinical language and communication. The metadata template employed here was developed with 
the input of several clinicians who carefully considered each included field, establishing a structure 
for case report communications that does not otherwise exist. The variety of communication 
patterns across all included case reports provides a good representation of the multitude of ways 
that a clinician might write about lab results, signs and symptoms, family history, and therapeutic 
approaches. With this structure imposed upon the reports, data scientists can begin to model 
clinical language, develop improved named entity recognition (NER) models [33, 34], and conduct 
downstream text-mining analyses. As the collection expands and a wider range of diseases are 
represented on the platform, the dataset will become ever more useful to data scientists who 
require very large bodies of structured text data on which to train machine learning algorithms. 
Currently, an automated system for identifying symptoms via NER and mapping them to ICD 
codes is in development. Once it is implemented and integrated on the MitoCases platform, the 
amount of data available will increase exponentially and provide a much greater representation of 
RMD symptomology as a whole. 
The MitoCases “Use cases” page houses potential analysis approaches for researchers of 
all types. To continue expanding functionality, submissions from text-mining researchers are 
welcomed for incorporation on the platform, providing access for clinician and basic researchers to 
conduct more advanced studies of their data. These analysis methods will be cited and attributed 
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to the author, expanding their ability to reach domain scientists and amplify their usage statistics. 
Furthermore, testing new models and tools on text data from CCRs provides a solid method for 
rigor-testing against real-world challenges in the biomedical field.
Conclusions
We identified the need for a more FAIR and structured representation of mitochondrial biology and 
mitochondrial disease and set out to improve these deficiencies by contributing to mitochondrial 
Gene Wiki pages, enforcing structure on RMD CCRs with a standardized metadata template, 
and creating the MitoCases RMD Knowledge Platform to house the structured data. In addition, 
we used these efforts as an educational platform for training students pursuing biomedical 
degrees and pre-medical studies in mitochondrial physiology in health and disease, as well as 
important research techniques for literature curation, review, knowledge extraction, and scientific 
communication. 
Our extensive contributions to Gene Wiki pages on mitochondrial genes and proteins have elevated 
the available content with significantly more references, Semantic Wiki Links to key relations, as 
well as linkages to key knowledgebases and informatics resources. This serves the biomedical 
community and the public at large by communicating complex concepts and current research in an 
easily interpreted manner and on a heavily utilized platform. Researchers and students studying 
a particular gene or protein will frequently initiate their search on Wikipedia, where one can find 
a wealth of information neatly summarized and heavily cited. This provides a useful starting point 
and also increases the exposure of the references used on the pages to a much wider audience. 
Vast quantities of structured information are also stored on Wikidata, displayed in the Gene Wiki 
infobox on individual gene and protein pages, and is represented through Semantic Wiki Links. This 
structured data provides a mechanism by which data scientists can begin studying relationships 
between proteins, genes, diseases, and drugs that are represented on Wikipedia. Because of the 
vibrant community, the information is reliably accurate and always well cited, increasing its utility 
tremendously. Patients with rare mitochondrial diseases or their family members, many of whom 
have no scientific background, also use Wikipedia to begin learning about their diagnosis and to 
find information about relevant societies and patient groups. This is a critical resource for making 
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knowledge available to many communities, and we view the mitochondrial representation as an 
important subset of the overall resource.
Clinical case reports are widely used among clinicians and medical students, but their inherent 
lack of structure and limited mechanisms for effective indexing and categorization hinders the 
discovery of relevant cases, particularly for rare diseases. These deficiencies also limit the success 
of text-mining and information extraction applications. We recognized the need for structured, 
machine-readable metadata in RMD CCRs and generated a large dataset using our MACCRs 
standardized metadata template [24, 25]. We also codified the symptomology of each patient in 
each CCR with the ICD-10 [26] and ICD-11 [27] clinical coding systems employed in electronic 
health records (EHRs) by clinicians and health care professionals around the world [35]. These 
data are housed on the MitoCases platform (http://mitocases.org/), providing clinicians with a 
powerful tool to more effectively discover case reports of patients with similar presentations to 
one of their own. Similarly, researchers and clinician investigators can use the tool to construct 
in silico cohorts of disease, study drug interactions and treatment paradigms, and design studies 
with translational value in mind. The MitoCases platform also accepts metadata uploads from 
researchers and physician investigators interested in contributing their expertise. 
Ultimately, we aim to achieve a complete representation of all 58 rare mitochondrial diseases in the 
dataset, in addition to as-yet undiscovered mitochondrial diseases. Data scientists interested in 
text-mining and NLP can use the structured data to develop named entity extraction tools and train 
machine learning algorithms for modeling clinical language. Future directions entail development 
of NLP and NER pipelines to automate metadata extraction of patient demographics, symptoms, 
drug treatments, and genetic etiology on the full corpus of RMD CCRs. The MitoCases platform 
may also provide a useful example on which to model additional resources dedicated to the 
structured representation of clinical case information across a much wider range of diseases. As 
a fully open-source and FAIR resource, all underlying source code is available and free to use, in 
part or in its entirety.
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Abstract
Tafazzin, which is encoded by the TAZ gene, catalyzes transacylation to form mature cardiolipin 
and shows preference for the transfer of a linoleic acid (LA) group from phosphatidylcholine (PC) to 
monolysocardiolipin (MLCL) with influence from mitochondrial membrane curvature. The protein 
contains domains and motifs involved in targeting, anchoring, and an active site for transacylase 
activity. Tafazzin activity affects many aspects of mitochondrial structure and function, including 
that of the electron transport chain, fission-fusion, as well as apoptotic signaling. TAZ mutations 
are implicated in Barth syndrome, an underdiagnosed and devastating disease that primarily 
affects male pediatric patients with a broad spectrum of disease pathologies that impact the 
cardiovascular, neuromuscular, metabolic, and hematologic systems, and its overexpression has 
been linked to various cancers.
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1. Introduction
TAZ, also known as G4.5, is a 10kb gene located at position 28 on the q arm of chromosome X 
within a gene-rich, 450kb cluster of 13-16 small genes with CpG islands initially identified by Bione 
et al. as potential candidates for involvement in neuromuscular and cardiovascular disorders [1, 
2]. TAZ encodes the transacylase protein tafazzin (Table 1), so named by Bione et al. based 
on a masochistic comic character named Tafazzi from an Italian sports show, apparently due to 
the difficulty they encountered in the original identification and characterization of this protein 
[2]. Tafazzin, located in the inner and outer mitochondrial membranes (IMM and OMM), acts 
as an acyl-specific transacylase that is essential to lipid metabolism through cardiolipin (CL) 
remodeling. CL remodeling, in turn, is essential for mitochondrial respiratory chain homeostasis, 
and disruptions to this process as a result of TAZ mutations have been shown to be a major 
cause of the complex, multi-system Barth syndrome. Mutations in the TAZ gene are associated 
with severe cardiovascular defects observed in Barth syndrome (BTHS), including endocardial 
fibroelastosis (EFE), X-linked dilated cardiomyopathy 3A (CMD3A, and left ventricular 
noncompaction (LVNC). As such, the gene is known by several aliases, including BTHS, EFE 
and EFE2, CMD3A, and LVNCX (Table 1). Due to similar naming conventions and associations 
with various cancers for both proteins, the TAZ gene and its tafazzin protein product have been 
confused in the literature with the TAZ protein, which is encoded by the WWTR1 gene. To date, 
there is no cure for Barth syndrome, and treatments for tafazzin deficiencies have focused on 
symptom-based management. Deeper investigation of TAZ, tafazzin, and cardiolipin is necessary 
to increase our collective understanding of mitochondrial biology and may help find treatments for 
Barth syndrome and mitochondrial myopathies. 
2. Structure
Tafazzin is part of a superfamily of acyltransferases based on conserved regions and motifs 
identified through sequence alignment with other acyltransferase proteins involved in phospholipid 
biosynthesis [3, 4]. The crystal structure of tafazzin has not been determined by x-ray 
crystallography; the closest homologous protein is plant glycerol-3-phosphate acyltransferase 
(G3PAT) from Cucurbita moscata and Spinacea oleracea (PDB ID: 1IUQ) [5], which has just 
18.1% sequence identity with human tafazzin [6]. The half-life of tafazzin in mammalian cells is 
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much shorter than that of many other mitochondrial proteins at only 3-6 hours [7]; the median half-
life for mouse mitochondrial proteins is 17.2 days in the heart and 4.26 days in the liver [8]. This 
rapid turnover rate has likely contributed to the difficulty in elucidating the structure of tafazzin 
or acquiring a detailed understanding of its post-translational modifications (PTMs) from mass 
spectrometry data. 
2.1. Tafazzin active site.
The putative phospholipid-binding site of human tafazzin is a 57 amino acid cleft with two open 
ends and a stretch of conserved, positively charged residues, based on homology modeling using 
ALAdeGAP for improved amino acid sequence alignment [9, 10]. Tafazzin and related hydrolases 
contain a conserved histidine residue required for their enzymatic action [3]. In human tafazzin, 
His-69 (His-77 in yeast) and Asp-74 form part of a conserved HX4D motif seen in acyltransferases 
composed of a histidine (His) and aspartic acid (Asp) separated by any 4 amino acids (X4) [11-
13]. The HX4D motif facilitates the Asp-His dyad mechanism seen commonly in serine proteases, 
whereby Asp raises the pKa of His and aids the deprotonation of a hydroxyl group [14]. 
2.2. Mitochondrial localization and membrane anchoring.
Mitochondrial localization and membrane anchoring domains in tafazzin are of critical importance 
to its role in cardiolipin remodeling. In the H9c2 rat cardiomyocyte cell line, TAZ encodes two 
peptides external to the active site of the tafazzin protein that act independently to direct it to 
mitochondria [15]. The first of these sequences, encoded in exon 3 and spanning residues 84-
95 on the tafazzin protein, targets exclusively to mitochondria, while the second, encoded in 
exon 7/8 and forming residues 185-220, also targets other cytosolic compartments [15]. The 
yeast TAZ1 orthologue is homologous to human TAZ and has been used extensively to study the 
structure of tafazzin, its function, and in modeling Barth syndrome [16-19]. In yeast, tafazzin has 
been shown to localize to membrane leaflets facing the intermembrane space (IMS) between the 
IMM and OMM, where it associates peripherally due to its lack of a transmembrane domain [12, 
20]. A hydrophobic sequence from residues 215-232 in yeast tafazzin confers its characteristic 
interfacial anchoring behavior in both the IMM and OMM [21]. Together, the translocase of the 
outer membrane (TOM) and the translocase of the inner membrane (TIM) facilitate tafazzin’s 
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movement across and insertion into the outer membrane, as well as its anchoring to inner 
membrane regions of intermediate density [21]. 
2.3. TAZ mutations and effects on tafazzin structure.
In characterizing the mutations of a family of patients with Barth syndrome, many unique forms 
of tafazzin were identified based on differential splicing events, ranging in length from 129 to 
292 amino acids and affecting regions throughout the protein [2]. Many of the shorter forms of 
the protein lack a 30-residue hydrophobic N-terminus thought to contain a localization signal 
sequence, as well as modifications to the hydrophilic center of the protein in a 71 amino acid 
domain profuse with glycine and glutamic acid [2]. Mutations within the localization region result 
in mistargeting that directs the protein into inner membrane leaflets facing the matrix, rather than 
facing the IMS [21]. Whited et al. categorized TAZ mutations into 7 functional classes based on 
the pathogenic loss-of-function mechanisms of each mutation [22]. The largest class of mutations, 
Class 1, contains frameshift and splice-site mutations along the length of the gene. Class 2 
and 3 mutations are both found in the membrane anchor domain: Class 2 mutations, including 
V224R, V223D, and I226P variants, represent pleiotropic biochemical defects and often result 
in mitochondrial mistargeting, while Class 3 mutations (G230R) affect tafazzin macromolecular 
assembly. Class 4 mutations are composed primarily of missense mutations resulting in catalytically 
inactive tafazzin and Class 5 mutations, including L90P and N109V, encode hypomorphic alleles 
which retain transacylase activity. Class 6 mutations, including A88R and L148H, have folding and 
assembly defects, and Class 7 mutations result in temperature sensitive proteins that undergo 
activity loss before degradation. There is limited knowledge regarding a link between the different 
classes of TAZ mutations and disease severity. Whether tafazzin is rendered catalytically inactive, 
mistargeted, or incapable of membrane anchoring, there does not appear to be a clear distinction 
between phenotypic presentations of patients with different mutations. The diverse nature of TAZ 
mutations is clearly demonstrated in the expansive database maintained and regularly updated by 
the Barth Syndrome Foundation, which actively collects new data from healthcare professionals 
on both pathogenic and benign variants (https://barthsyndrome.org/research/tazdatabase.html). 
Mutations along the length of the TAZ gene, their frequency, and their pathogenicity (benign, 
pathogenic, or unknown effect) are depicted in Figure 1. Exonic, pathogenic variants along the 
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length of the tafazzin protein, their frequency, and the type of genetic mutation from which they 
arise (deletion, frame shift, point mutation, or stop codon) are represented in Figure 2, along with 
the primary protein domains extracted from the literature. 
3. Function
Tafazzin plays a critical role in cardiolipin remodeling, limits the structural diversity of CL molecular 
species, and restricts CL composition to two fatty acids, typically linoleic and oleic acids [23]. 
Tafazzin displays a preference for the transfer of linoleic acid (LA) from phosphatidylcholine (PC) 
to monolysocardiolipin (MLCL) and may be affected by and contribute to the negative curvature of 
the IMM and OMM [24]. Through its effects on CL, tafazzin impacts many aspects of mitochondrial 
structure-function, including inner membrane curvature, oxidative phosphorylation (OXPHOS), 
supercomplex formation, oxidative stress repair, apoptosis, and fission and fusion [25-29].
3.1. Transacylase activity.
Tafazzin is an acyl-specific transferase that catalyzes reversible acyl transfer reactions between 
phospholipids and lysophospholipids in a CoA-independent manner, playing a critical role in 
the deacylation-reacylation cycle of cardiolipin [13, 24, 30]. Generally, transacylases exhibit 
phospholipase activity and catalyze acylation and deacylation through a free enzyme acyl 
intermediate. Tafazzin, on the other hand, does not exhibit phospholipase activity, nor does it 
utilize the free enzyme acyl intermediate mechanism; it acylates and re-acylates, but deacylation 
occurs independently of tafazzin [13]. After de novo synthesis of CL from phosphatidylglycerol 
by CL synthase (Crd1 in yeast, hCLS1 in humans) [31, 32], the remodeling process is initiated 
with cardiolipin deacylation to form MLCL by the cardiolipin specific phospholipase Cld1 in yeast 
[33] or the calcium-independent phospholipase A2 (iPLA2) in humans [34-38]. In order for MLCL 
produced by Cld1 to be exposed to tafazzin in the IMS, it must be transported through a different 
and unknown remodeling step [39]. In mammals, tafazzin functions along with other enzymes 
to achieve CL remodeling, including MLCL acyltransferase (MLCLAT), acyl-CoA:lysocardiolipin 
acyltransferase (ALCAT), and phospholipase [31]. Remodeling by tafazzin adds an acyl residue 
to immature CL, most frequently in the form of a linoleoyl residue in humans [40, 41]. Tafazzin 
reacylates MLCL in a single-step acyl group transfer reaction (Figure 3) from a variety of 
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phospholipids (PL), including CL, PC, phosphatidylethanolamine (PE), and phosphatidic acid (PA). 
Thus, tafazzin effectively acts as a shuttle for specific acyl groups between different phospholipids 
[13, 42]. 
3.2. Acyl specificity and sensing curvature.
Tafazzin shows a clear preference for the transfer of an LA group from PC to MLCL to form mature 
CL [24]. This remodeling process converts cardiolipin into a mature composition that contains a 
predominance of tetralinoleoyl moieties. This results in an enrichment of tetralinoleoyl-cardiolipin 
(CL4) in the IMM [41]. Indeed, Xu et al. report that, in Drosophila melanogaster, tafazzin can 
catalyze acyl transfer using multiple substrates, yet has a preference for the transfer of linoleoyl 
groups from PC to MLCL at a rate 10 times greater than that of oleoyl groups and twenty times 
greater than that of arachidonoyl groups, indicating a clear predilection for CL and PC substrates 
[13]. Conflicting explanations for this preference have been proposed, namely that tafazzin 
has an inherent enzymatic preference for specific acyl residues, or that it acts on the basis of 
energy minimization and is influenced by the surrounding mitochondrial microenvironment. Abe 
et al. propose that tafazzin exhibits acyl specificity for the PC to MLCL reaction, and that its 
function is predominately centered on the transacylation of unsaturated acyl PC to MLCL under 
any conditions [12]. Schlame et al., on the other hand, propose the ‘thermodynamic remodeling’ 
hypothesis, whereby a perturbation of the lipid bilayer state and the physical properties of the 
lipid membrane determines tafazzin’s preference for specific acyl groups [30, 43]. Schlame et 
al. propose that alternative phospholipases and acyltransferases (MLCAT and ALCAT), as well 
as the thermodynamic properties of lipids, provide the acyl specificity in CL remodeling and that 
tafazzin itself has no kinetic properties that suggest any sort of acyl-specificity. This mechanism 
proposes that since CL formation by tafazzin is reversible and has a minimal overall free energy, 
tafazzin’s role is to non-specifically transfer acyl groups among phospholipids to achieve optimal 
lipid composition and reduce the impact of membrane constraints [24, 43]. 
According to the model proposed by Schlame et al. tafazzin specificity ultimately depends on 
the physical characteristics and packing properties of the lipid domain, including structural 
order and state. In D. melanogaster, tafazzin requires phospholipids that have a propensity to 
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form non-bilayer phases such as HII phase, which is characterized by its negative curvature, 
disorganized acyl chains, and low packing order [24, 43]. Stable lipid bilayers were found to 
have the lowest rate of reaction by tafazzin, while lipids in the hexagonal or micellar phases, 
which were characterized by packing order changes due to positive or negative curvature, had 
significantly higher reaction rates. In addition to the rate of reaction, curvature was also shown to 
determine the specificity of acyl transfer [30]. The cristae of the IMM have negatively curved lipid 
monolayers and a predominance of phospholipids with small polar head groups, such as CL, and 
asymmetric, unsaturated hydrocarbon chains, such as linoleic acid. CL and linoleic acid specificity 
may thus be driven by curvature segregation of phospholipids based on physical properties of the 
lipid domains, which causes tafazzin to transacylate phospholipids that are located in negatively 
curved monolayers [20, 43]. In Saccharomyces cerevisiae, however, Abe et al. determined that 
tafazzin can efficiently catalyze a transacylation reaction even in a highly ordered lipid bilayer 
domain. Further, they posit that tafazzin has a unique acyl chain specificity for the PC to MLCL 
reaction in which tafazzin acts selectively to transfer PC’s sn-2 acyl chain to MLCL’s sn-1 and 
sn-2 positions. They determined that these reactions can occur in any environment, regardless of 
packing order and thermodynamic considerations [12]. These studies illustrate the propensity of 
tafazzin to transfer a linoleoyl group from PC to MLCL; however, more research into the specific 
mechanisms is required to fully understand the process and specificity of tafazzin’s actions. 
Further experiments with NMR analysis by groups such as Epand et al. may aid in elucidating 
these mechanisms due to its ability to probe curvature properties of lipid assemblies and observe 
structures with minor isotropic resonance [30].
3.3. Tafazzin and cardiolipin in mitochondrial structure and function.
Cardiolipin, modified by tafazzin, constitutes 13 - 20% of the total phospholipid mass and exhibits 
a cone-shaped structure that facilitates its distribution into mitochondrial cristae [27, 44]. In the 
tafazzin-impaired fibroblasts of Barth syndrome patients, a greater proportion of saturated acyl 
chain substitution compromises this cone-shaped structure, and CL is heavily depleted with 
a concurrent accumulation of MLCL species [45]. CL assists in various aspects of OXPHOS, 
supporting the stability and function of the mitochondrial respiratory chain complexes through 
linkages between acyl chains [41]. CL binds selectively to the c-rings of ATP synthase, which 
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is required for the function and assembly of the ATP synthase. It also smooths the rotation [46] 
and facilitates dimerization for efficient ATP synthesis [47]. The structural properties of CL and its 
pK above 8 facilitate trapping proteins in the IMS. This is thought to achieve proton localization 
for ATP synthase function and minimization of pH fluctuations [26]. CL also interacts with other 
proteins such as the ATP/ADP translocase, pyruvate carrier, and carnitine carrier, assisted by 
glycerol bridges which enable flexibility for interaction with diverse surface shapes. 
The lipid-to-protein mass ratio of OXPHOS complexes located in the mitochondrial cristae is 
22:78 [48], meaning that each complex is surrounded by just 40-400 lipid molecules [49]. The 
molecular packing of lipids in a bilayer with such a high protein density causes elastic stress 
on the curvature of the membrane [50]. Tafazzin remodeling is triggered by OXPHOS complex 
assembly so as to mitigate this stress and stabilize the membrane by generating CL species with 
reduced free energy [49]. The OXPHOS complexes I, III, and IV also form supercomplexes within 
the mitochondrial cristae such as the I1III2IVn=1–4 “respirasome” [51-54]. CL is directly involved in 
the formation and maintenance of supercomplexes, providing structural support for trimer- and 
tetramerization [55, 56]. Furthermore, supercomplexes are disrupted and destabilized in Barth 
syndrome patients due to the loss of mature CL from the IMM [57].
Cardiolipin’s intimate association with the electron transport chain brings it into close proximity 
with reactive oxygen species (ROS) generated by OXPHOS complexes and which have been 
shown to target CL. The proximity and its enrichment in long-chain polyunsaturated fatty acid 
(PUFA) chains make CL susceptible to the attack. In the process of lipid peroxidation, highly 
reactive oxygen free radicals oxidize the fatty acid chains of CL to form lipid peroxides [58]. 
Oxidative damage leads to a loss of functional CL, a basis for mitochondrial dysfunction [59, 60]. 
CL remodeling removes and replaces acyl chains damaged by oxidative stress and is thought 
to play a key role in oxidative stress repair mechanisms [25] and the recovery of the normal 
oxidative functions of mitochondria [39]. Aside from its damaging effects, ROS is also critical 
in mitochondrial and intracellular signaling, particularly in the context of cardioprotection from 
ischemia-reperfusion injury [61]. Phospholipids in the bilayer, such as cardiolipin, can be oxidized 
to form hydroperoxy fatty acids, which act as secondary messengers from mitochondria [62].
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CL forms membrane domains localized to negatively curved regions and induced by mitochondrial 
creatine kinase (mtCK) and cytochrome c that play critical roles in energy transfer, apoptosis, and 
functional recovery from ischemic insult [63-65]. The microdomains occur at contact sites where 
the IMS narrows such that the IMM and OMM are positioned in close proximity to one another 
[63, 64, 66]. The IMS at these contact sites is replete with mtCK, which induces their formation, 
recruits CL, and provides stabilization [63, 67]. Mature tetralinoleoyl-CL species generated by 
tafazzin remodeling are required for the formation of these domains and CL4 depletion disrupts 
their formation, which may explain the mitochondrial impairment observed in Barth syndrome 
and cardiac ischemia-reperfusion injury [66, 68, 69]. Further, mtCK is functionally coupled to 
adenine nucleotide translocase (ANT) in the IMM to facilitate efficient energy transfer by shuttling 
high-energy phosphates from the mitochondria to the cytosol through the voltage-dependent 
anion channel (VDAC) of the outer membrane [65, 70]. During ischemia, for example, this IMS 
structure-function is disrupted, reducing the functional coupling of mtCK and ANT and increasing 
the permeability of the OMM to ADP, thereby limiting energy transfer processes and exacerbating 
damage from an ischemic event such as a heart attack [65]. The cardioprotective ischemic 
preconditioning (IPC) protocol opens the mitochondrial ATP-sensitive K+-channel (mitoKATP), 
which causes matrix swelling and results in preservation of IMS volume, contact sites, and tight 
coupling between mtCK and ANT [61, 65, 71]. CL clustering at these contact sites is dependent on 
the octameric structure of mtCK, which readily binds to anionic phospholipids and may mediate 
intermembrane contact by binding to VDAC on the OMM [63].
Cardiolipin mediates apoptosis through its interactions with members of the Bcl-2 family, caspases, 
Bid, Bax, and Bak, with a direct impact on the apoptotic signaling cascade [28]. The total level of 
CL as well as the oxidative state of its acyl side chains directly impacts apoptosis by regulating 
cytochrome c mobilization; decreased CL content or oxidation of the normally unsaturated acyl side 
chains releases cytochrome c from the membrane [28]. This can be prevented with antioxidants 
[72, 73] and by the presence of mitochondrial redox proteins [74, 75]. Therefore, CL remodeling 
by tafazzin restores cytochrome c affinity for CL and its localization in the membrane by replacing 
oxidized fatty acids with non-oxidized acyl groups [31]. Mobilized cytochrome c released from the 
mitochondrial membrane activates caspases 8 and 9, which cleave Bid to produce its truncated 
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and active form, tBid [76]. Once recruited by mitochondrial carrier homologue 2 (MTCH2), tBid 
activates apoptosis via Bax and Bak activation [77]. Caspases 8 and 9, activate caspase 3, which 
drives apoptosis and inhibits ROS production [78]. The apoptotic pathway is further amplified by 
this ROS inhibition, as it is a ROS signal that is responsible for protective mitoKATP opening that 
blocks the mitochondrial permeability transition (MPT) and prevents apoptosis [62, 79]. 
Additionally, through interactions with both inner and outer mitochondrial membranes and 
proteins such as the GTPase Opa1, CL plays an important role in mitochondrial fission, fusion, 
and mitophagy [29, 80]. TAZ deficiency reduces the generation of mitophagosomes and prevents 
initiation of mitophagy, further exacerbating the already reduced function of mitochondrial 
populations in TAZ-deficient organisms [80]. Under mitochondria-stress conditions, CL promotes 
mitochondrial fusion and membrane tethering with L-Opa1 and trans-Opa1, respectively, further 
illustrating its multifunctional importance in mitochondrial form and function [81].
4. Clinical Significance
Considering its critical role in the construction and maintenance of the IMM, it is of little surprise that 
TAZ has been implicated in a broad spectrum of disease pathologies that impact the cardiovascular, 
neuromuscular, metabolic, and hematologic systems. TAZ mutations are specifically associated 
with the multi-faceted Barth syndrome, and its expression levels have been studied in several 
varieties of cancer, including thyroid [82], rectal [83], prostate [84], and cervical [85] cancers.
4.1. Barth syndrome. 
TAZ mutations cause Barth syndrome, also known as 3-Methylglutaconic Aciduria Type II 
(3MGA2), an X-linked autosomal recessive disorder that encompasses a complex phenotype, 
with cardiovascular, musculoskeletal, neurological, metabolic, and hematologic consequences 
[86-88]. Characterized initially by Barth et al. in 1983 [88] as a uniformly lethal disease that affects 
only males, it has now been found that the age distribution ranges between 0 to 49 years, and 
symptoms peak around puberty [89]. At least one female patient with BTHS has been identified 
[90]. The Barth Syndrome Foundation reports that 151 living Barth patients have been identified 
up to 2012 and 10 new patients are diagnosed each year in the United States with no apparent 
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racial or ethnic predilections. BTHS is estimated to appear in 1 out of every 300,000 to 400,000 live 
births, although predictions have suggested that the prevalence is actually closer to 1 out of every 
140,000 live births as a result of the generally accepted notion that the disease is underdiagnosed 
[91, 92]. In an effort to impose structure on otherwise unstructured clinical language contained in 
clinical case reports on BTHS (among other diseases), Caufield et al. extracted metadata from 
the reports and characterized patient symptomology using codes from the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10) [93, 94]. The MitoCases platform 
(http://mitocases.org/) houses data on mitochondrial diseases, including Barth syndrome. Figure 
4 displays the distribution of 997 instances of 206 unique ICD-10 codes represented across 54 
clinical case reports covering 133 patients with BTHS, including top symptoms overall as well as 
top cardiovascular symptoms. Classifying Barth syndrome symptomology using ICD-10 codes 
has the potential to facilitate a greater understanding of the disease, its phenotypes, as well as to 
aid in diagnosis and treatment.
BTHS diagnosis and treatment is complicated and frequently delayed due to the complexity 
and variation of disease presentation. Early cardiomyopathy and hypertrophy combined with 
neutropenia (a low neutrophil count in the blood) is a hallmark of the disease, but confirmation 
of the diagnosis typically relies on genetic analysis of TAZ. Over 160 mutations or errors in the 
TAZ gene have been identified in BTHS patients, with a wide variety of onset, progression, and 
severity [87]. 3-methylglutaconic acid (3-MGA) and CL content levels are often used to identify 
BTHS, but they are not always a reliable indicator, which led some to propose using an HPLC-
tandem mass spectrometry blood spot assay to measure the ratio of MLCL to CL4. Although 
indirect, this highly specific biochemical measure of tafazzin function has the potential to provide a 
clinically valid method for BTHS diagnosis [95-98]. Combining biochemical analyses with physical 
tests, such as the 6-minute walk test (6MWT), may allow clinicians to determine the extent of 
the musculoskeletal impact and cardiac function in patients who survive infancy and those with 
unknown mitochondrial deficiencies. A combination of these procedures may help to improve 
diagnostic abilities and shape patient-specific treatment plans [98].
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4.1.1. Cardiovascular pathology. 
Cardiomyopathy is a major characteristic of BTHS resulting from TAZ mutations. TAZ mutations 
lead to altered acyl chain composition and lipid peroxidation, and this can result in a failure of 
the sarcomeric action required to generate a sufficient power stroke. Disruption of the uniform 
contraction of sarcomeres can severely weaken the tissue, enlarge the left ventricular chamber, 
result in partial or incomplete contraction, and lead to decreased ejection volume. This results 
in the gradual thinning of the ventricular wall, stretching and dilation of cardiac chambers, and a 
cardiomyopathic phenotype of Barth syndrome, characterized by a weakened heart and diminished 
contractility [89, 99]. Among all patients, about 95% exhibited a history of cardiomyopathy, with 
41.5% of all diagnosed cardiomyopathies occurring from birth to one month of age. Furthermore, 
statistical analysis revealed that cardiac function of patients declines over time [100]. Contrary 
to ATP depletion, Wang et al. suggest ROS as the main cause of cardiomyocyte dysfunction 
and cardiovascular impairments such as defective sarcomere assembly and contractile stress 
[101]. The typical approach to treating the cardiovascular symptoms of Barth syndrome is to 
follow the treatment paradigm for heart failure. This includes: 1) diuretics for fluid retention 
(e.g., spironolactone or furosemide), 2) angiotensin-converting enzyme (ACE) inhibitors for 
vasodilation to reduce afterload (e.g., captopril), 3) positive inotropes to increase contractility and 
as an antiarrhythmic (e.g., digoxin), and 4) beta blockers to reduce heart rate (e.g., propranolol, 
carvedilol). Regular echocardiography is used to monitor cardiovascular function and ejection 
fraction [102, 103]. Severe forms of cardiac symptoms in BTHS patients necessitate heart 
transplantation. Spencer et al. reported nine out of 73 (12%) patients referred to the BTHS 
Registry (https://barthsyndromeregistry.patientcrossroads.org) who have undergone cardiac 
transplantation are alive at the last update [86, 100]. Transplantation is generally successful [86]; 
among four BTHS patients described in Mangat et al., one developed a severe infection but they 
did not show an increased rate of rejection and rated their quality of life as good [104, 105]. 
Cardiomyopathy in BTHS includes dilated cardiomyopathy (DCM) and left ventricular 
noncompaction (LVNC) [89]. DCM is a specific type of cardiomyopathy characterized by an 
enlarged heart that is limited in function due to its inability to contract and pump blood efficiently 
[106 , 107]. A patient with BTHS resulting from a c.83T>A mutation in tafazzin exhibited DCM 
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with an ejection fraction of 30%, providing a direct association between the gene and DCM [108]. 
LVNC is a condition that exhibits prominent trabeculations and deep intertrabecular recesses 
in the left ventricle that resemble a spongy structure on the ventricular wall [109]. One such 
case involves a family of 6 affected members that presented with LVNC with BTHS due to TAZ 
mutations [110]. Isolated noncompaction of the ventricular myocardium (INVM) has also been 
found to affect the right ventricle and the interventricular septum [89, 110]. Despite the general 
occurrence of cardiomyopathy, there have been instances of BTHS caused by TAZ mutations with 
mild or late-onset cardiac involvement, as seen in Woiewodski et al. and again in Rigaud et al. 
Each discuss a cohort of BTHS patients exhibiting varying levels of cardiomyopathy, including two 
infantile patients who did not present with cardiomyopathy at the time of diagnosis [111], another 
infantile patient whose autopsy revealed no cardiomyopathy, and one 12-year-old patient with no 
manifestation of cardiomyopathy [112]. There is no clear structural or functional reason for the 
relatively mild presentations of certain patients, nor a direct mechanistic link between different 
mutations and disease presentations, representing an intriguing area of research necessary to 
glean a greater understanding of tafazzin and its role in disease.
4.1.2. Musculoskeletal pathology.
Although skeletal myopathy is often a typical characteristic of patients with disease-causing TAZ 
mutations, it manifests itself in a wide range of symptoms from nonexistent to severe. One of the 
most common musculoskeletal symptoms in BTHS patients is general and localized weakness. 
This includes overt muscle weakness and increased exertional fatigue due to skeletal myopathy 
and exaggerated by the cardiovascular complications associated with Barth syndrome [113]. 
Hypotonia, fatigue, and weakness can present early in life, persist, and may result in delayed 
motor development; most patients can walk unassisted by 2 years of age. Common phenotypes 
include short stature and facial dysmorphia and can extend to rarer phenotypes such as clubfoot 
(bilateral talipes) [114]. Christodoulou et al. describes 6 cases of BTHS from four families with 
dysmorphic features, all of which exhibited persistent short stature. Four of the patients had also 
been found to exhibit similar myopathic facial appearances in conjunction with neuromuscular, 
cardiovascular and infectious symptoms [115]. A growth curve generated by examining 73 BTHS 
patients in Roberts et al. revealed a common down-shift in weight, length, and height relative to 
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the normal population. Developmental delays are prevalent in BTHS patients with motor skills 
being the most affected, as indicated by a 65% prevalence of a delay in sitting up and a 71.6% 
delay in walking [100]. 
Developmental delay has been treated with some success using cornstarch supplementation. 
This alternate source of glucose production ameliorates muscle wasting due to overnight fasting 
[86]. Other treatments, including oral arginine and carnitine supplementation, have centered on 
treating metabolic deficiencies, which improves cardiac function and muscle weakness in some 
patients [27, 112, 116]. However, while carnitine supplementation was initially offered as a treatment 
paradigm for all cases of BTHS [117], its effect has subsequently been called into question, and 
no formal assessment of the utility of arginine supplementation has been published. Thus far, both 
carnitine and arginine have demonstrated efficacy only in patients with those specific deficiencies 
[27, 112, 116].
4.1.3. Neurological pathology.
Neurological complications tend to manifest as mild cognitive impairments in BTHS patients 
with TAZ mutations. While these patients were found to have a higher incidence of cognitive 
impairment [118] and mild learning and speech difficulties [100], many patients were found to have 
normal cognitive development, including a three-generation family with no cognitive impairment 
despite BTHS diagnosis [114]. The limited neurologic involvement of BTHS is interesting given 
that tafazzin has been shown to play an important role in brain mitochondrial respiration and 
normal cognitive function [119]. One postulate contends that the brain’s reliance on glucose, over 
tissues in the heart and liver that require high mitochondrial activity, allows the brain to have a 
more diverse and less tetralinoleoyl-dependent CL composition. Reducing the need for highly 
symmetric remodeled tetralinoleoyl-CL to achieve sufficient mitochondrial function may allow the 
brain to mitigate or avoid the detrimental effects of a tafazzin deficiency [41]. Indeed, CL in the 
brain has higher amounts of arachidonic (AA) and docosahexaenoic (DHA) acids, distinct from the 
preference for tetralinoleoyl-CL seen in other tissues [41]. Over 80% of CL in the liver and heart 
take the 18:2n-6 form, whereas the brain demonstrates less of a preference and has a higher 
concentration of saturated acyl chains, with only 48% polyunsaturated fatty acids and just 20% 
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of its CL in the 18:2n-6 form [120]. It has also been proposed that the higher ROS scavenging 
capability of the brain, which is about 100 times higher than the rate of ROS generation [121], may 
allow the brain to avoid the harmful effects more effectively than in other tissues even though it 
generates higher total levels of ROS [119].
4.1.4. Metabolic disorder.
3-methylglutaconic aciduria (3-MGA) is a major indicator of a variety of syndromes including 
BTHS, and is the result of mutations, including those in TAZ, that are linked to mitochondrial 
dysfunction [122]. 3-MGA refers to increased levels of the organic acids 3-methylglutaconic 
acid, 3-methylglutaric acid, and 2-ethyl-hydracrylic acid in urine [123]. BTHS patients typically 
demonstrate a large and consistent increase in the excretion of 3-MGA [124]. A diagnosis of 3-MGA 
type II is synonymous with BTHS. While most BTHS patients exhibit varying severities of 3-MGA, 
a case report by Schmidt et al. describes a 15 year-old-boy with typical BTHS symptoms, such as 
dilated cardiomyopathy, but normal levels of organic acids, amino acids, and mucopolysaccharides 
in urine. Thus, there was no diagnosis of 3-MGA, despite a TAZ missense mutation in nucleotide 
877 at exon 8 [125]. Therapeutics such as riboflavin or coenzyme Q10 have been reported to 
show substantial improvement in some patients with 3-MGA [123]. Overall, however, metabolic 
treatments vary between patients and are largely designed to target symptomatic deficiencies 
rather than the underlying cause of the disease [86, 126].
4.1.5. Hematologic pathology. 
Neutropenia is one of the most frequent characteristics of BTHS caused by TAZ mutations, 
characterized by a decline in total number of circulating neutrophils accompanied by an increase 
in monocytes and eosinophils with no fluctuations in lymphocyte numbers [86]. Makaryan et al. 
found that neutropenia in BTHS is caused by a disruption of mitochondrial membrane potential 
as well as caspase-3 activation resulting in an increased rate of apoptosis of myeloid progenitor 
cells [127, 128]. Neutropenia is a particularly variant symptom, and can present itself in many 
different forms, from severe to mild, cyclical to non-cyclical, and intermittent to chronic [129]. 
Severe chronic neutropenia (SCN), defined by an absolute neutrophil count of < 500/μL, is the 
most detrimental phenotype [130]. 
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In a cohort study, Roberts et al. describe 73 patients with BTHS and indicate that 69.1% self-
reported neutropenia with varying severity [100]. Ranging from a complete lack of neutrophils 
to a mild decline, neutropenia may be absent at presentation and change over the course of the 
disease in the same patient [86]. For instance, all seven members of a family with TAZ mutations 
exhibited no signs of neutropenia [131], while another case of siblings with severe BTHS both 
exhibited intermittent neutropenia [97]. Including persistent or intermittent forms of neutropenia, 
nearly 90% of BTHS patients exhibit the symptom to some degree [86], though it is mentioned in 
just over 65% of available clinical case reports on Barth syndrome (Figure 4). Neutropenia is an 
immune system deficiency that results in diminished response to invading organisms. Therefore, 
decreased defense mechanisms leads to serious bacterial infections including prolonged upper 
respiratory tract infections, mouth ulcers (chronic aphthous stomatitis) due to Candida infections, 
inflamed gums and perianal dermatitis, as well as sepsis and multi-organ failure, which are 
frequently treated by prophylactic antibiotics [86, 89, 130]. Among 73 BTHS patients in Roberts et 
al., 65% of those with neutropenia exhibited mouth ulcers, relative to only 35% of patients without 
neutropenia, while 28% had a history of pneumonia and 10% had a history of blood infections 
[100]. Granulocyte colony-stimulating factor (G-CSF) has been identified as an effective and safe 
treatment for SCN [130], leading to improvement in many BTHS patients with symptoms including 
aphthous ulcers, bacterial infections, and lethargy [86].
4.1.6. Therapies in Barth syndrome.
Although several therapeutic strategies have proved successful in select clinical presentations, 
treatments are focused on treating the cardiovascular, musculoskeletal, and metabolic disorders, 
rather than the root cause of the disease. There is currently no cure for Barth syndrome [92]. 
Based on the observation that the fatty acid environment of cells impacts CL composition, ATP 
synthesis, membrane potential, and ROS production, dietary fatty acids have been suggested 
as a therapeutic strategy to target mitochondrial lipid metabolism and ameliorate effects on 
bioenergetics and cardiac function in mitochondrial diseases such as BTHS [132]. It is unclear 
whether these treatments have significant effects in clinical practice. Direct modulation of CL 
content by lipid replacement therapy using CL nanodisks has also been tested in cell and 
animal models of Barth syndrome. Apoptosis induced by shRNA-mediated knockdown of TAZ 
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in cultured HL60 myeloid progenitor cells [127] is attenuated by incubation with CL nanodisks 
and confers a significant increase in cellular CL content [133]. However, translation to an in vivo 
setting was unsuccessful, with no alteration in the CL profile of either wildtype mice or a TAZ 
knockdown mouse model of Barth syndrome [134]. Another study aimed to investigate whether 
overexpression of an alternate CL remodeling enzyme could restore CL in TAZ-deficient cells. 
Lymphoblasts from Barth syndrome patients transfected with MLCLAT1 saw increased CL levels, 
improved mitochondrial basal respiration and proton leak, and reduced superoxide production, but 
only partial compensation for respiratory function and no restoration of OXPHOS supercomplex 
formation [135, 136]. These results show some promise, but it remains to be seen whether they 
can be recapitulated in a live animal model.
Elevated ROS and oxidative stress have been proposed as significant culprits in Barth syndrome 
and the development of cardioskeletal myopathy in these patients [137-139]. In vitro studies of 
TAZ-deficient cardiomyocytes treated with the mitochondrially-targeted Mito-Tempo antioxidant 
demonstrated improved contractile function, cardiac hypertrophy, and cell death [101, 140]. Mice 
with TAZ deficiency (TAZKD) and mitochondria-specific overexpression of catalase, however, 
developed cardiomyopathy and muscle weakness similar to the Barth syndrome mouse, indicating 
that amelioration of oxidative stress is insufficient in the in vivo setting [141]. 
Peroxisome proliferator-activated receptors (PPARs) and the PPAR-gamma coactivator-1alpha 
(PGC-1a) are central to energy metabolism and bioenergetics in mitochondria, presenting 
opportunities for treatment in a variety of mitochondrial and metabolic disorders. Bezafibrate is a 
fibric acid derivative pan-agonist of PPAR signaling pathways that activates oxidative metabolism 
genes [142]. In patients with dyslipidemia or metabolic syndrome, bezafibrate reduces triglyceride 
levels and the incidence of myocardial infarction [143]. It also significantly decreases HbA1c in 
diabetic patients with dyslipidemia [144]. Because of its role in mitochondrial bioenergetics, it has 
been proposed as a potential treatment for Barth syndrome as well. In a TAZKD mouse model with 
isoproterenol (iso) treatment to induce more significant cardiac dysfunction, bezafibrate rescued 
iso-induced heart failure with marked increases in left ventricular fractional shortening and ejection 
fraction and prevention of the development of cardiomyopathy [142]. However, the treatment also 
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caused a significant reduction in CL content and increase in MLCL/CL ratio in both wild type 
and TAZ knockdown mice, a common biomarker for Barth syndrome. Concurrently, mitochondrial 
biogenesis was amplified drastically, as indicated by a two-fold increase in mtDNA content and 
mitochondrial citrate synthase activity in bezafibrate-treated hearts. Additionally, the dose used 
in the mouse model was 60-80 times greater than is typically prescribed in dyslipidemic humans. 
The modification of CL content and dosage discrepancy presents significant hurdles to determine 
the mechanism of action, further evaluate the importance of MLCL and CL concentrations, and 
conduct toxicity studies before any enrollment in clinical trials [142]. 
Gene replacement therapy presents another avenue of exploration that has the potential to 
address underlying tafazzin deficiencies resulting from the TAZ mutations that cause Barth 
syndrome. Recombinant adeno-associated virus (rAAV) vectors provide stable and long-lasting 
gene transfer to the nucleus of an organism’s cells using a non-pathogenic virus with minimal 
immune response [145]. The successful application of an AAV-delivered gene therapy in spinal 
muscular atrophy also establishes an important precedent for the safety and efficacy of this 
approach in a clinic setting [146]. AAV serotype 9 (AAV9) demonstrates high affinity for the heart 
and skeletal muscle, making it ideal for application to Barth syndrome [147]. In the TAZKD mouse 
model of Barth syndrome, an AAV9-TAZ vector with a desmin promotor resulted in significant TAZ 
gene and tafazzin protein expression levels in the heart and muscle and minimal levels in the liver 
[148]. Measures of muscular strength and fatigue as well as whole body activity (e.g., exercise 
and distance travelled) of the treated mice improved significantly. Increased fractional shortening 
and ejection fraction as well as decreased heart weight/body weight ratio indicate significant 
improvements in cardiac function. Mitochondrial structure and function defects were ameliorated, 
with improved cristae and sarcomeric organization, greater numbers and size, as well as improved 
mitochondrial respiration and OXPHOS complex activity [148]. In further studies, multiplex tandem 
mass tagging-based proteomics has provided a deeper mechanistic insight into the progression 
of Barth syndrome and its impact on critical proteins involved in cardiac development, heart 
failure, transcription, translation, and carnitine biosynthesis. [149]. The striking result of AAV9-TAZ 
gene therapy across a range of treatment ages in the mouse model of Barth syndrome paints an 
optimistic picture for its potential as a future clinical option for these patients.  
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Elamipretide (MTP-131, SS-31, Bendavia) is a novel mitochondria-targeted tetrapeptide 
designed to temporarily bind to CL and protect it from oxidative damage by blocking CL-mediated 
conversion of cytochrome c into a peroxidase, thereby preserving cristae structure, promoting 
OXPHOS, and maintaining mitochondrial integrity [150, 151]. In the canine model of intracoronary 
microembolization-induced chronic heart failure [152], long-term therapy with elamipretide was 
demonstrated to improve left ventricular ejection fraction, normalize key plasma biomarkers 
including tumor necrosis factor-alpha (TNF-a) and C-reactive protein (CRP), and reverse 
mitochondrial deficiencies in the heart [153] and skeletal muscle [154]. In explanted human 
cardiac ventricular tissue from patients with a wide demographic range, elamipretide improved 
impaired mitochondrial function in heart failure and had no effect on normal mitochondrial function 
in nonfailing hearts. Additionally, supercomplex function was improved, but no change was 
observed in the activities of OXPHOS complexes II or V [155]. In a clinical trial for patients with 
heart failure with reduced ejection fraction (HFrEF), elamipretide was safe, well-tolerated, and 
achieved significant decreases in left ventricular end-diastolic volume (LVEDV) and end-systolic 
volume (LVESV) in the highest dose cohort. Ejection fraction also improved in the treatment group 
as compared to those administered a placebo, though the measures did not reach statistical 
significance [156]. Elamipretide is currently in Phase 2 clinical trials (TAZPOWER) to treat Barth 
syndrome specifically, and recruitment is in progress for a Phase 3 clinical trial (MMPOWER-3) 
in patients with primary mitochondrial myopathies [157]. The previous animal studies and clinical 
trials in heart failure bode well for successful applications of Elamipretide in the Barth syndrome 
and mitochondrial myopathy patient populations.
4.2. Cancer.
TAZ overexpression, distinct from Barth syndrome-causing mutations, has been linked to various 
cancers, most commonly rectal cancer, thyroid neoplasm, and cervical cancer. In a cohort study 
analysis of 140 rectal cancer patients, TAZ overexpression was linked to increased expression 
of oncogenes FXYD-3 and Livin, cell anti-apoptosis response, and abnormal cell growth, as well 
as an indicator of the stage, type, and progression of rectal cancer [83]. In thyroid neoplasms, 
TAZ overexpression distinguishes follicular variants of papillary carcinomas from classic papillary 
carcinomas [82], which may present opportunities to provide patients with personalized approaches 
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to treatment based on the difference in prognosis between variants [158]. In human cervical 
cancer cell lines, tafazzin levels were observed to increase from normal tissue, to squamous 
intraepithelial lesions, to squamous cervical carcinoma, leading to the proposal that TAZ induces 
cervical cancer progression by inhibiting apoptosis and promoting cancer cell growth, viability, 
and tumorigenesis [85]. TAZ is hypothesized to inhibit apoptosis in cervical cancer cells by 
limiting cleavage of caspase 3 and caspase 9, which play key roles in apoptotic pathways [85]. 
Cytochrome c released by mitochondria activates caspase 9, which cleaves and activates Bid into 
tBid. Caspase 3, once activated by caspase 9, inhibits ROS production, driving apoptosis [78]. 
Low concentration signaling ROS is responsible for protective mitoKATP opening, which blocks 
the mitochondrial permeability transition (MPT) and prevents apoptosis [79]. Tafazzin’s role in 
establishing lipid content in CL as a consequence of remodeling has also been implicated in 
prostate cancer with the finding that palmitoleic acid content of CL was higher in prostate tumor 
tissue and that palmitic acid had the ability to stimulate prostate cancer cell proliferation and 
reduce the rate of apoptosis [84]. Extensive studies into the mechanistic role of tafazzin and CL 
remodeling in the context of cancer has yet to surface, but the effects of impaired mitochondrial 
function, injury to mitochondrial respiration [159], reduced apoptotic activity, and altered lipid 
environments [160] are common threads in explaining increased cancer cell proliferation and 
tumor growth. 
5. Conclusions
Tafazzin is a transacylase responsible for remodeling cardiolipin in the mitochondrial membrane 
and plays an integral role in maintaining mitochondrial structure and function. The tight bends 
of the cristae in the inner membrane require a specific acyl profile, afforded by the activity of 
tafazzin. The protein has targeting and anchoring domains that direct it to the IMM and OMM and 
position it to face the IMS, build mature, tetra-linoleoyl cardiolipin species, and repair damaged 
membranes. Mutations in TAZ produce a dysfunctional or improperly localized protein that causes 
Barth syndrome, a multi-factorial and devastating disease that presents in infancy and results 
in heart failure, neutropenia, and musculoskeletal abnormalities. Current therapeutic paradigms 
are wide-ranging and attempt to treat the symptoms of individual systems. No cure exists for 
Barth syndrome, though there are a number of different treatments in development aimed at 
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modulating metabolic processes, reducing oxidative stress, protecting CL from degradation, as 
well as conducting targeted gene-replacement of TAZ. Overexpression of TAZ may also lead 
to cancer by affecting cell proliferation and apoptosis. Additional studies are necessary to fully 
characterize and understand the unique and integral role of tafazzin in mitochondrial biology and 
in the manifestation of Barth syndrome and various cancers.
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Figures and Tables
Species Homo sapiens (human) Mus musculus (mouse)
Gene TAZ TAZ
Synonyms BTHS, EFE, EFE2, CMDA3, LVNCX, G4.5
5031411C02Rik, 9130012G04Rik, 
AW107266, AW552613, G4.5
NCBI Gene ID 6901 66826
Chromosomal location chrXq28:154,411,524-154,421,726 chrX:74,282,697-74,290,151
Length (nt) 10,171 7,454
Exons/Introns 11/10 10/9
NCBI Gene ID 6901 66826
UniProt ID Q16635 I7HJS2
Ensembl ID ENSG00000102125 ENSMUST00000069722.12
Length (aa) 292 263
Molecular weight (Da) 33,459 30,433
Table 1. Essential properties and identifiers of TAZ and tafazzin. The table contains a 
summary of the essential properties, identifiers, and names of the TAZ gene and the encoded 
tafazzin protein in Homo sapiens (human) and Mus musculus (mouse) [161].
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Figure 1. TAZ genetic mutations, frequency and pathogenicity. The frequency of intronic and 
exonic mutations across the length of the TAZ gene are shown here, categorized by pathogenicity 
and mapped to the nucleotide (nt) position on the gene, with exons represented by thick grey bars 
below the x-axis. Patient mutation data was acquired from the Barth Syndrome Foundation TAZ 
database (https://barthsyndrome.org/research/tazdatabase.html).
Figure 2. Tafazzin domains, mutation frequency, and mutation type. The frequency of 
pathogenic, exonic mutations across the length of the tafazzin protein are shown here, categorized 
by mutation type, with key functional domains of the tafazzin protein displayed below the x-axis. 
Tafazzin contains a transmembrane helix (TM helix) and a membrane anchor at positions 15-
34 and 215-232, respectively. The acyltransferase active site spans 176 amino acids (aa) from 
residue 41-217, with His77 forming part of the His-Asp motif (HX4D). Mitochondrial targeting 
domains are encoded in exon 3 as well as exon 7/8, spanning protein residues 84-95 and 185-
220, respectively. Patient mutation data was acquired from the Barth Syndrome Foundation TAZ 
database (https://www.barthsyndrome.org/research/tazdatabase.html).
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Figure 3. Mechanism of acyltransferase activity by tafazzin. Tafazzin acts as a shuttle for 
specific acyl groups between different phospholipids to generate mature cardiolipin, Tafazzin 
transfers an acyl side chain from a phospholipid such as phosphatidylcholine (PC) to reacylate 
monolysocardiolipin (MLCL) in a single-step acyl group transfer reaction, resulting in the formation 
of lysophosphatidylcholine (LPC) and the mature tetralinoleoyl form of cardiolipin. The red acyl 
side chains indicate the acyl group that is transferred by tafazzin, and the blue circles indicate the 
location on MLCL where the new acyl chain is added to form the mature tetralinoleoyl cardiolipin.
Tafazzin ++
PCMonolysocardiolipin LPCTetralinoleoylcardiolipin
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Figure 4. Complex symptomology of Barth syndrome codified by ICD-10. Symptom 
occurrence codified using the 10th edition of the International Statistical Classification of Diseases 
and Related Health Problems (ICD-10) from 133 Barth syndrome patients described in 54 clinical 
case reports (please see References Cited: Clinical Case Reports). Panel (A) presents the 
full collection of 997 instances of 206 unique ICD-10 codes across all patients in these reports, 
grouped by disease category [93, 94]. Cardiovascular diseases and symptoms are the most highly 
represented among all ICD-10 categories (n = 272). Panel (B) highlights the top 10 symptoms 
from all ICD-10 categories. Panel (C) depicts the top 10 cardiovascular symptoms. All data is 
housed on the MitoCases platform (http://mitocases.org/) along with detailed metadata on the 
medical information contained in the text of each CCR.
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Chapter 7. Conclusion
At the outset of this collection of projects, we recognized that mitochondrial knowledge is scattered, 
fragmented, and unstructured. This presents a barrier for researchers, clinicians, data scientists, 
and students attempting to find and access information to facilitate their contributions to science 
and patient care. Clinical case reports (CCRs) present a unique challenge due to the complexity 
of clinical presentations and clinical language, the inconsistency and lack of standardization 
among reports, and the inherent absence of structure in text data. These characteristics prevent 
investigators from extracting the rich clinical insights contained within, and it prevents integrating 
CCRs into computational pipelines and machine learning models of disease. We aimed to 
make knowledge pertaining to mitochondrial biology and related diseases more FAIR (Findable, 
Accessible, Interoperable, and Reusable) through standardization, integrating existing ontologies, 
knowledgebases, and coding systems, and imposing structure on otherwise unstructured text data. 
We focused on elevating the quantity, quality, and structure of FAIR knowledge on mitochondrial 
genes and proteins as well as rare mitochondrial diseases (RMDs).
We devised a multifaceted set of approaches to accomplish this overarching goal, including 
assembling a collection of informatics tools and resources pertaining to mitochondria, addressing 
the lack of mitochondrial coverage on Gene Wiki, designing a standardized approach for 
supplementing CCR corpora with highly structured metadata, and establishing a knowledge 
platform to house those data and integrate with existing ontologies and knowledgebases. We used 
a combination of all of these resources, approaches, and resulting data to conduct a thorough 
review of Barth syndrome, an RMD of particular interest because of its prominent cardiovascular 
phenotypes and deep underpinnings in mitochondrial form and function.
Many informatics resources are available that are either mitochondria-specific or contain 
mitochondrial subsets within the data. Most are active and updated regularly, but some are 
underutilized, unintegrated, and/or defunct or out of date. The review presented in Chapter 2 
provides an extensive index and analysis of a wide variety of tools and resources, including 
large, generalized omics databases with subsets of mitochondrial data, mitochondria-specific 
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resources, and informatics tools and pipelines for data processing and analysis. These comprise 
the key components of a modern mitochondrial researcher’s informatics tool chest. 
Despite the availability of ample resources for the study of mitochondrial biology and copious 
biomedical knowledge contained in the literature, we found that mitochondrial genes and proteins 
were severely underrepresented on Gene Wiki [1, 2]. We addressed the gap in coverage of this 
vital organelle by evaluating 672 proteins identified in comprehensive mass spectrometry datasets 
of the cardiac mitochondria proteome [3-5]. The “Mitochondrial Gene Wiki Project” contributed 
over 4MB of content and nearly 6,000 references across 541 pages on mitochondrial genes 
and proteins to improve the findability and accessibility of essential mitochondrial knowledge, 
papers, and data resources for each entity. The Mitochondrial Gene Wiki Project became a key 
training effort for new members and volunteers in the lab as well, providing deep physiological 
knowledge and clinical insight for students from all educational levels, as well as training in critical 
aspects of research, from curating and evaluating literature to synthesizing knowledge and writing 
appropriate scientific communications. 
Students, investigators, and patients alike commonly begin a research project on Wikipedia, in 
hopes of finding a well-organized, highly informative, and comprehensively cited article on their 
gene or protein of interest. Students and researchers can use this article as a launch point to 
find interacting partners through integration with IntAct [6], related pathways on Reactome [7], or 
pertinent articles on PubMed through the links in the references section. Clinicians and medical 
students also benefit from the biomedical content on Wikipedia as a quick a reliable source of 
information on pharmaceuticals, therapeutics, disease symptomology, and biological entities 
ranging from genes to proteins to metabolites. The structured data contained within Semantic 
Wiki Links [8-10] and the integrated Wikidata [11] entities also provides data scientists with an 
avenue for extracting detailed relationships between entities. Patients or their family members 
might be visiting to get a sense of what a particular diagnosis for a rare mitochondrial disease 
means and what kind of patient advocacy groups exist. Each of these key stakeholder groups 
benefits from the comprehensive representation of each mitochondrial gene, protein, channel, 
pathway, processes, and diseases. 
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The Gene Wiki Project also presents significant opportunities in training and education beyond 
the focused efforts undertaken here. In collaboration with the University of California, Los Angeles 
School of Life Sciences, we are developing a streamlined implementation of our Gene Wiki 
training methodologies for use in the Life Sciences 7C Physiology and Human Biology course. 
This course is the culmination of a year-long series that forms the core curriculum of a variety 
of undergraduate life science majors. The associated weekly discussion sessions give students 
the opportunity to work with a smaller group of classmates, guided by graduate student Teaching 
Assistants (TAs) from a wide range of research backgrounds. These sessions are a perfect setting 
for group work on Gene Wiki pages. Many students will gain their first experience in using PubMed, 
critically evaluating scientific publications, interacting with informatics resources, and conducting 
collaborative writing efforts, all of which are vital skills for future researchers and clinicians. Over 
1,200 students take the LS Core Education Courses each year, providing a significant pool of 
potential contributors to this essential resource. Implementing these training efforts will ensure 
that the students will encounter the most prominent resources and become familiar with some 
of the most crucial activities for developing one’s scientific career. Furthermore, this presents 
the opportunity to introduce the FAIR Principles and data science approaches to a wide swath of 
students at one of the top universities in the country, amplifying the reach and consideration of the 
increasingly complex world of data and scientific knowledge. 
Natural language generation (NLG) with GPT-2 [12, 13] presents an interesting avenue of research 
with potential application to Gene Wiki writing tasks. Given a prompt, the GPT-2 algorithm is 
capable of generating coherent paragraphs of text after training on vast stores of text data. 
This technology is still in its infancy, but it does show promise for processing large amounts of 
information about a gene or protein and generating a summary of those contents. NLG-derived 
gene summaries could identify and summarize a large quantity of relevant research articles, 
reducing the time devoted to manual curation efforts. The process would require human guidance 
and careful manual review to ensure the accuracy of the content, but it would greatly increase 
the comprehensiveness of Gene Wiki articles and the representation of scientific literature in the 
public domain. Gene Wiki also provides an ideal testing and training ground for the development 
of this nascent technology using a semi-supervised approach. 
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We amplified the unstructured text data in CCRs by designing a standardized metadata template 
with which to extract detailed and structured metadata characterizing the clinical presentations, 
treatment regimens, and diagnostic procedure described in the reports. We generated MACCRs 
(Metadata Annotated from CCRs) templates for over 3,100 CCRs across a wide range of diseases 
to establish a large dataset of structured data with which to study clinical language. For a subset 
of 384 CCRs on 8 RMDs, we further extracted and codified all patient symptoms from each report 
using the clinical codes from the 10th and 11th revisions of the International Statistical Classification 
of Diseases and Related Health Problems (ICD). The manually curated and annotated datasets 
are now housed on the newly formed MitoCases RMD Knowledge Platform (http://mitocases.
org/).
MitoCases provides a more effective way to search for clinical reports on RMDs by symptoms, 
genetics, age rage, gender, or any other medical term contained within the reports. The extensive 
case information available on each report permits granular searches that are not possible when 
restricted to Medical Subject Heading (MeSH) terms and the content in titles and abstracts for 
indexing. This is of particular use to clinicians searching for cases similar to a patient they are 
seeing. Searching for CCRs with a set of symptoms as keywords on PubMed typically returns no 
results – MeSH was simply not designed to accommodate this level of detail, and the abstracts 
rarely provide extensive descriptions of symptoms. Physician investigators and researchers can 
also make use of this feature when attempting to construct an in silico cohort of a disease or trying 
to find cases in which a certain drug was used or a particular protein was measured or identified. 
By demonstrating the utility of the MitoCases platform for CCRs on mitochondrial diseases and 
engaging those clinicians who undertake the effort to write these reports, we hope to inspire them 
to include symptomology metadata in their future publications and to lobby publishers to use the 
metadata for indexing purposes. One possibility is to simply include a patient’s coded ICD symptom 
list from their EHR, which presents a very low barrier to entry into this effort. Our initial outreach 
efforts have focused on the mitochondrial disease community at the United Mitochondrial Disease 
Foundation symposia and we aim to expand these efforts to other biomedical communities and 
clinical societies. It is important to note that the structured metadata for CCRs and EHRs should 
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not replace the unstructured patient narratives but act instead as supplemental material to bolster 
the FAIRness of these documents. Unstructured narratives provide a nuanced and detailed 
view of patients’ medical history, as well as the lines of reasoning undertaken by clinicians in 
their differential diagnosis efforts [14]. Combining these narratives with a structured component 
representing symptomology, disease diagnosis, genetic background, and treatment regimens 
serves to amplify the utility of CCRs and leverage their inherent value by making them more 
readily Findable, Accessible, Interoperable, and, ultimately Reusable. 
Data scientists interested in studying clinical language may find particular utility in the large set of 
structured clinical narratives across a diverse set of presentations. This provides the opportunity 
to work with well-structured biomedical data and can serve as useful testing grounds for machine 
learning models, natural language processing (NLP) applications, named entity recognition (NER) 
[15, 16], and phrase mining [17]. These technologies might be applied to identify distinct entities 
and phrases within clinical text referring to patient symptoms, drug treatments, genes, proteins, 
and disease names. These approaches can be further enhanced via entity typing (ClusType) [18] 
to identify classes of entities detected through NER and attribute detection methods (MetaPAD) 
[19] to contextualize the conditions around observed entities and their interactions. With defined 
entity types, corpus-based set expansion (SetExpan) [20]g ontologies and knowledgebases 
may be used to discover additional instances of entities with matching features throughout the 
corpus of RMD CCRs. The projects presented here welcome the development of text-mining 
and automation tools to achieve a more comprehensive representation of the 58 known rare 
mitochondrial diseases and their available case presentations.
Text corpora standardization provides the basis for efficient document search and curation by 
exposing contents to search algorithms and enabling integration into knowledge graphs. The 
overarching aim of this project is to enable text data contained within CCRs to be machine-readable, 
facilitating downstream analysis and meta-analysis. There has been extensive development 
of metadata templates for structured data [21-24], but standardization of text data can only be 
accomplished and implemented with community consent and participation. The genomics and 
proteomics fields have seen significant successes in standardization by way of a community-
160
driven process that identifies challenges, builds consensus, and leads to solutions. We envision 
clinicians and their co-authors as well as biomedical and data science researchers acting as an 
interdisciplinary community to establish and implement widely used standards for structuring text 
data. MitoCases is a model for wider implementation of metadata standard templates that will 
increase the utility of CCRs and our ability to derive knowledge from the clinical insights contained 
within. We recognize that a universal metadata template for all CCRs across every disease is 
impractical. Instead, we envision an opportunity to engage research and biomedical communities 
to form working groups that can leverage domain-specific expertise to create a compendium of 
templates capable of handling text data from a wide range of scientific and clinical documents. 
Ideally, the National Library of Medicine (NLM) could become involved and eventually incorporate 
more detailed metadata on PubMed for greater indexing capabilities of CCRs and other scientific 
literature. 
These efforts depend upon dedication to the FAIR Principles throughout research such that all 
pieces of knowledge and data may be incorporated into the larger scheme of a holistic scientific 
knowledge representation. Ultimately, we envision the representation of all clinical and biomedical 
knowledge in a fully integrated knowledge graph that incorporates basic scientific concepts, 
experimental data, and clinical insights from all corners of research. With such a knowledge 
model, we could identify points of contention, opposing mechanistic hypotheses, or wholly missing 
pieces of critical knowledge. This would provide a roadmap to those explorations in need of further 
attention and resolution, driving research groups to test reproducibility, acquire more positive 
evidence for a claim, or to reject the underlying hypothesis. We will gain a deeper mechanistic 
understanding of genetics, protein biology, and disease presentations through the instantiation 
and development of such a resource, paving the way for improved patient care. 
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